Common use of Terms Defined Elsewhere Clause in Contracts

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Agreement Preamble Biogen Idec License Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: A&R Company Bylaws Section 2.3(a) A&R Company Charter Section 2.3(a) A&R Company OP Partnership Agreement and a reference to the Section hereof in which such term is defined: 2.3(b) Acceptable Confidentiality Agreement Section 7.4(b)(i) Acquisition Agreement Section 7.4(a) Agreement Preamble Biogen Idec License Agreement Book-Entry Share Section 4.7 Biogen Idec Supply Agreement 3.1(a)(ii) Certificate Section 4.7 Books and Records 3.1(a)(ii) Certificate of Limited Partnership Section 2.12(f)(24.1(c) Claim Notice Certificate of Partnership Merger Section 8.3(a2.1(d)(ii) Change in Company Recommendation Section 7.4(b)(iii) Change in Parent Recommendation Section 7.4(b)(iii) Chosen Court Section 10.7(b) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Code Recitals Company Preamble Company 401(k) Plan Section 4.14(b) Company Articles of Merger Section 2.1(a)(ii) Company Board Recitals Company Board Designees Section 7.21 Company Bylaws Section 4.1(c) Company Certificate of Merger Section 2.1(a)(ii) Company Charter Section 4.1(c) Company Common Stock Recitals Company Data Partners Section 2.8 4.22(a) Company Development Properties Section 4.12(g) Company Development Property Section 4.12(g) Company Disclosure Schedule Article IV Company Expenses Schedule Employee Programs Section 2.13 4.14(a) Company Equity Award Consideration Section 3.2(e) Company Governing Documents Section 4.1(c) Company LLC Agreement Section 2.3(a) Company Merger Section 2.1(a)(i) Company Merger Certificates Section 2.1(a)(ii) Company Merger Effective Time Section 2.1(a)(ii) Company OP GP Recitals Company Parties Preamble Company Preferred Stock Section 4.3(a) Company Privacy Policy Section 4.22(a) Company Privacy Requirements Section 4.22(a) Company Properties Section 4.12(a) Company Recommendation Section 4.2(b) Company SEC Reports Section 4.8(a) Company Stockholder Approval Section 4.18 Company Stockholder Meeting Section 7.1(c) Company Subsidiaries Section 4.1(b) Company Subsidiary Section 4.1(b) Company Tax Protection Agreement Section 6.1(x) Consent Solicitations Section 7.19(b) Continuing Employee Section 7.8(a) Continuing Employees Section 7.8(a) Contribution Section 2.1(c)(i) Contribution and Issuance Effective Time Section 2.1(c)(ii) Debt Offer Documents Section 7.19(b) Deemed Liquidation Section 7.9(a) DGCL Section 2.1(b)(i) DLLCA Section 2.1(a)(i) Drop Dead Date Section 9.1(b)(iv) DRULPA Section 2.1(d)(i) DSOS Section 2.1(a)(ii) Encumbrances Section 4.12(a) Exchange Agent Section 3.3(a) Exchange Fund Section 3.3(a) Exchange Ratio Section 3.1(a)(ii) Extra Space Merger Sub Preamble Extra Space OP Merger Sub Preamble Form S-4 Section 4.6 Fractional Share Consideration Section 3.1(a)(ii) Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e7.5(a) Indemnifying Party Section 8.3(a7.5(a) Instrument Interim Period Section 2.12(c6.1 Intervening Event Notice Section 7.4(b)(v) Intervening Event Notice Period Section 7.4(b)(v) Issuance Section 2.1(c)(i) JV Ownership Interest Rights Section 5.5 JV Partners Section 5.5 Letter of Transmittal Section 3.3(c) LLC Conversions Recitals Maryland SDAT Section 2.1(a)(ii) Material Company Real Property Lease Section 4.12(a) Material Parent Real Property Lease Section 5.12(a) Maximum Premium Section 7.5(c) MD LLC Act Section 2.1(b)(i) Merger Certificates Section 2.1 2.1(d)(ii) Merger Certificate Consideration Section 2.2 Merger Sub 3.1(a)(ii) Mergers Section 2.1(d)(i) MGCL Section 2.1(a)(i) Minority Limited Partner Recitals New Parent OP Units Section 3.1(b)(iv) Note Offers and Consent Solicitations Section 7.19(b) Notice Period Section 7.4(b)(iv) Offers to Exchange Section 7.19(b) Offers to Purchase Section 7.19(b) OP Unit Form S-4 Section 7.1(a) Other Filings Section 7.2 Parent Preamble Parent Preamble 401(k) Plan Section 5.14(b) Parent Board Recitals Parent Bylaws Section 5.1(d) Parent Charter Section 5.1(d) Parent Common Stock Election Section 3.1(b)(v) Parent Common Stock Election Date Section 3.1(b)(v)(A) Parent Common Stock Election Form Section 3.1(b)(v)(A) Parent Common Stock Issuance Section 5.2(a) Parent Data Partners Section 5.22(a) Parent Development Properties Section 5.12(g) Parent Development Property Section 5.12(g) Parent Disclosure Schedule Article V Parent Indemnified Employee Programs Section 5.14(a) Parent Equity Award Section 5.3(d) Parent Governing Documents Section 5.1(d) Parent OP Preamble Parent OP Certificate of Limited Partnership Section 5.1(d) Parent OP Governing Documents Section 5.1(d) Parent OP Unit Recitals Parent Parties Preamble Parent Partnership Agreement Section 8.2(a)(i5.1(d) parties Parent Preferred Stock Section 5.3(a) Parent Privacy Policies Section 5.22(a) Parent Privacy Requirements Section 5.22(a) Parent Properties Section 5.12(a) Parent Recommendation Section 5.2(b) Parent SEC Reports Section 5.8(a) Parent Stockholder Approval Section 5.18 Parent Subsidiaries Section 5.1(c) Parent Subsidiary Section 5.1(c) Parent Tax Protection Agreement Section 6.2(v) Parent Trust Recitals Parties Preamble Payee Partnership Preamble Partnership Agreement Section 8.5 Payor 4.1(c) Partnership Governing Documents Section 8.5 Per Diem 4.1(c) Partnership Merger Section Partnership Merger Effective Time Section 2.1(d)(ii) Partnership OP Unit Recitals Party Preamble Permit Section 4.7 Permitted REIT Dividend Section 6.1(b) Preferred Unitholder Section 3.1(b)(vi) Preferred Unitholder Election Section 3.1(b)(vi) Preferred Unitholder Election Form Section 3.1(b)(vi)(A) Preferred Unitholder Notice Section 3.1(b)(vi)(A) Proxy Statement/Prospectus Section 3.3(a) Qualified REIT Subsidiary Section 4.11(f) Qualifying Income Section 9.4(a) Registered Intellectual Property Section 4.21(a) REIT Section 4.11(b) REIT Dividend Section 7.17(b) Requested Changes Section 2.5 ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.8(a) Securities Laws Section 4.8(a) Security Incident Section 4.22(b) Series A Preferred Liquidation Payment Section 3.1(b)(vi)(A) Series A Preferred Units Recitals Superior Proposal Notice Section 7.4(b)(iv) Surviving Entity Section 2.1(a)(i) Takeover Statutes Section 4.26 Tax Protection Agreement Section 4.11(l) Taxable REIT Subsidiary Section 4.11(f) Transfer Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g7.9(c)

Terms Defined Elsewhere. The For purposes of this Agreement, the following is a list of additional terms (as capitalized below) will have the following meanings when used in this Agreement and a reference to the Agreement: Action Section hereof in which such term is defined: 6.10(b) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.04(a) Alternative Proposal Section 4.7 Books and Records 6.04(i) Annual Bonus Section 2.12(f)(26.06(e) Claim Notice Approval Request Section 8.3(a6.01(b) Articles of Merger Section 2.03 Book-Entry Shares Section 3.01(a) Burdensome Condition Section 6.07(d) Capex Budget Section 4.13(a)(i) Certificate of Merger Section 2.03 Certificates Section 3.01(a) Change of Recommendation Section 6.04(f) Closing Section 2.3 2.02 Closing Date Section 2.3 2.02 Code Section 3.02(b)(iii) Common Stock Section 3.01(a) Company Preamble Company Common Stock Section 2.8 Board Recitals Company Disclosure Schedule Letter Article IV Company Expenses Schedule Employee Section 2.13 6.06(a) Company Indemnified Employees Section 6.06(a) Company Incentive Plan Section 6.06(e) Company Product Section 4.21 Company Related Parties Section 8.2(a)(ii8.03(a) Contracts Company SEC Reports Section 4.8(a4.06(a) Covered Party (PartiesCompany Shareholders’ Meeting Section 6.05(b) Confidentiality Agreement Section 8.2(a)(ii6.03(b) Damages control Definition of Affiliates, Section 8.2(a)(i) 1.01 controlled by Definition of Affiliates, Section 1.01 DGCL Section 2.1 Document Retention Period 2.01 Dissenting Shares Section 2.12(f)(23.01(c)(ii) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.03 End Date Section 8.01(b) Enforcement Expenses Section 8.03(b) Exchange Fund Section 3.02(a) First Extended Date Section 8.01(b) G▇▇▇▇▇▇ S▇▇▇▇ Section 4.25 Indemnified Party Section 6.10(b) Intervening Event Section 6.04(k) Intervening Event Notice Section 6.04(g) Leases Section 4.10(b) Legal Restraint Section 7.01(b) Mass Layoff Section 4.18(a) Material Contract Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Maximum Amount Section 2.10(e6.10(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c4.02(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 3.01(a) Merger Sub Preamble Multiemployer Plan Section 4.18(j) New Plans Section 6.06(b) Notice Period Section 6.04(f) OFAC Definition of Sanctions, Section 1.01 Old Plans Section 6.06(b) Oregon Act Section 2.01 Owned Real Property Section 4.10(a) Parent Preamble Parent Disclosure Schedule Article V Material Adverse Effect Section 5.01 Parent Indemnified Related Parties Section 8.2(a)(i8.03(a) parties Parties Preamble Payee Party Preamble Paying Agent Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a3.02(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Payoff Amount Section 2.10(f6.18 Payoff Letter Section 6.18 Plant Closing Section 4.18(a) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority President Definition of CFIUS Approval, Section 2.12(b1.01 Recommendation Section 4.04 Remedial Action Section 6.07(d) Replacement Credit Facility Section 6.01(a)(x)(A)(v) Required Company Shareholder Vote Section 4.24 Sanctioned Countries Definition of Sanctions Target, Section 1.01 Share Section 3.01(a) Significant Customers Section 4.22 Significant Suppliers Section 4.22 Specified Regulatory Approvals Section 7.01(c) Superior Proposal Section 6.04(j) Superior Proposal Notice Section 6.04(f) Surviving Corporation Section 2.1 Third Milestone 2.01 Takeover Statutes Section 2.10(g4.23 Tax Proceeding Section 4.17(f) Third Milestone Payment Amount Tax Sharing Agreement Section 2.10(g4.17(l) Termination Date Section 6.01(a) under common control with Definition of Affiliates, Section 1.01 Union Employees Section 6.06(f) Voting Subsidiary Debt Section 4.03(d) WARN Act Section 4.18(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: ADS Employees Section hereof in which such term is defined: 6.12 After Consultation Section 5.3(b) Agreement Preamble Biogen Idec License Agreement Appointment Date Section 4.7 Biogen Idec Supply Agreement 5.1 Appraisal Section 4.7 Books and Records 6.16 Articles of Merger Section 2.12(f)(21.6 Audited Income Statement Section 3.26 Balance Sheet Date Section 3.8(a) Claim Notice Base Premium Section 8.3(a6.6(c) Canceled Stock Rights Section 2.5(a) Certificates Section 2.2(b) CGCL Recitals Closing Section 2.3 1.7 Closing Date Section 2.3 1.7 Code Recitals Company Preamble Company Affiliate Section 6.9 Company Agreements Section 3.5 Company Articles Section 1.3(b) Company Benefit Plans Section 3.11(a) Company Board of Directors Recitals Company Bylaws Section 1.3(b) Company Change in Recommendation Section 5.4(a) Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Article IV III Company Expenses Schedule Section 2.13 8.2(d) Company Indemnified Parties Financial Advisor Section 8.2(a)(ii3.20 Company Financial Statements Section 3.6(a) Contracts Company Governing Documents Section 4.8(a1.3(b) Company Intellectual Property Section 3.15 Company Material Contract Section 3.13 Company Options Section 2.5(a) Company Permits Section 3.16(b) Company Preferred Stock Section 3.2(a) Company Recommendation Section 5.4(a) Company Rights Recitals Company Rights Agreement Recitals Company SEC Documents Section 3.6(a) Company Stock Rights Section 3.2(a) Confidentiality Agreement Section 5.3(b) Continuing Directors Section 1.3(b) Contribution Recitals Contribution Agreement Recitals Covered Party (PartiesPersons Section 6.6(a) D&O Insurance Section 8.2(a)(ii) Damages Section 8.2(a)(i6.6(c) DGCL Recitals Dissenters Provisions Section 2.1 Document Retention Period 2.3(a) Dissenting Shares Section 2.12(f)(22.3(a) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 1.6 Equity Interests Section 4.13(a3.2(a) ERISA Affiliate Exchange Act Section 4.13(a1.1(a) Finally Determined Exchange Agent Section 8.5(b1.4(a) First Milestone Form 10 Section 2.10(e6.13 GAAP Section 3.6(a) First Milestone Payment Amount Governmental Entity Section 2.10(e3.5 HSR Act Section 3.5 Incorporated Open Source Materials Section 3.15(c) Indemnifying Party Indemnification Agreements Section 8.3(a6.6(a) Instrument Indemnification and Tax Matters Agreement Annex I Information Statement Section 2.12(c1.10(a) Initial Expiration Date Section 1.1(a) Junior Preferred Stock Section 3.2(a) Media Distribution Service Agreement Recitals Merger Recitals Merger Consideration Section 2.1(c) Merger Exchange Fund Section 2.1 Merger Certificate 2.2(a) Minimum Condition Section 2.2 Merger 1.1(a) Monthly Unaudited Financial Information Section 6.14 Nasdaq Section 1.1(b) Noncompetition Agreement Annex I Notice of Recommendation Change Section 5.4(b) Offer Recitals Offer Consideration Recitals Offer Documents Section 1.1(c) Offer Exchange Fund Section 1.4(a) Offer to Exchange Section 1.1(a) Officer Confidentiality Agreement Annex I Outside Date Section 8.1(b)(iv) Permitted Liens Section 3.14 Post Production Services Agreement Annex I Post Signing Returns Section 6.8(a) PPB Appraisal Report Section 6.16 PPB Fair Market Value Section 6.16 PPB Sub Preamble Parent Prospectus Section 1.1(c) Public Disclosure Section 5.4(a) Purchaser Preamble Parent Disclosure Purchaser Agreements Section 4.5 Purchaser Common Stock Recitals Purchaser Expenses Section 8.2(b) Purchaser Financial Statements Section 4.6 Purchaser Governing Documents Section 4.3(c) Purchaser Options Section 4.3(a) Purchaser Preferred Stock Section 4.3(a) Purchaser SEC Documents Section 4.6 Purchaser Stock Rights Section 4.3(a) Registration Statement Section 1.1(c) Regulation M-A Section 1.1(c) Representatives Section 5.3(a) Restricted Stock Section 2.5(b) SAR Section 2.5(a) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 3.6(a) Schedule Article V Parent Indemnified Parties 14D-9 Section 8.2(a)(i1.2(a) parties Preamble Payee Schedule TO Section 8.5 Payor 1.1(c) SEC Section 8.5 Per Diem Taxes 1.1(c) Section 8.7(a16 Section 6.12 Securities Act Section 3.6(a) Proceeding Shares Recitals Significant Subsidiaries Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent 4.2 Spin-Off Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Support Agreement Recitals Surviving Corporation Section 2.1 Third Milestone 1.5(a) Termination Fee Section 2.10(g8.2(b) Third Milestone Payment Amount Party Section 2.10(g)5.3(a) Top-Up Closing Section 2.4(c) Top-Up Exercise Event Section 2.4(b) Top-Up Exercise Notice Section 2.4(c) Top-Up Notice Date Section 2.4(c) Top-Up Notice Receipt Section 2.4(c) Top-Up Option Section 2.4(a) Top-Up Option Shares Section 2.4(a) Transactions Recitals Unaudited Income Statement Section 3.26 Voting Debt Section 3.2(a) Working Capital Reconciliation Agreement Annex I

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 401(k) Termination Date Section hereof in which such term is defined: 7.7(c) Acceptance Time Section 1.1(f) Adjusted Option Section 3.4(b) Adjusted RSU Section 3.4(d) Agreement Preamble Biogen Idec License Agreement Arrangements Section 4.7 Biogen Idec Supply Agreement 7.14 Book-Entry Shares Section 4.7 Books and Records 3.2(b) Cancelled Shares Section 2.12(f)(23.1(b) Claim Notice Certificates Section 8.3(a3.2(b) Change of Recommendation Section 6.3(a) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 COBRA Section 4.10(d) Company Preamble Company Benefit Plans Section 4.10(a) Company Board of Directors Recitals Company Board Recommendation Recitals Company Capitalization Date Section 4.2(a) Company Common Stock Recitals Company Compensation Committee Section 2.8 7.14 Company Disclosure Schedule Letter Article IV Company Expenses Equity Schedule Section 2.13 4.2(b) Company Permits Section 4.9(b) Company Preferred Stock Section 4.2(a) Company SEC Documents Section 4.5(a) Company Shares Recitals Company Stockholders Recitals Convertible Senior Notes Section 7.15 DGCL Recitals Dissenting Shares Section 3.3(a) DOJ Section 7.2(b) Enforceability Limitations Section 4.3(c) Exchange Agent Section 3.2(a) Exchange Fund Section 3.2(a) Fractional Share Consideration Section 3.1(a) FTC Section 7.2(b) GAAP Section 4.5(b) Indemnified Parties Section 8.2(a)(ii7.4(a) Contracts Indenture Section 4.8(a7.15 Intervening Event Section 6.3(d) Covered Party (PartiesMaterial Contract Section 4.17(a) Minimum Condition Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g1.1(a)(i)

Terms Defined Elsewhere. The For purposes of this Agreement each of the following is a list of additional terms (capitalized below) when used in this Agreement and a reference will have the meaning ascribed to such term in the Section hereof in which set forth opposite such term is definedterm: 401(k) Plan Section 6.4(c) Acceleration Date Section 3.2(a)(iii) Acceptance Time Section 1.1(a)(ii) Affiliate Transaction Section 4.24 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.3(d) Book-Entry Share Section 4.7 Books and Records 3.4(c) CARES Act Section 2.12(f)(24.11(c) Claim Notice Certificate Section 8.3(a3.4(b) Certificate of Merger Section 2.2 Closing Section 2.3 2.2 Closing Amount Recitals Closing Date Section 2.3 2.2 Code Section 3.6 Company Preamble Company Board Recitals Company Board Recommendation Section 4.2 Company Bonus Plan Section 6.4(d) Company Cash-Out Stock Option Section 3.2(a)(i) Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Letter Article IV Company Expenses Schedule Equity Plan Section 2.13 3.2(a) Company Indemnified Parties Equity Plans Section 8.2(a)(ii3.2(a) Contracts Company ESPP Section 4.8(a3.2(a) Covered Party (PartiesCompany Material Contract Section 4.12(a) Company Organizational Documents Section 8.2(a)(ii4.1(c) Damages Company Real Property Section 8.2(a)(i4.10(b) Company Registered Intellectual Property Section 4.13(a) Company RSUs Section 3.2(a)(iv) Company SEC Documents Section 4.6(a) Company Securities Section 4.3(e) Company Stock Options Section 3.2(a)(iii) Company Systems Section 4.13(j) Compensation Action Section 6.8 Confidentiality Agreement Section 9.4 of Company Disclosure Letter Current Employees Section 6.4(a) CVR Agreement Recitals CVRs Recitals DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period Section 2.12(f)(23.3(a) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a4.16(d) ERISA Affiliate Exchange Act Section 4.13(a1.1(a)(i) Finally Determined Excluded Benefits Section 8.5(b6.4(a) First Milestone Expiration Date Section 2.10(e1.1(a)(i) First Milestone Payment FCPA Section 4.19(g) FDA Section 4.19(a) FDCA Section 4.19(a) HSR Act Section 4.5 Indemnified Party Section 6.5(b) Initial Expiration Date Section 1.1(a)(i) Intentional Breach Section 8.5(a) Labor Agreements Section 4.12(a)(ii) Last Exercise Date Section 3.2(a)(iii) Maximum Amount Section 2.10(e6.5(c) Indemnifying Party Measurement Date Section 8.3(a) Instrument Section 2.12(c4.3(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate 3.1(a) Minimum Tender Condition Annex I(a) Nasdaq Section 2.2 Merger Sub Preamble 1.1(a)(ii) OECD Convention Section 4.19(g) Offer Recitals Offer Conditions Section 1.1(a)(i) Offer Documents Section 1.1(b) Offer Price Recitals Outside Date Section 8.2(b) Parent Preamble Parent Disclosure Bonus Plan Section 6.4(d) Paying Agent Section 3.4(a) Payment Date Section 6.4(d) PHSA Section 4.19(a) Pre-Closing Period Section 6.1(a) Privacy Policies Section 4.19(i) Prohibited Payment Section 4.19(i) Purchase Orders Section 4.12(a)(x) Purchaser Preamble Regulatory Authorizations Section 4.19(a) Regulatory Correspondence Section 4.19(a) Rights Agent Recitals ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Section 4.9(d) Schedule Article V Parent Indemnified Parties 14D-9 Section 8.2(a)(i1.2 Schedule TO Section 1.1(b) parties Preamble Payee SEC Section 8.5 Payor 1.1(a)(i) Securities Act Section 8.5 Per Diem Taxes Section 8.7(a4.6(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Share Recitals Shares Recitals Stockholder Representative Preamble Super Majority List Date Section 2.12(b) 1.3 Stockholder Litigation Section 6.12 Surviving Corporation Section 2.1 Third Milestone Tender and Support Agreements Recitals Treasury Regulations Section 2.10(g3.6 UK Bribery Act Section 4.3(g) Third Milestone Payment Amount WARN Section 2.10(g4.18(b)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Acquisition Proposal Section 5.04(a) Agreement Preamble Biogen Idec License Agreement Audited Financial Statements Section 4.7 Biogen Idec Supply Agreement 3.06 Articles of Merger Section 4.7 Books and Records 2.05 Balance Sheet Section 2.12(f)(23.06 Balance Sheet Date Section 3.06 Basket Section 8.04(a) Claim Notice Benefit Plan Section 8.3(a3.18(a) Cap Section 8.04(a) Closing Section 2.3 2.03 Closing Date Section 2.3 2.03 Closing Statement Section 2.02 Common Stock Section 3.04(a) Company Preamble Company Common Stock Board Recitals Company Board Recommendation Section 2.8 3.02(b) Company Disclosure Schedule Article IV Charter Documents Section 3.01(a) Company Expenses Schedule Counsel Section 2.13 10.14(a) Company Special Meeting Section 5.05 Company Subsidiary Charter Documents Section 3.01(b) Confidentiality Agreement Section 5.03(c) Continuing Employees Section 5.12(a) Direct Claim Section 8.05(c) Disputed Amounts Section 2.16(b)(iii) Dissenting Shares Section 2.10 D&O Indemnified Parties Party Section 8.2(a)(ii5.11(a) Contracts D&O Tail Policy Section 4.8(a5.11(b) Covered Party (PartiesEarn-out Calculation Section 2.17(b)(i) Earn-out Calculation Objection Notice Section 8.2(a)(ii2.17(b)(iii) Damages Earn-out Calculation Statement Section 8.2(a)(i2.17(b)(i) DGCL Section 2.1 Document Retention Earn-out Review Period Section 2.12(f)(22.17(b)(ii) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.05 End Date Section 4.13(a9.01 Escrow Funds Section 2.12(b) ERISA Affiliate Excess Working Capital Section 4.13(a2.16(c)(ii) Finally Determined Financial Statements Section 8.5(b3.06 FIRPTA Statement Section 6.07 Government Contracts Section 3.09(a)(v) First Milestone Indemnification Escrow Fund Section 2.10(e2.12(a)(i) First Milestone Payment Amount Independent Accountant Section 2.10(e2.16(b)(iii) Indemnifying Party Insurance Policies Section 8.3(a3.14 Interim Balance Sheet Section 3.06 Interim Balance Sheet Date Section 3.06 Interim Financial Statements Section 3.06 iSun Residential Preamble iSun Residential Board Recitals Letter of Transmittal Section 2.11(c) Instrument Liabilities Section 2.12(c3.07 Lockup Period Section 5.15 Majority Holders Section 10.01(e) Material Contracts Section 3.09(a) Material Customers Section 3.13(a) Material Suppliers Section 3.13(b) Merger Section 2.1 Merger Certificate Section 2.2 Recitals Merger Sub Preamble Merger Sub Board Recitals Parent Preamble Parent Disclosure Schedule Article V Board Recitals Parent Indemnified Equity Awards Section 4.11(b)(i) Parent Indemnitees Section 8.02 Parent Preferred Stock Section 4.11(a) Parent Restricted Share Section 4.11(b)(i) Parent SEC Documents Section 4.01 Parent Securities Section 4.11(b)(ii) Parent Stock Plans Section 4.11(b)(i) Parent Stock Option Section 4.11(b)(i) Parent Subsidiaries Preamble Parent Subsidiary Securities Section 4.11(d) Parent Voting Debt Section 4.11(c) Party Preamble Parties Preamble Permitted Encumbrances Section 8.2(a)(i3.10(a) parties Preamble Payee Post-Closing Adjustment Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a2.16(c) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority PPP Escrow Fund Section 2.12(b) Preferred Stock Section 3.04(a) Privileged Communications Section 10.14(d) Registrable Shares Section 5.14(a) Registration Statement Section 5.14(a) Representative Losses Section 10.01(f) Requisite Company Vote Section 3.02(a) Resolution Period Section 2.16(b)(ii) Review Period Section 2.16(b)(ii) Revised Closing Statement Section 2.16(b)(i) Termination Fee Section 9.02(a) Third Party Claim Section 8.05(a) SEC Section 4.01 Series A Preferred Stock Section 3.04(a) Series B Preferred Stock Section 3.04(a) Series C Preferred Stock Section 3.04(a) Shareholder Representative Group Preamble Shareholder Indemnitees Section 8.03 Shares Section 2.09(a) Signing Date Preamble Statement of Objections Section 2.16(b)(ii) Straddle Period Section 6.04 Surviving Corporation Section 2.1 Third Milestone 2.01 Tax Claim Section 2.10(g6.05 Undisputed Amounts Section 2.16(b)(iii) Third Milestone Payment Amount Union Section 2.10(g3.19(b) VBCA Recitals Working Capital Escrow Fund Section 2.12(a)(ii) Working Capital Shortfall Section 2.16(c)(iii)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.11(b) Agreement Preamble Biogen Idec License Agreement Anglo China Preamble Anti-Corruption Laws Section 4.7 Biogen Idec Supply Agreement 4.5(b) Table of Contents Bankruptcy and Equity Exception Section 4.7 Books and Records 4.3(a) Britain Ukan Preamble Cayman Companies Law Recitals Certificates Section 2.12(f)(2) Claim Notice Section 8.3(a3.2(c) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 6.4(c)(i) Company Disclosure Schedule Article IV Board Recitals Company Expenses Schedule Financial Advisors Section 2.13 4.3(b) Company Financial Statements Section 4.6(b) Company Group Section 8.2(d) Company Intellectual Property Section 4.14(b) Company Material Contract Section 4.11(a) Company Plan(s) Section 4.9(a) Company Recommendation Section 4.3(b) Company Representatives Section 6.3(a) Company SEC Filings Section 4.6(a) Company Shareholders Meeting Section 6.2(e) Company Subsidiary Section 4.1 D&O Insurance Section 6.12(b) Dissenter Rights Section 3.1(f) Dissenting Shares Section 3.1(f) Dissenting Shareholders Section 3.1(f) Effective Time Section 2.3 End Date Section 8.1(b)(i) Exchange Fund Section 3.2(a) Financing Section 5.6 Founder Vehicle Preamble HKIAC Section 9.7(c) Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Independent Committee Recitals Investments Section 4.8(a4.2(d) Covered Party (PartiesLeased Real Property Section 4.17(b) Lender Section 8.2(a)(ii) Damages 5.6 Loan Agreement Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) 5.6 Merger Section 2.1 Merger Certificate Section 2.2 Recitals Merger Sub Preamble Notice Period Section 6.4(d)(iii) Owned Real Property Section 4.17(a) Parent Preamble Table of Contents Parent Disclosure Group Section 8.2(d) Parent Representatives Section 6.3(a) Party Preamble Paying Agent Section 3.2(a) Per ADS Merger Consideration Section 3.1(b) Per Share Merger Consideration Section 3.1(b) Plan of Merger Section 2.2 Proxy Statement Section 6.2(a) Registrar of Companies Section 2.3 Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b4.4(b) Surviving Corporation Section 2.1 Third Milestone Transaction Litigation Section 2.10(g) Third Milestone Payment Amount 6.8 Uncertificated Shares Section 2.10(g3.2(c)

Terms Defined Elsewhere. The For purposes of this Agreement each of the following is a list of additional terms (capitalized below) when used in this Agreement and a reference will have the meaning ascribed to such term in the Section hereof in which set forth opposite such term is definedterm: 401(k) Plan Section 6.4(c) Acceleration Date Section 3.2(a)(ii) Acceptance Time Section 1.1(a)(ii) Affiliate Transaction Section 4.25 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.3(d) Book-Entry Share Section 4.7 Books and Records 3.5(b) CARES Act Section 2.12(f)(24.11(c) Claim Notice Certificate Section 8.3(a3.5(b) Certificate of Merger Section 2.2 Closing Section 2.3 2.2 Closing Amount Recitals Closing Date Section 2.3 2.2 Code Section 3.7 Company Preamble Company Board Recitals Company Board Recommendation Section 4.2 Company Cash-Out Stock Option Section 3.2(a)(i) Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Letter Article IV Company Expenses Schedule Material Contract Section 2.13 4.12(a) Company Indemnified Parties Organizational Documents Section 8.2(a)(ii4.1(c) Contracts Company Real Property Section 4.8(a4.10(b) Covered Party (PartiesCompany Registered Intellectual Property Section 4.13(a) Company SEC Documents Section 8.2(a)(ii4.6(a) Damages Company Securities Section 8.2(a)(i4.3(f) Company Stock Options Section 3.2(a)(ii) Company Systems Section 4.13(k) Compensation Action Section 6.8 Current Employees Section 6.4(a) CVR Agreement Recitals CVRs Recitals DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period Section 2.12(f)(23.4(a) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a4.16(d) ERISA Affiliate Exchange Act Section 4.13(a1.1(a)(i) Finally Determined Excluded Benefits Section 8.5(b6.4(a) First Milestone Expiration Date Section 2.10(e1.1(a)(i) First Milestone Payment Amount FCPA Section 2.10(e4.19(m) Indemnifying FDA Section 4.19(a) FDCA Section 4.19(a) Healthcare Correspondence Section 4.19(f) Indemnified Party Section 8.3(a6.5(a) Instrument Initial Expiration Date Section 2.12(c1.1(a)(i) Intentional Breach Section 8.5(a) Labor Agreements Section 4.12(a)(ii) Last Exercise Date Section 3.2(a)(ii) Material Suppliers Section 4.20 Measurement Date Section 4.3(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate 3.1(a) Minimum Tender Condition Annex I, Section 2.2 Merger Sub Preamble 1(a) Nasdaq Section 1.1(a)(ii) OECD Convention Section 4.19(m) Offer Recitals Offer Conditions Section 1.1(a)(i) Offer Documents Section 1.1(b) Offer Price Recitals Out-of-the-Money Option Section 3.2(a)(ii) Outside Date Section 8.2(b) Parent Preamble Parent Disclosure Paying Agent Section 3.5(a) PHSA Section 4.19(a) Pre-Closing Period Section 6.1(a) Privacy Policy Section 4.19(o) Privacy Requirements Section 4.19(o) Prohibited Payment Section 4.19(o) Promissory Note Recitals Purchase Orders Section 4.12(a)(xi) Purchaser Preamble Regulatory Authorizations Section 4.19(a) Regulatory Correspondence Section 4.19(a) Rights Agent Recitals ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Section 4.9(d) Schedule Article V Parent Indemnified Parties 14D-9 Section 8.2(a)(i1.2 Schedule TO Section 1.1(b) parties Preamble Payee SEC Section 8.5 Payor 1.1(a)(i) Securities Act Section 8.5 Per Diem Taxes 4.6(a) Security Incident Section 8.7(a4.19(p) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Share Recitals Shares Recitals Stockholder Representative Preamble Super Majority List Date Section 2.12(b1.3 Stockholder Litigation Section 4.6(a) Surviving Corporation Section 2.1 Third Milestone Treasury Regulations Section 2.10(g3.7 UK Bribery Act Section 4.3(h) Third Milestone Payment Amount WARN Section 2.10(g4.18(b)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 280G Approval Section hereof in which such term is defined: 5.7(b) 280G Waiver Section 5.7(a) 401(k) Plan Section 5.12 Acquired Company Licensed IP Section 2.10(a) Acquired Company Registered IP Section 2.10(a) Adjustment Resolution Period Section 1.17(c) Adjustment Review Period Section 1.17(c) Advisory Group Section 9.2(b) Agreement Preamble Biogen Idec License Agreement Date Preamble Alternative Arrangements Section 4.7 Biogen Idec Supply Agreement 7.3(f) Anti-Corruption Laws Section 4.7 2.22(a) Balance Sheet Date Section 2.6(b) Board Recitals Books and Records Section 2.12(f)(22.15(b) Cancelled Shares Section 1.9(d) Certificate of Incorporation Section 2.1(d) Certificate of Merger Section 1.2(a) Certificates of Merger Section 1.2(b) Charter Documents Section 2.1(d) Closing Section 1.4(a) Closing Date Section 1.4(a) Closing Statement Section 1.17(b) Company Preamble Company Audited Financial Statements Section 2.6(a) Company Authorizations Section 2.13 Company Board Resolutions Section 2.3(a) Company Group Section 9.17 Company Indemnitees Section 4.6(a) Company Interim Financial Statements Section 2.6(a) Company Stockholder Approval Recitals Company Stockholder Consent Recitals Confidentiality Agreement Section 5.18 Continuing Claim Section 7.4(e) Contributor Section 2.10(h) Current Balance Sheet Section 2.6(b) D&O Indemnifiable Matters Section 4.6(a) D&O Tail Policy Section 4.6(b) Deductible Amount Section 7.3(a) Deficiency Amount Section 1.17(e) Delaware LLC Act Section 1.1 Determination Date Section 1.17(d) DGCL Section 1.1 Director and Officer Resignation Letter Section 1.4(b)(ii) Disclosure Schedule Article II Dissenting Shares Section 1.13(a) DOJ Section 5.10(a) Effective Time Section 1.2(a) Embargoed Countries Section 2.21 End Date Section 8.1(b) Estimated Closing Cash Amount Section 1.17(a) Estimated Closing Indebtedness Amount Section 1.17(a) Estimated Closing Statement Section 1.17(a) Estimated Closing Third Party Expenses Section 1.17(a) Estimated Closing Working Capital Adjustment Amount Section 1.17(a) Excess Amount Section 1.17(f) Exchange Documents Section 1.11(b)(ii) Expense Fund Section 9.2(c) Export Approvals Section 2.21 FCPA Section 2.22(a) Final Closing Statement Section 1.17(d) Financials Section 2.6(a) FIRPTA Compliance Certificate Section 1.4(b)(x) First Merger Recitals First-Step Surviving Corporation Section 1.1 FTC Section 5.10(a) Healthcare Laws Section 2.20(g) Inbound Licenses Section 2.10(f) Indemnification Claim Notice Section 8.3(a7.4(a) Closing Indemnification Claim Objection Notice Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses 7.4(b) Indemnification Schedule Section 2.13 Company 4.6(a) Indemnified Parties Section 8.2(a)(ii7.2(a) Contracts Indemnifying Parties Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e7.2(a) Indemnifying Party Section 8.3(a7.2(a) Instrument Independent Accountant Section 2.12(c1.17(c) Intended Tax Treatment Recitals Interested Party Section 2.12 Interim Period Section 5.1 Invoice Section 5.16 IP Agreement Section 2.10(h) Joinder and Lock-Up Agreement Section 1.4(b)(ix) Key Supplier Section 2.23 Lease Agreements Section 2.9(b) Leased Real Property Section 2.9(b) Letter of Transmittal Section 1.11(b)(i) Lock-Up Legend Section 4.4(b) Loss Section 7.2(a) Material Contract Section 2.11(a) Measuring Period Section 1.14(b) Merger Section 2.1 Merger Certificate Section 2.2 Sub I Preamble Merger Sub II Preamble Merger Subs Preamble Mergers Recitals New Plans Section 5.11(b) Non-Continuing Employee Release Section 5.18 Notice of Adjustment Disagreement Section 1.17(c) Notices Section 5.13 OFAC Section 2.21 Option Release Agreements Section 5.17 Option Release Individual Section 2.2(f) Outbound Licenses Section 2.10(f) Parent Preamble Parent Disclosure Schedule Article V III Parent Indemnified Financial Statements Section 3.12(b) Parent Parties Section 8.2(a)(i9.15 Parent Prepared Returns Section 4.2(a)(ii) parties Preamble Payee Parent Stock Issuance Recitals Permitted Actions Section 8.5 Payor 5.15.1 Press Release Section 8.5 Per Diem Taxes 5.9 Privacy Requirements Section 8.7(a2.10(a) Proceeding Prohibited Party Lists Section 4.17 Royalties 2.21 Prospectus Section 2.10(h4.4(b) Registrable Securities Section 4.4(b) Registration Statement Section 4.4(b) Resolved Matters Section 1.17(c) Representative Losses Section 9.2(b) Restraint Section 6.1(a) Restrictive Covenant Agreement Recitals Retained Holdback Amount Section 7.4(e) Retained Milestone Payments Section 7.4(b) Rule 144 Section 4.4(g) Second Milestone Certificate of Merger Section 2.10(f1.2(b) Second Milestone Payment Effective Time Section 1.2(b) Second Merger Recitals Securities Act Legend Section 4.4(e) Selling Stockholder Questionnaire 4.4(h) Spinoff Plan Section 5.12 Specified Non-Continuing Employee Amount Section 2.10(f5.18 Spreadsheet Section 4.3 Statement No. 5 Section 2.6(d) Stockholder Consent Recitals Notice Section 4.1(a) Stockholder Representative Preamble Super Majority Stockholder Representative Engagement Agreement Section 2.12(b9.2(b) Stockholder Representative Group Section 9.2(b) Survival Date Section 7.1 Surviving Corporation Entity Section 2.1 Third Milestone 1.1 Tax Section 2.10(g2.8(a)(i) Tax Contest Section 4.2(c) Tax Refunds Section 4.2(f) Tax Return Section 2.8(a)(ii) Taxes Section 2.8(a)(i) Terminated Agreements Section 1.4(b)(ii) Third Milestone Payment Amount Party Claim Section 2.10(g7.5 Third Party Notice Section 7.5 Trade Laws Section 2.21 Transaction Communication Section 9.17 Unresolved Matters Section 1.17(c) Unresolved Setoff Claims Section 7.4(b) U.S. Data Security Program Section 2.10(a) Waived 280G Benefits Section 5.7(a)

Terms Defined Elsewhere. The Each of the following terms is a list of additional terms used defined in this Agreement and a reference to the Section hereof in which set forth opposite such term is definedterm: Acceptable Company Confidentiality Agreement 6.02(b) Acceptable Parent Confidentiality Agreement 7.02(b) Agreement Preamble Biogen Idec License Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books Ancillary Scheme Documentation 3.01(b) Assumed Company Option 2.03(a) Assumed Company RSU 2.03(c) Bankruptcy and Records Section 2.12(f)(2Equity Exceptions 4.02(a) Claim Notice Section 8.3(aBenefits Continuation Period 8.03(a) Capitalization Date 4.05(a) Closing Section 2.3 1.02 Closing Date Section 2.3 1.02 Company Preamble Company Common Stock Section 2.8 401(k) Plan 8.03(c) Company Disclosure Schedule Article IV Adverse Recommendation Change 6.02(a) Company Expenses Schedule Section 2.13 Approval Time 6.02(b) Company Indemnified Parties Section 8.2(a)(iiBoard Recitals Company Board Recommendation 4.02(b) Contracts Section 4.8(aCompany Directors 2.05(d) Covered Party (PartiesCompany Exchange Fund 2.01(b) Section 8.2(a)(iiCompany Material Contract 4.15(a) Damages Section 8.2(a)(iCompany Material Subsidiaries 4.06(a) DGCL Section 2.1 Company Organizational Document Retention Period Section 2.12(f)(24.01 Company Permits 4.12 Company Registered IP 4.19(a) Drug Company Regulatory Agency Section 4.25 4.14(a) Company Regulatory Permits 4.14(a) Company Retention Plan 8.03(d) Company SEC Documents 4.07(a) Company Termination Payment 10.03(a) Conditions 8.06(b)(iii) Continuing Employees 8.03(a) Court Documentation 3.02(a)(i) Court Sanction Hearing 3.02(b)(i) Depositary Custodian 2.01(b) EC 4.14(a) Effective Date 1.03 Effective Time Section 2.2 ERISA Section 4.13(a1.03 EMA 4.14(a) ERISA Affiliate Section 4.13(aEnd Date 10.01(b)(i) Finally Determined Section 8.5(bExchange Agent 2.01(b) First Milestone Section 2.10(eExchange Ratio 2.02(a) First Milestone Payment FDA 4.14(a) FDCA 4.14(a) Foreign Antitrust Laws 4.03 Forms of Proxy 3.01(b) HMRC 4.03 HMRC Clearance 4.03 Indemnified Party 7.03(b) Intended U.S. Tax Treatment 8.07(b) internal controls 4.07(f) Leases 4.20 Maximum Amount Section 2.10(e7.03(c) Indemnifying Party Section 8.3(aMHRA 4.14(a) Instrument Section 2.12(cNasdaq 4.03 New Company Plans 8.03(b) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Non-U.S. Plan 4.17(j) Offer Document 8.06(b)(i) Other Required Filing 3.01(c) Panel 4.25 Parent Preamble Parent Disclosure Adverse Recommendation Change 8.04 Parent Approval Time 7.02(b) Parent Board Recitals Parent Board Recommendation 5.02(b) Parent Material Contract 5.14(a) Parent Option 2.03(a) Parent Organizational Documents 5.01 Parent Registered IP 5.17(a) Parent Regulatory Agency 5.13(a) Parent Regulatory Permits 5.13(a) Parent RSU 2.03(c) Parent SEC Documents 5.06(a) Parent Share Issuance 3.01(a) Parent Stockholder Meeting 3.01(a) Parent Stockholders 3.01(a) Parent Termination Payment 10.03(b) Parties Preamble Per ADS Share Deliverable 2.01(a) PHSA 4.14(a) Proxy Statement 3.01(a) Real Properties 4.20 Registration Statement 8.06(b)(i) Regulation S-K 4.10 Schedule Article V Parent Indemnified Parties Section 8.2(a)(i14D-9 8.06(b)(ii) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(aScheme Document Annex 3.01(a) Proceeding Section 4.17 Royalties Section 2.10(hScheme Technical Defect 3.05(b)(i) Second Milestone Section 2.10(fRequest 8.02(c) Second Milestone Payment Amount Section 2.10(fShare Consideration 2.02(a) Stockholder Consent Share Deliverable 2.02(a) Takeover Code Recitals Stockholder Representative Preamble Super Majority Section 2.12(bTechnical Revision 3.05(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(gTransaction Recitals Transaction Documentation 3.01(d) Third Milestone Payment Amount Section 2.10(gTransaction Litigation 8.08 Transfer Taxes 11.04 SCHEME OF ARRANGEMENT (under Part 26 of the Companies Act 2006) THE SCHEME SHAREHOLDERS (as hereinafter defined)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Acquisition Sub Preamble Acquisition Sub Stockholder Approval Section 6.2(e) Agreement Preamble Biogen Idec License Agreement Certificates Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a3.4(b) Closing Section 2.3 Closing Date Section 2.3 Commitment Letters Section 5.5(a) Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Group Section 2.13 6.4(a) Company Indemnified Parties Intellectual Property Section 8.2(a)(ii4.13(a) Contracts Company Options Section 4.8(a3.2(a) Covered Party (PartiesCompany SEC Documents Section 4.7(a) Company Stockholders Meeting Section 8.2(a)(ii6.2(d) Damages Consent Section 8.2(a)(i4.6 Dissenting Shares Section 3.3 ERISA Affiliate Section 4.16(a) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Employee Plans Section 4.13(a4.16(a) ERISA Affiliate Equity Commitment Letters Section 4.13(a5.5(b) Finally Determined Exchange Agent Section 8.5(b3.4(a) First Milestone Exchange Fund Section 2.10(e3.4(a) First Milestone Payment Amount HLHZ Section 2.10(e4.21 Indemnified Officers Section 6.8(a) Indemnifying Party Lenders Section 8.3(a5.5(a) Instrument Licenses Section 2.12(c4.13(e) Material Contracts Section 4.10(a) Maximum Premium Section 6.8(b) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Consideration Section 3.4(a) Non-qualified Employee Plan Section 4.16(h) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Pension Plan Section 8.2(a)(i4.16(d) parties Preamble Payee Per Share Merger Consideration Section 8.5 Payor 3.1(a) Proxy Statement Section 8.5 Per Diem Taxes Section 8.7(a6.2(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Required Cash Amount Section 2.10(f5.5 Section 409A Section 4.16(h) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Shares Section 2.12(b3.1(a) Surviving Corporation Section 2.1 Third Milestone Transaction Financing Section 2.10(g5.5(a) Third Milestone Payment Amount Voting Company Debt Section 2.10(g4.3(a) Welfare Plan Section 4.16(d)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below. Location of AAA Section hereof in which such term is defined: 12.5(c) Affiliates Section 7.17 Agreement Preamble Biogen Idec License Agreement of Merger Section 2.3 ▇▇▇▇▇▇ Employment Agreement Section 4.7 Biogen Idec Supply Agreement 11.3(w) Basket Section 4.7 Books and Records 12.2(c)(i) CCC Recital B CERCLA Section 2.12(f)(2) Claim Notice Section 8.3(a12.2(c)(iii) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Closing Date Severance Working Capital Section 3.11(a) Closing Date Working Capital Section 3.3(a) COBRA Section 7.14(e) Company Preamble Company 401(K) Plan Section 10.7(d) Company Board Recommendation Section 7.3(a) Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Recital A Company Indemnified Parties Section 8.2(a)(ii12.2(b) Contracts Company Indemnified Party Section 4.8(a12.2(b) Covered Company Indemnifying Parties Section 12.2(a) Company Indemnifying Party (PartiesSection 12.2(a) Contingent Purchase Price Payment Section 8.2(a)(ii3.4(d) CTS Section 11.3(v) Customers Section 7.11(a) Damage Payment Section 12.2(d) Damages Section 8.2(a)(i12.2(a) DGCL Determination Date Section 2.1 Document Retention Period 3.3(b) Disclosure Letter Article VII Dispute Notice Section 2.12(f)(23.4(b) Drug Regulatory Agency Dissenting Shareholder Section 4.25 3.6(a) Dissenting Shares Section 3.6(a) Effective Time Section 2.2 2.3 Environmental Law Section 7.18 ERISA Section 4.13(a7.14(a) ERISA Affiliate Section 4.13(a7.14(a) Finally Determined Escrow Section 8.5(b3.7(a) Escrow Agreement Section 3.7(a) Estimated Severance Working Capital Section 3.10 Estimated Severance Working Capital Statement Section 3.10 Estimated Working Capital Section 3.2 Estimated Working Capital Statement Section 3.2 Excess Payments Section 3.6(d) Expenses Section 10.6 Final Net Sales Statement Section 3.4(c) First Milestone Release Date Section 2.10(e3.7(a)(i) First Milestone Payment Amount GAAP Section 2.10(e7.4(b) Indemnifying Party Governmental Entity Section 8.3(a7.3(b) Instrument Hazardous Substance Section 2.12(c7.18 Insurance Policies Section 9.1 Intellectual Property Rights Section 7.19(a) Interim Balance Sheet Section 7.4(a) Interim Financial Statements Section 7.4(a) KLO Preamble KLO Agreement of Merger Section 2.1 4.3 KLO Board Recommendation Section 7.3(a) KLO Dissenting Shareholder Section 4.9(a) KLO Dissenting Shares Section 4.9(a) KLO Excess Payments Section 4.9(d) KLO Merger Certificate Recital D KLO Merger Effective Time Section 2.2 4.3 KLO Merger Sub Preamble KLO Required Shareholder Vote Section 7.12 KLO Surviving Entity Section 4.1 Liens Section 7.2(f) Material Agreement Section 7.13(a) Merger Recital B Merger Sub Preamble MT Recital E MT Payment Date Section 5.2(b) MT Purchase Agreement Section 5.1 MT Purchase Price Section 5.2(a) MT Stock Section 5.1 Net Sales Statement Section 3.4(a) Notice Section 12.3(a) Notice of Set-Off Dispute Section 3.5 Objection Notice Section 12.3(c) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i12.2(a) parties Preamble Payee Parent Indemnified Party Section 8.5 Payor 12.2(a) Parent Indemnifying Parties Section 8.5 Per Diem 12.2(b) Parent Indemnifying Party Section 12.2(b) Parent Objection Notice Section 12.3(d) Percentage of Contingent Purchase Price Payment Section 3.4(d) Permits Section 7.8(a) Post-Closing Tax Period Section 9.2(d) Pre-Closing Return Section 9.2(d) Real Property Section 7.16(a) Required Shareholder Vote Section 7.12 Second Release Date Section 3.7(a)(ii) Seller Representative Letter Section 3.8(g) Selling Entity Employees Section 7.20(b) Set-Off Notice Section 3.5 Set-Off Review Period Section 3.5 Severance Working Capital Statement Section 3.11(a) Straddle Period Section 12.2(a)(vi) Surviving Entity Section 2.1 Tax Contest Section 9.2(d) Third Party Claim Section 12.4(a) Third Party Notice Section 12.4(a) Transfer Taxes Section 8.7(a9.2(e) Proceeding Violation Section 4.17 Royalties 7.3(c) Working Capital Statement Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g3.3(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 2004 Plan Section hereof in which such term is defined: 2.4 2009 Plan Section 2.4 Acceptance Time Section 1.1(b) Agreement Preamble Biogen Idec License Agreement Annex I Section 4.7 Biogen Idec Supply Agreement 1.1(a) ARRA Section 4.7 Books and Records 3.14(k) Balance Sheet Section 2.12(f)(23.9(b) Claim Notice Book-Entry Shares Section 8.3(a2.2(b) Breakup Fee Section 7.3(b) Certificate of Merger Section 1.5 Certificates Section 2.2(b) Change of Board Recommendation Section 5.4(b) Closing Section 2.3 1.5 Closing Date Section 2.3 1.5 COBRA Section 3.14(k) Company Preamble Company Board Recitals Company Board Recommendation Recitals Company Bylaws Section 3.2 Company Charter Section 3.2 Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Preamble to Article IV III Company Expenses Schedule Representatives Section 2.13 5.3(a) Company Securities Section 3.3(a) Company Stockholder Approval Section 3.4(b) Comparable Carrier Section 5.16 Continuing Directors Section 1.3(b) DGCL Recitals Dissenting Shares Section 2.3 DOJ Section 5.8 D&O Insurance Section 5.16 Effective Time Section 1.5 Equivalent Coverage Section 5.16 ERISA Affiliate Section 3.14(a) Exchange Act Section 1.1(a) Expiration Date Section 1.1(d) Financial Advisor Section 3.22 FTC Section 5.8 Go-Shop Party Section 5.4(b) Go-Shop Period Termination Date Section 5.4(a) Holding Company Recitals Indemnification Agreements Section 5.16 Indemnified Parties Section 8.2(a)(ii5.16 Initial Expiration Date Section 1.1(d) Insurance Policies Section 3.20 Insured Persons Section 5.16 IP Contracts Section 4.8(a3.19(e) Covered Party (PartiesLeased Real Property Section 3.16(b) Material Contracts Section 8.2(a)(ii3.13(a) Damages Material Leased Real Property Section 8.2(a)(i3.16(b) DGCL Material Real Property Leases Section 2.1 Document Retention Period Section 2.12(f)(23.16(d) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)5.16

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Acquired Assets Acquired Assets Permits Acquired Assets Regulatory Filings Aggregate Threshold Agreed Amount Agreement and a reference to the Antitrust Approvals Assigned Contracts Assigned IP Contracts Assumed Liabilities Assumption Agreements Bill of Sale Burdensome Term or Condition Section hereof in which such term is defined: Agreement 1.01(a) Section 2.12(a) Section 2.12(a) Section 6.05(b)(ii) Section 6.04 (b) Preamble Biogen Idec License Agreement Section 4.7 Biogen Idec Supply Agreement 4 .03(b) Section 4.7 Books and Records 1.01(a)(iv) Section 2.12(f)(21.01(a)(iv) Section 1.01(d) Section 1.01(d) Section 1.03(b)(iii) Section 4 .03(f) 49 Ame ric as 9 2 4 2 5 1 0 0 Buyer Preamble Buyer FDA Letter Section 5.03(e) Buyer Group Section 1.01(a) Buyer Indemnified Parties Section 6.02 Buyer Orphan Designation Letter Section 5.03(e) Cap Section 6.05(b)(i) CF Enterprise Recitals Claim Notice Section 8.3(a6.04 (b) Claimed Amount Section 6.04 (b) Closing Section 2.3 1.03(a) Closing Date Section 2.3 Company 1.03(a) Confidentiality Agreement Section 4 .02 Contingent Payment Section 1.02(b) CTAs Section 2.10(a)(viii) DOJ Section 4 .03(a) Electronic Delivery Section 10.07 Excluded Assets Section 1.01(b) Excluded Liabilities Section 1.01(e) FDA Section 2.12(a) FDCA Section 2.12(a) FTC Section 4 .03(a) Fundamental Representations Section 6.01(a) Guarantor Preamble Company Common Stock HSR Act Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.05(c) Indemnified Party Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party 6.04 (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(ea) Indemnifying Party Section 8.3(a6.04 (a) Instrument IP Assignment Agreements Section 2.12(c1.03(b)(iv) Merger Material Contract Section 2.1 Merger Certificate 2.10(a) MTAs Section 2.2 Merger Sub 2.10(a)(viii) NDAs Section 2.10(a)(viii) Non‑Compete Period Section 9.05(a) Outside Date Section 7.01(f)(ii) Parties Preamble Parent Party Preamble Parent PHSA Section 2.12(a) Pre‑Closing Period Section 4 .01(a) Research and Testing Agreement Recitals Registered Business IP Section 2.09(a) Regulatory Authority Section 2.12(a) Regulatory Filings Section 4 .03(a) Related Agreements Section 2.03 Restricted Names Section 9.02 Safety Notice Section 2.12(d) Ame ric as 9 2 4 2 5 1 0 0 Seller Preamble Seller Board Section 2.03 Seller Board Approval Section 2.20 Seller Change of Recommendation Section 4 .07(c) Seller Disclosure Schedule Letter Article V Parent II Seller FDA Letter Section 5.02(f) Seller Indemnified Parties Section 8.2(a)(i6.03 Seller Orphan Designation Letter Section 5.02(f) parties Preamble Payee Supplement Section 8.5 Payor 4 .04 Termination Fee Section 8.5 Per Diem 7.02(b) Third Party Claim Section 6.04 (a) Third Party IP Section 2.09(f) Transfer Taxes Section 8.7(a8.01(a) Proceeding Transferred IP Section 4.17 Royalties 1.01(a)(ii) Transferred IP Documentation Section 2.10(h1.01(a)(iii) Second Milestone Transferred Permits Section 2.10(f1.01(a)(vi) Second Milestone Payment Amount Transition Services Agreement Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g1.03(b)(vii)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement Agreement, as indicated below: “Agreement” Preamble “Alternative Acquisition Agreement” Section 5.5(d) “Bankruptcy and a reference to the Equitable Exceptions” Section hereof in which such term is defined: Agreement 3.3(a) “Certificate of Merger” Section 1.3 “Certificates” Section 2.2(b) “Change of Board Recommendation” Section 5.5(d) “Claim” Section 5.10(a) “Closing” Section 1.2 “Closing Date” Section 1.2 “Common Shares” Section 2.1(a) “Common Share Merger Consideration” Section 2.1(a) “Company” Preamble Biogen Idec License Agreement “Company Benefit Plan” Section 4.7 Biogen Idec Supply Agreement 3.12(a) “Company Board” Section 4.7 Books and Records 3.3(b) “Company Board Recommendation” Section 2.12(f)(25.2(c) Claim Notice “Company Bylaws” Section 8.3(a3.1(b) Closing “Company Certificate” Section 3.1(b) “Company Disclosure Schedule” Article 3 “Company Financial Advisor” Section 3.22 “Company Financial Statements” Section 3.8(c) “Company Intellectual Property” Section 3.17(b) “Company Material Contract” Section 3.14(a) “Company Options” Section 2.3 Closing Date “Company Permits” Section 3.7(a) “Company Representatives” Section 5.4(a) “Company Rights Agreement” Section 3.3(b) “Company Rights Agreement Amendment” Section 3.3(b) “Company SEC Documents” Section 3.8(a) “Company Stock Option Plans” Section 2.3 “Company Preamble Company Common Stock Stockholder Approval” Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 3.4 “Confidentiality Agreement” Section 2.13 Company Indemnified Parties 5.4(b) “Continuing Employees” Section 8.2(a)(ii5.9(a) Contracts “D&O Insurance” Section 4.8(a5.10(b) Covered Party (Parties“DGCL” Section 1.1 “Dissenting Shares” Section 2.1(f)(i) “Effective Time” Section 8.2(a)(ii) Damages 1.3 “ERISA” Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g3.12(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: 401(k) Termination Date Section 7.7(c) Acceptance Time Section 1.1(f) Adjusted RSU Section 3.3(d) Agreement and a reference to the Annex C, Preamble Arrangements Section hereof in which such term is defined: Agreement Preamble Biogen Idec License Agreement 7.13 Base Amount Section 4.7 Biogen Idec Supply Agreement 7.4(c) Book-Entry Shares Section 4.7 Books and Records 3.2(b)(ii) Cancelled Shares Section 2.12(f)(23.1(b) Claim Notice Certificate of Merger Section 8.3(a2.3 Certificates Section 3.2(b)(i) Change of Recommendation Section 6.3(a) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Annex C, Preamble Company Acquisition Agreement Section 6.3(a) Company Benefit Plan Section 4.10(a) Company Board of Directors Recitals Company Board Recommendation Recitals Company Capitalization Date Section 4.2(a) Company Common Stock Recitals Company Compensation Committee Section 2.8 7.13 Company Disclosure Schedule Letter Article IV Company Expenses Schedule Leases Section 2.13 4.16 Company Permits Section 4.9(b) Company Preferred Stock Section 4.2(a) Company Registered Intellectual Property Section 4.14(a) Company SEC Documents Section 4.5(a) Company Stockholders Recitals Continuing Employees Section 7.7(b) Converted Shares Section 3.1(b) Current ESPP Offering Periods Section 3.3(e) DGCL Recitals DOJ Section 7.2(b) Effective Time Section 2.3 Enforceability Limitations Section 4.3(c) Exchange Agent Section 3.2(a) Exchange Fund Section 3.2(a) Form S-4 Section 1.1(g)(ii) Fractional Share Consideration Section 3.1(a) FTC Section 7.2(b) GAAP Section 4.5(b) ▇▇▇▇▇▇▇ ▇▇▇▇▇ Section 4.22 ICT Infrastructure 36 Indemnified Parties Section 8.2(a)(ii7.4(a) Intervening Event Section 6.3(d) IP Contracts Section 4.8(a4.14(h) Covered Party (PartiesMaterial Contract Section 4.17(a) Material Customer Section 8.2(a)(ii4.19(a) Damages Material Customer Agreement Section 8.2(a)(i4.19(a) DGCL Material Reseller Section 2.1 Document Retention Period 4.19(c) Material Reseller Agreement Section 2.12(f)(24.19(c)Section 4.19(a) Drug Regulatory Agency Material Supplier Section 4.25 Effective Time 4.19(a) Material Supplier Agreement Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c4.19(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate 3.1(a) Minimum Condition Section 2.2 Merger Sub 1.1(a)(i) OFAC Section 4.9(e) Offer Recitals Offer Documents Section 1.1(g)(i)(A) Offer to Purchase Section 1.1(a) Outside Date Section 9.1(d) Parent Annex C, Preamble Parent Preamble Capitalization Date Section 5.2(a) Parent Disclosure Schedule Letter Article V Parent Indemnified Governing Documents Section 5.1 Parent Preferred Stock Section 5.2(a) Parent SEC Documents Section 5.5(a) Parties Preamble Party Preamble PTO 33 Purchaser Annex C, Preamble Purchaser Shares Section 3.1(c) Restricted Parties Section 8.2(a)(i4.9(g) parties Preamble Payee ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 8.5 Payor 4.5(a) Schedule 14D-9 Section 8.5 Per Diem Taxes 1.2(b) Schedule TO Section 8.7(a1.1(g)(i)(A) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Standards Body Agreements 36 Surviving Corporation Company Section 2.1 Third Milestone Surviving Company Stock Section 2.10(g3.1(b) Third Milestone Payment Amount Tender and Support Agreement Recitals Termination Fee Section 2.10(g9.2(b)(i) Transactions Recitals willful breach Section 9.2(a) Notwithstanding any other provisions of the Agreement (as defined below) or the Offer, and in addition to (and not in limitation of) Parent’s and Purchaser’s rights to extend, amend or terminate the Offer in accordance with the provisions of that certain Agreement and Plan of Merger, dated as of February 3, 2019 (the “Agreement”) by and among Telsa, Inc., a Delaware corporation (“Parent”), Cambria Acquisition Corp., a Delaware corporation and a wholly owned direct subsidiary of Parent (“Purchaser”), and ▇▇▇▇▇▇▇ Technologies, Inc., a Delaware corporation (the “Company”) (capitalized terms that are used but not otherwise defined in this Annex C shall have the respective meanings ascribed thereto in the Agreement), and applicable Law, and in addition to (and not in limitation of) the obligations and rights of Purchaser to extend the Offer pursuant to the terms and conditions of the Agreement and applicable Law, neither Parent nor Purchaser shall be required to accept for payment or, subject to any applicable rules and regulations of the SEC (including Rule 14e-1(c) promulgated under the Exchange Act (relating to the obligation of Purchaser to pay for or return tendered shares of Company Common Stock promptly after termination or withdrawal of the Offer)), pay for any shares of Company Common Stock that are validly tendered in the Offer and not validly withdrawn prior to the expiration of the Offer in the event that, at any expiration of the Offer:

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: Action Section 4.12 Acceptable Confidentiality Agreement and a reference to the Section hereof in which such term is defined: 6.4(b) Alternative Acquisition Agreement Section 6.4(c)(2) Alternative Financing Section 6.6 Agreement Preamble Biogen Idec License Agreement Anti-Corruption Laws Section 4.7 Biogen Idec Supply Agreement 4.5(b) Bankruptcy and Equity Exception Section 4.7 Books and Records 4.3(a) Cashed-Out Option Section 2.12(f)(23.1(f)(ii) Claim Notice Cayman Companies Law Preamble Certificates Section 8.3(a3.2(c) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 6.4(b)(i) Company Disclosure Schedule Article IV Board Preamble Company Expenses Schedule Financial Advisor Section 2.13 4.3(b) Company Financial Statements Section 4.6(b) Company Group Section 8.2(e)(i) Company Intellectual Property Section 4.14(b) Company Material Contract Section 4.11(b) Company Plan(s) Section 4.9(a) Company Recommendation Section 4.3(b) Company SEC Filings Section 4.6(a) Company Shareholders Meeting Section 6.2(e)(i) Company Subsidiary Section 4.1 Company Workers Section 4.14(f) D&O Insurance Section 6.12(b) Dissenter Rights Section 3.1(e) Dissenting Shares Section 3.1(e) Dissenting Shareholders Section 3.1(e) Effective Time Section 2.3 Equity Commitment Letters Section 5.6 Equity Financing Section 5.6 Equity Financing Commitments Section 5.6 End Date Section 8.1(b)(i) Exchange Fund Financing Financing Commitments Section 3.2(b) Section 5.6(a) Section 5.6(a) Guarantor Preamble HKIAC Section 9.7(c) Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Independent Committee Preamble Investments Section 4.8(a4.2(d) Covered Party (PartiesLeased Real Property Section 4.17(b) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Limited Guarantee Preamble Merger Section 2.1 Merger Certificate Section 2.2 Preamble Merger Sub Preamble Notice Period Section 6.4(d)(iii) Owned Real Property Section 4.17(a) Parent Preamble Parent Disclosure Group Parent Material Adverse Effect Section 8.2(e)(i) Section 5.4(a) Party Preamble Paying Agent Section 3.2(a) Per ADS Merger Consideration Section 3.1(b) Per Share Merger Consideration Section 3.1(b) Plan of Merger Section 2.3 Proxy Statement Section 6.2(a) Registrar of Companies Section 2.3 Rollover Securities Preamble SAFE Rules and Regulations Section 4.5(c) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i4.4(b) parties Services Provider Section 4.14(g) Support Agreement Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Company Transactions Section 2.1 Third Milestone Preamble Transaction Litigation Section 2.10(g) Third Milestone Payment Amount 6.8 Uncertificated Shares Section 2.10(g3.2(c)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Adverse Recommendation Change Section hereof in which such term is defined: 6.02(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.02(c) Arbitrator Section 4.7 Books and Records 10.08(b) Assumed Option Section 2.12(f)(23.03(b) Claim Notice Base Premium Section 8.3(a7.05(d) Benefit Plan Section 4.15(b) BlueCity Holdings Limited Section 2.06 Closing Section 2.3 2.02 Closing Date Section 2.3 2.02 Company Preamble Company Common Stock Board Recitals Company Board Recommendation Recitals Company Equity Interests Section 2.8 4.02(b) Company Disclosure Schedule Article IV Group Section 9.02(h) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.02(e) Competing Proposal Section 8.2(a)(ii) Contracts Section 4.8(a6.02(g) Covered Party (PartiesPersons Section 7.05(a) Deposit Agreement Section 8.2(a)(ii3.05 Depositary Section 3.05 Dissenting Shareholders Section 3.06(a) Damages Dissenting Shares Section 8.2(a)(i3.06(a) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.03 Enforceability Exceptions Section 4.03 Equity Commitment Letter Section 5.05(a) Equity Financing Section 5.05(a) Exchange Ratio Section 3.03(b) Financial Statements Section 4.06(b) HKIAC Section 10.08(b) HKIAC Rules Section 10.08(b) Indemnification Agreements Section 7.05(a) Insurance Policies Section 4.18 Intervening Event Section 6.02(e) Legal Proceeding Section 5.08 Limited Guarantee Recitals Material Contracts Section 4.16(a)(xiv) Merger Recitals Merger Consideration Section 3.02(a) Merger Consideration Fund Section 3.02(a) Merger Sub Preamble Nasdaq Section 4.02(c) Non-Required Remedy Section 7.02(d) Operating Subsidiary Section 4.16(a)(xi) Parent Preamble Parent Group Section 9.02(h) Parent Termination Fee Section 9.02(f) Parties Preamble Party Preamble Paying Agent Section 3.02(a) Per ADS Merger Consideration Section 3.01(b) Per Share Merger Consideration Section 3.01(a) Plan of Merger Section 2.03 PRC Subsidiaries Section 4.09(a) Proxy Statement Section 4.05 Record ADS Holders Section 6.04(a) Record Date Section 6.04(a) Registrar of Companies Section 2.03 Rollover Shareholders Recitals S▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.06(a) Schedule 13E-3 Section 6.03(a) SEC Documents Section 4.06(a) Securities Act Section 4.06(a) Share Certificates Section 3.02(b)(i) Social Insurance Section 4.15(k) Special Committee Recitals Superior Proposal Section 6.02(h) Support Agreement Recitals Surviving Company Section 2.01 Takeover Statute Section 4.23 Tax Returns Section 4.13(a) ERISA Affiliate Transaction Litigation Section 4.13(a7.08 Transactions Recitals U.S. GAAP Section 4.06(b) Finally Determined Uncertificated Shares Section 8.5(b3.02(b)(i) First Milestone VIE Contracts Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g4.09(c)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement: 401(k) Termination Date Section hereof in which such term is defined: 7.7(c) Agreement Preamble Biogen Idec License Agreement AI Technology Section 4.7 Biogen Idec Supply Agreement 4.14(f) Alternative Financing Section 4.7 Books and Records 7.13(g) Applicable Antitrust Laws Section 2.12(f)(28.1(e) Claim Notice Approvals Section 8.3(a7.2(a) Aggregate Spread Value Section 3.1(a)(i)(D) Alternative Financing Section 7.13(g) Base Amount Section 7.4(c) Book-Entry Shares Section 3.1(a)(i)(E) Cancelled Shares Section 3.1(a)(ii) Capitalization Date Section 4.2(a) Cash Consideration Section 3.1(a)(i)(A) Cash Election Section 3.1(a)(i)(A) Cash Election Number Section 3.2(a)(ii)(A) Cash Election Shares Section 3.1(a)(i)(A) Certificate Section 3.1(a)(i)(E) Certificate of Merger Section 2.3 Change of Recommendation Section 6.3(a) Citi Section 4.22 Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Acquisition Agreement Section 6.3(a) Company Board of Directors Recitals Company Board Recommendation Recitals Company Common Stock Equivalent Section 2.8 3.1(a)(i)(D) Company Disclosure Schedule Letter Article IV Company Expenses Schedule Leases Section 2.13 4.16(b) Company Permits Section 4.9(b) Company Preferred Stock Section 4.2(a) Company RSU Stock Section 3.1(a)(i)(D) Company SEC Documents Section 4.5(a) Company Stockholder Approval Section 4.3(a) Company Stockholders Recitals Company Stockholders Meeting Section 7.12(c)(ii) Continuing Employees Section 7.7(a) Copyrights Section 1.1 COVID-19 Measures Section 1.1 Credit Facility Terminations Section 7.14 Current ESPP Offering Period Section 3.3(f) Debt Commitment Letter Section 5.12(a) Definitive Agreements Section 7.13(g) DGCL Recitals DGCL 262 Section 3.1(b) Dissenting Shares Section 3.1(b) DOJ Section 7.2(f) Effective Time Section 2.3 Election Section 3.2(b)(i) Election Deadline Section 3.2(b)(iv) Election Period Section 3.2(b)(iii) Enforceability Limitations Section 4.3(b) Exchange Agent Section 3.2(c) Exchange Fund Section 3.2(d) Exchange Ratio Section 3.1(a)(i)(D) Excluded Shares Section 3.1(a)(iv) Financing Section 5.12(a) Financing Agent Section 7.14 Form of Election Section 3.2(b)(ii) Form S-4 Section 4.21 Fractional Share Cash Amount Section 3.1(d) FTC Section 7.2(f) GAAP Section 4.5(b) ▇▇▇▇▇▇▇ ▇▇▇▇▇ Section 4.25 HIPAA Section 1.1 Holder Section 3.2(b) Indemnified Parties Section 8.2(a)(ii7.4(a) Information Statement Section 4.4(a) Infringing Section 4.14(c) Integration Committee Section 7.1(c) Integration Plan Section 7.1(c) Leased Real Property Section 4.16(b) Letter of Transmittal Section 3.2(e) Malicious Code Section 4.15(c) Material Contracts Section 4.8(a4.17(a) Covered Party (PartiesMaterial Customer Section 4.19(a) Material Customer Agreement Section 8.2(a)(ii4.19(a) Damages Material Supplier Section 8.2(a)(i4.19(b) DGCL Material Supplier Agreement Section 2.1 Document Retention Period 4.19(b) Maximum Cash Share Number Section 2.12(f)(23.2(a)(i) Drug Regulatory Agency Maximum Parent Stock Number Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c3.2(a)(i) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 3.1(a)(i)(D) Merger Sub Preamble Multiemployer Plan Section 4.10(d) New Plans Section 7.7(b) Net Option Stock Section 3.1(a)(i)(D) Non-Election Shares Section 3.1(a)(i)(C) Non-Recourse Party Section 10.14 Old Plans Section 7.7(b) -17- Outside Date Section 9.1(d) Parent Preamble Parent Disclosure Schedule Letter Article V Parent Indemnified Governing Documents Section 5.1 Parent Permits Section 5.9(b) Parent Preferred Stock Section 5.2(a) Parent SEC Documents Section 5.5(a) Parties Preamble Party Preamble Patents Section 1.1 Payoff Letter Section 7.14 Per Share Cash Consideration Section 3.1(a)(i)(D) Prohibited Modification Section 7.13(g) Proxy Statement Section 4.4(a) Relevant Matters Section 10.9(a) Replacement Target Compensation Section 6.1(a)(2)(vi) Restricted Parties Section 8.2(a)(i4.10(f) parties Preamble Payee ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 8.5 Payor 4.5(a) Shortfall Number Section 8.5 Per Diem Taxes 3.2(a)(ii)(B) Stock Consideration Section 8.7(a3.1(a)(i)(B) Proceeding Stock Election Section 4.17 Royalties 3.1(a)(i)(B) Stock Election Shares Section 2.10(h3.1(a)(i)(B) Second Milestone Support Agreement Recitals Trade Secrets Section 2.10(f1.1 WARN Act Section 4.11(b) Second Milestone Payment Amount Written Consent Delivery Time Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g7.12(a)

Terms Defined Elsewhere. The following is a list of additional terms As used in this Agreement, the following capitalized terms are defined in this Agreement and a reference to as referenced in the following table: Antitrust Authority Section hereof in which such term is defined: Agreement Preamble Biogen Idec License Agreement 6.9(b) Antitrust Laws Section 4.7 Biogen Idec Supply Agreement 6.9(b) BC Registrar Section 4.7 Books and Records 5.4 Book-entry Shares Section 2.12(f)(23.3(b)(i) Claim Notice Cap Amount Section 8.3(a6.10(b) Certificate of Merger Section 2.6(b) Certificates Section 3.3(b)(i) Closing Section 2.3 Closing Date 2.6(a) Company Board Recitals Company Board Recommendation Section 2.3 4.3(a) Company Preamble Company Common Capital Stock Section 2.8 4.2(a) Company Change of Recommendation Section 6.3(d) Company Disclosure Schedule Letter Article IV Company Expenses Schedule Easement Real Property Section 2.13 4.14(a) Company Indemnified Parties Intellectual Property Section 8.2(a)(ii4.15 Company Leased Real Property Section 4.14(a) Contracts Company Owned Real Property Section 4.8(a4.14(a) Covered Party (PartiesCompany Permits Section 4.9 Company Plans Section 4.10(a) Company Real Property Easements Section 8.2(a)(ii4.14(a) Damages Company Real Property Section 8.2(a)(i4.14(e) DGCL Company RSU Consideration Section 2.1 Document Retention Period 3.2(a)(i) Company Shareholders’ Meeting Section 2.12(f)(24.4 Company Voting Agreement Section 4.2(b) Drug Regulatory Agency Competition Law Notifications Section 4.25 6.9(b) Confidentiality Agreement Section 6.8(b) Creditors’ Rights Section 4.3(a) Parent Conversion Section 2.4 Divestiture Action Section 6.9(c) D&O Insurance Section 6.10(b) Effective Time Section 2.2 ERISA 2.6(b) Election of Directors Section 4.13(a2.10(a) ERISA Affiliate Eligible Shares Section 4.13(a3.1(a)(ii)(A) Finally Determined End Date Section 8.5(b8.1(b)(ii) First Milestone Exchange Agent Section 2.10(e3.3(a) First Milestone Payment Amount Exchange Fund Section 2.10(e3.3(a) Indemnifying Party Exchange Ratio Section 8.3(a3.1(a)(ii)(A) Instrument HSR Act Section 2.12(c4.4 Indemnified Liabilities Section 6.10(a) Indemnified Persons Section 6.10(a) Information Circular Section 6.7 Interim Period Section 6.1(a) Letter of Transmittal Section 3.3(b)(i) Merger Section 2.1 Recitals Merger Certificate Sub Board Recitals Name Change Section 2.2 Merger Sub Preamble New Parent Preamble Option Section 3.2(a)(ii)(A) New Parent Warrant Section 3.2(b) Non-Voting Parent Common Shares Section 2.3 Parent Board Recitals Parent Disclosure Schedule Documents Section 5.5(a) Parent Disclosure Letter Article V Parent Indemnified Parties Financial Statements Section 8.2(a)(i5.5(b) parties Preamble Payee Parent Balance Sheet Date Section 8.5 Payor 5.6(a) Parent Common Shares Recitals Parent Material Leased Real Property Section 8.5 5.11 Parent Material Real Property Lease Section 5.11 Parent Owned Real Property Section 5.11 Parent Permits Section 5.9(a) Parent Share Capital Section 5.2(a) Parent Shareholders’ Meeting Section 6.6 Parent Stock Issuance Recitals Parent Voting Agreement Section 6.7(c) Per Diem Taxes Share Merger Consideration Section 8.7(a3.1(a)(ii)(A) Proceeding Registration Statement Section 4.17 Royalties 4.8 Share Amendment Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) 2.3 Surviving Corporation Section 2.1 Third Milestone Tail Period Section 2.10(g6.10(b) Third Milestone Payment Amount Terminable Breach Section 2.10(g8.1(b)(iii) Transaction Expenses Section 8.3(a)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Accelerated Options Section 2.12(a) Acquisition Sub Preamble Affected Employees Section 6.9 Agreement Preamble Biogen Idec License Agreement Amended Severance Policy Section 4.7 Biogen Idec Supply Agreement 6.9 BRINC Preamble BRLLC Preamble BRLLC Expenses Section 4.7 Books and Records 2.10(a) Certificate of Merger Section 2.12(f)(22.3 Change of Control Payment Statement Section 2.10(c) Change of Control Payments Section 2.10(c) Claim Notice Section 8.3(a10.4(a) Closing Section 2.3 2.4(a) Closing Date Section 2.3 Company Preamble Company Common Stock 2.4(a) Closing Working Capital Section 2.8 Company 2.14(a)(i) Confidential Information Section 6.5(a)(i) Copyright Office Section 6.16(b) Customer Information Section 3.16 D&O Tail Section 6.19(b) Damages Section 10.2(a) Decline Date Section 2.14(e) Delivering Party Section 6.5(a)(ii) DGCL Recitals Disclosure Schedule Article IV Company Expenses Schedule III Dispute Notice Section 2.13 Company 10.4(b) Disputed Line Items Section 2.14(e) Dissenting Shares Section 2.16(a) Dissenting Shares Reduction Amount Section 2.16(b) DOJ Section 6.6 Effective Time Section 2.3 Environmental Costs Section 3.14(c)(ii) Equityholder Indemnified Parties Section 8.2(a)(ii10.2(b) Estimated Working Capital Section 2.14(b) Estimated Working Capital Deficiency Section 2.14(c) EU Personal Data Section 5.8 Excess Negative Adjustment Amount Section 2.14(g) Expense Statement Section 2.10(a) Final Tax Returns Section 9.2(a)(i) Form Working Capital Statement Section 2.14(a)(i) FTC Section 6.6 Fundamental Representation Distributions Section 10.2(d) Funded Indebtedness Statement Section 2.10(d) Gannett Preamble General Survival Date Section 10.1 Indemnified Executive Section 6.19(a) Indemnity Escrow Amount Shortfall Section 2.14(g) Information Statement Section 6.3(a) Initial Calculation Section 2.14(d) Insolvent Section 5.6 Kenexa Indemnified Parties Section 10.2(a) Kenexa Technology Preamble Labor Union Section 3.11(a)(i) Letter of Transmittal Section 2.11(b) Material Client Contract Section 3.10(a)(i) Material Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c3.10(a) Merger Section 2.1 Merger Certificate 2.2 Negative Adjustment Amount Section 2.2 Merger Sub Preamble 2.14(f) Notice of Disagreement Section 2.14(e) Off-the-Shelf Software Section 3.15(c) Organizational Documents Section 2.4(c)(ii) Outside Date Section 8.1(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Positive Adjustment Amount Section 2.10(f2.14(f) Stockholder Consent Recitals Stockholder Post Preamble Privacy Policy Section 3.16 Qualified Plan Section 3.11(b)(ii)(I) Receiving Party Section 6.5(a)(iii) Registered Intellectual Property Section 3.15(e) Regulatory Agreements Section 3.25(b) Relevant Group Section 3.13(a)(i) Representative Preamble Super Majority Required Exchange Documents Section 2.12(b2.11(b) Requisite BRINC Vote Section 3.3(b) Safe Harbor Section 5.8 Selling Members Recitals Settlement Accountants Section 2.14(e) Severance Payment Statement Section 2.10(b) Severance Payments Section 2.10(b) Straddle Periods Section 9.2(a)(ii) Surviving Corporation Section 2.2 Takeover Statutes Section 3.25(a)(iii) Tax or Taxes Section 3.13(a)(ii) Tax Return Section 3.13(a)(iii) Terminated Plan Section 3.11(b)(i) Transactions Section 2.4(a) Transfer Section 2.1 Third Milestone Transfer Taxes Section 2.10(g3.13(a)(iv) Third Milestone Payment Amount Tribune Preamble USPTO Section 2.10(g6.16(b) WARN Act Section 3.11(a)(i)

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: Accounting Firm Section 2.4(b) Agreement Preamble Biogen Idec License Antitrust Laws Section 6.2(d) Applicable Limitation Date Section 6.4 Binder Agreement Section 4.7 Biogen Idec Supply Agreement 6.3(a) Buyer Preamble Buyer Released Party Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a) 6.9 Closing Section 2.3 2.5 Closing Date Section 2.3 2.5 Closing Item Section 2.4(a) Closing Statement Section 2.4(a) Company Preamble Company Common Stock Employee Benefit Plan Section 2.8 3.14(a) Company Disclosure Schedule Article IV Company Proprietary Rights Section 3.10(a) Continuing Employees Section 6.13 control Section 1.1 D&O Indemnified Persons Section 6.10(a) D&O Provisions Section 6.10(a) Dispute Notice Section 2.4(b) Estimated Book Value Section 2.3 Estimated Closing Statement Section 2.3 Estimated Indebtedness Section 2.3 Estimated Statutory Surplus Section 2.3 Estimated Transaction Expenses Schedule Section 2.13 Company Indemnified 2.3 Excess Amount Section 2.4(d) Final Book Value Section 2.4(a) Final Indebtedness Section 2.4(a) Final Statutory Surplus Section 2.4(a) Final Transaction Expenses Section 2.4(a) Financial Statements Section 3.4(a) Interests Recitals Investment Guidelines Section 3.16(f)(iii) IRS Section 3.14(a) K&E Section 8.11 Key Employee Offer Letters Recitals Latest Balance Sheet Section 3.4(a) Material Contract Section 3.9(b) New Mandeville Lease Recitals New Plans Section 6.13 Non-Party Affiliates Section 6.15 Outside Date Section 7.1(c) Ordinary Course of Business Section 8.5 Party Preamble Payoff Letters Section 2.6(b)(v)(K) Policies Section 3.15 Post-Closing Representation Section 8.11 Pre-Closing Period Section 6.1(a) 15 Privacy and Information Security Policies Section 3.22(a) Privacy Agreements Section 3.22(a) Regulatory Approvals Section 6.2(a) Released Funds Section 2.4(e) Resolution Period Section 2.4(b) Review Period Section 2.4(b) R&W Insurance Policy Section 6.3(a) Seller Preamble Shortfall Amount Section 2.4(e) Stuatory Statements Section 3.4(b) Tail Policy Section 6.10(b) Transfer Taxes Section 6.5(c) Transition Services Agreement Section 2.6(b)(v)(I) Waived 280G Benefits Section 6.17 Waiving Parties Section 8.2(a)(ii) Contracts 8.11 Withholding Agent Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)2.7

Terms Defined Elsewhere. The following is a list of additional terms As used in this Agreement, the following capitalized terms are defined in this Agreement and a reference to as referenced in the Section hereof in which such term is definedfollowing table: Agreement Preamble Biogen Idec License Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2Bylaws Capitalization Date Change of Recommendation Charter 3.2 5.2(a) Claim Notice Section 8.3(a7.2(d) (i)(F) 3.1 Closing Section 2.3 2.1 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Approvals Company Disclosure Schedule Article IV Letter Company Expenses Schedule Section 2.13 Personal Information Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Recommendation Company Tax Representation Letter Continuation Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 D&O Insurance Delisting Period Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Exchange Fund FDA FDA Licenses Fundamental Action Governmental Antitrust Entity Interim Period Legal Restraint Material Contract Material Customer Material Vendor Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Non-Wholly Owned Subsidiary Notice of Redemption Notice Notice Period Outside Date Parent Parent Approvals Parent DSU Parent Option Parent RSU Parent Tax Representation Letter Parent SAR Parties Permitted Confidentiality Agreement Potential Purchasers Potential Sale Transaction Privacy and Security Measures Privacy-Related Contracts Proxy Statement 2.1 Preamble Parent Preamble Parent Disclosure Schedule 5.4(a) Article V Parent Indemnified Parties Section 8.2(a)(i5.18(l) parties 5.3(b) 7.18(c) 7.11(a) 7.12(b) 7.17(a) 2.2 4.3(a)(i) 5.20(a) 5.20(a) 7.2(d)(iii) 7.6(b)(ii) 7.1(a) 8.1(c) 5.11(a) 5.12(a) 5.12(b) Recitals Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a5.2(f) Proceeding Section 4.17 Royalties Section 2.10(h7.13(a) Second Milestone Section 2.10(f7.2(d)(iii) Second Milestone Payment Amount Section 2.10(f7.2(d)(iii) Stockholder Consent Recitals Stockholder Representative 9.2(a) Preamble Super Majority Section 2.12(b6.4(a) 4.2(f) 4.2(a) 4.2(c) 7.18(c) 4.2(e) Preamble 7.2(b)(i) 7.6(d) 7.6(d) 5.18(k) 5.11(a)(vi) 7.3(a) -2- Stock Ownership Rep Support Agreement Surviving Corporation Section 2.1 Third Milestone Section 2.10(gTax Representation Letters Third-Party Consents 6.8 Recitals 2.3 7.18(c) Third Milestone Payment Amount Section 2.10(g)7.8

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: TERM SECTION ---- ------- 1999 EBITDA Section 2.12(a) ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇ 2.12 (a) 2b Content Section 4.20(a) 2b Marks Section 4.20(a) AAA Section 9.3(b) Act Section 6.13 Additional Merger Consideration Section 2.11(a) Adjustment Event Section 2.14 Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 9.3(b) Auditor Section 4.7 Books and Records 2.11(c) CERCLA Section 2.12(f)(24.13 COTS Section 4.20(i) Cap Section 9.5(b) Claim Notice Section 8.3(a9.3(a) Closing Section 2.3 Closing Conversion Share Amount Section 2.8(a) Closing Date Section 2.3 Common Stock Section 2.8(a) Company Preamble Company Common Shares Section 2.8(a) Contaminant Section 4.20(o) Content Section 4.20(a) Copyrights Section 4.20(a) Damages Section 9.2(a) Designated Software Agreements Section 4.20(m) Disabling Code Section 4.20(o) Disposition Section 6.11 Dispute Notice Section 9.3(b) Distribution Date Section 2.11(b) Earn-Out Amounts Section 2.11(b) TERM SECTION ---- ------- Earn-Out Dollar Amount Section 2.11(a) Effective Period Section 6.13 Effective Registration Average Section 2.8(b) Effective Registration Date Section 2.8(b) Effective Time Section 2.2 Employee Pension Benefit Plan Section 4.14(a) ERISA Section 4.14(a) Exchange Act Section 5.7 Hazardous Materials Section 4.13 Indemnified Party Section 9.3(a) Indemnitor Section 9.3(a) Initial Merger Consideration Section 2.8(a) Initial Shares Section 2.8(b) Initial Stock Price Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.8(a) Intellectual Property Rights Section 2.13 Company Indemnified Parties 4.20(a) IRS Installment Agreement Section 8.2(a)(ii7.3(f) Licensed Intellectual Property Section 4.20(l) Licensed Software Section 4.20(i) Licensed Software Agreements Section 4.20(l) Licensed Technology Agreements Section 4.20(l) Lock-up Period Section 6.11 Marks Section 4.20(a) Material Contracts Section 4.8(a) Covered Party (PartiesMaterial Systems Section 4.20(o) Matrix Section 8.2(a)(ii) Damages 10.12 Maximum Additional Parent Shares Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c2.8(b) Merger Section 2.1 Merger Certificate Articles Section 2.2 Merger Consideration Section 2.8(b) Merger Sub Preamble Multiemployer Plan Section 4.14(a) Other IP Rights Section 4.20(a) Other Licensed Technology Agreements Section 4.20(l) Outside Date Section 8.1(b) Owned Content Copyrights Section 4.20(a) Owned Software Section 4.20(i) Owned Trade Secrets Section 4.20(e) Parent Preamble Parent Disclosure Schedule Article V Financial Statements Section 5.7 Parent Indemnified Parties Section 8.2(a)(i9.2(a) parties Preamble Payee Patents Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a4.20(a) Proceeding Section 4.17 Royalties 4.18 Real Property Section 2.10(h4.5(c) Second Milestone Registration Statement Section 2.10(f6.13 Restricted Parent Shares Section 2.8(c) Second Milestone Payment TERM SECTION ---- ------- Revenue Adjustment Amount Section 2.10(f2.12(c) Stockholder Consent Recitals Stockholder Representative SEC Section 6.13 SEC Documents Section 5.7 Second Revenue Adjustment Amount Section 2.12(c) Settled Matters Section 4.12(b) Shareholders Preamble Super Majority Shareholder Indemnified Parties Section 2.12(b9.2(b) Software Section 4.20(a) Statement Section 2.11(a) Surviving Corporation Section 2.1 Third Milestone Tax Return Section 2.10(g4.12(a) Taxes Section 4.12(a) Third Milestone Payment Party 2b Content Section 4.20(c) Threshold Amount Section 2.10(g)9.5 Trade Secrets Section 4.20(a) Transferable Parent Shares Section 2.8(c) VSCA Section 2.1

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: Accounts Receivable Section 3.4(e) Adverse Recommendation Section 6.2 Agreement Preamble Biogen Idec License Agreement Alternative Company Acquisition Section 4.7 Biogen Idec Supply Agreement 6.3(g)(ii) Alternative Financing Section 4.7 Books and Records 6.11(c) Alternative Vistas Acquisition Section 2.12(f)(26.3(f)(i) Claim Notice Anghami Merger Sub Preamble Anghami Merger Surviving Company Section 8.3(a2.1(b) Cayman Plan of Merger for the Anghami Merger Section 2.1(b) Cayman Plan of Merger for the Vistas Merger Section 2.1(a) CFO Section 2.2(b)(i) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Closing Form 8-K Section 6.4(c) Closing Press Release Section 6.4(c) Communication Policy Section 6.3(h) Company Preamble Company Common Stock Acquisition Proposal Section 2.8 6.3(g)(ii) Company Disclosure Schedule Article IV Class A Shares Section 3.3 Company Expenses Schedule Class C Shares Section 2.13 3.3 Company Closing Statement Section 2.4(a)(i) Company Employee Benefit Plan Section 3.15(a) Company Permits Section 3.17(b) Company Seed Preferred Shares Section 3.3 Company Series A Preferred Shares Section 3.3 Company Series A+ Preferred Shares Section 3.3 Company Shareholders Section 3.3 D&O Claim Section 6.9(a) D&O Entity Section 6.9(a) D&O Indemnification Obligation Section 6.9(d) D&O Indemnified Parties Person Section 8.2(a)(ii6.9(a) Contracts Data Room Section 4.8(a) Covered Party (Parties) 10.5 Dispute Section 8.2(a)(ii) Damages 10.9 Dispute Notice Section 8.2(a)(i) DGCL Section 2.1 Document Retention 10.9 Dispute Resolution Period Section 2.12(f)(210.9 Equity Financing Section 6.11 Financial Statements Section 3.4(a) Drug Regulatory Agency ICDR Section 4.25 Effective Time 10.9 ICDR Rules Section 2.2 ERISA 10.9 Latest Balance Sheet Section 4.13(a3.4(a) ERISA Material Contract Section 3.10(a) Non-Party Affiliate Section 4.13(a10.7 Other Indemnitors Section 6.9(d) Finally Determined Outside Date Section 8.5(b9.1(c) First Milestone Party, Parties Preamble Post-Closing Pubco Board Section 2.10(e2.1(d) First Milestone Payment Amount Pre-Closing Period Section 2.10(e6.3 Registration Statement Section 6.1(a) Indemnifying Party Pubco Preamble Pubco Assumed Option Section 8.3(a2.3(b)(ii) Instrument Public Stockholders Section 2.12(c10.11 Relevant Period Section 3.22 Restrictive Covenant Agreement Recitals Signing Form 8-K Section 6.4(b) Signing Press Release Section 6.4(b) Sponsor Letter Agreement Recitals Registration Rights Agreement Section 8.2(d)(iv) Tail Policy Section 6.9(c) Transactions Recitals Vistas Preamble Vistas Acquisition Proposal Section 6.3(f)(i) Vistas Benefit Plans Section 5.14 Vistas Material Contract Section 5.8 Vistas Merger Section 2.1 Merger Certificate Section 2.2 Recitals Vistas Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Vistas Merger Surviving Company Section 8.2(a)(i2.1(a) parties Preamble Payee Vistas Preferred Shares Section 8.5 Payor 5.2 Vistas Public Securities Section 8.5 Per Diem Taxes 5.15 Vistas Record Date Section 8.7(a6.1(a) Proceeding Vistas SEC Documents Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)5.5

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acceptance Time Section hereof in which such term is defined: 2.01(e) Agreement Preamble Biogen Idec License Agreement Alternative Financing Section 4.7 Biogen Idec Supply Agreement 8.09(b) Alternative Financing Documents Section 4.7 Books and Records 8.09(b) Arbitrator Section 2.12(f)(211.08(b) Claim Notice Base Premium Section 8.3(a8.04(d) Change in the Company Recommendation Section 7.02(b) Closing Section 2.3 3.02 Closing Date Section 2.3 3.02 Company Preamble Company Common Stock Board Recitals Company Board Actions Recitals Company Board Recommendation Recitals Company Equity Interests Section 2.8 5.02(a) Company Disclosure Schedule Article IV Group Section 10.02(d) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 10.02(b) Competing Proposal Section 8.2(a)(ii7.02(d) Contracts Competition Laws Section 4.8(a5.05 Covered Persons Section 8.04(a) Covered Party (PartiesDebt Commitment Letter Section 6.05(a) Debt Financing Source Section 8.2(a)(ii6.05(a) Damages Deposit Agreement Section 8.2(a)(i) DGCL 4.05 Depositary Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 4.05 Effective Time Section 2.2 ERISA 3.03 Enforceability Exceptions Section 4.13(a5.03(a) ERISA Affiliate Expiration Time Section 4.13(a2.01(c)(ii)(B) Finally Determined Financing Section 8.5(b6.05(a) First Milestone Financing Condition Annex A Financing Document Section 2.10(e8.09(b) First Milestone Payment Amount GAAP Section 2.10(e5.06(b) Indemnifying Party Governmental Entity Section 8.3(a5.05 HKIAC Section 11.08(b) Instrument HKIAC Rules Section 2.12(c11.08(b) Indemnification Agreements Section 8.04(a) Intervening Event Section 7.02(g) Intervening Event Termination Section 7.02(g) Legal Proceeding Section 6.06 ▇▇▇ Preamble Merger Recitals Merger Consideration Section 2.1 Merger Certificate 4.02(a) Minimum Condition Annex A Non-Required Remedy Section 2.2 Merger Sub Preamble 8.02(e) Offer Recitals Offer Conditions 2.01(a) Offer Documents Section 2.01(f) Offer Price Recitals Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Termination Fee Section 10.02(c) Parties Preamble Party Preamble Paying Agent Section 8.2(a)(i4.02(a) parties Preamble Payee Payment Fund Section 8.5 Payor 4.02(a) Per ADS Merger Consideration Section 8.5 4.01(b) Per Diem Taxes Share Merger Consideration Section 8.7(a4.01(a) Proceeding Plan of Merger Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment 3.03 Required Amount Section 2.10(f6.05(c) Stockholder Consent ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 5.06(a) Schedule TO Section 2.01(f) Schedule 13E-3 Section 2.02(b) Schedule 14D-9 Section 2.02(b) SEC Documents Section 5.06(a) Securities Act Section 5.06(a) Share Certificates Section 4.02(b)(i) Special Committee Recitals Stockholder Representative Special Committee Recommendation Recitals Super ROI Preamble Super Majority ROI Group Section 2.12(b10.02(d) Superior Proposal Section 7.02(f) Surviving Corporation Company Section 2.1 Third Milestone 3.01 Takeover Statute Section 2.10(g) Third Milestone Payment Amount 8.05 Transaction Litigation Section 2.10(g8.07 Transactions Recitals Uncertificated Shares Section 4.02(b)(i)

Terms Defined Elsewhere. The In addition to the terms defined in Section 9.03, the following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Adverse Recommendation Change Section hereof in which such term is defined: 5.02(d) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Arbitration Action Section 4.7 Biogen Idec Supply Agreement 5.02(g)(i) Section 4.7 Books 9.09(c) Bankruptcy and Records Equity Exception Section 2.12(f)(23.04(a) Claim Notice Book-Entry Shares Section 8.3(a2.01(b) Certificates Section 2.01(b) Certificate of Merger Section 1.03 Closing Section 2.3 1.02 Closing Date Section 2.3 1.02 Company Preamble Company Common Board Recital B Company Board Recommendation Section 3.04(b) Company Bylaws Section 3.01(b) Company Capital Stock Section 2.8 3.03(a) Company Charter Section 3.01(b) Company Disclosure Schedule Letter Article IV III Company Expenses Schedule Financial Advisor Section 2.13 3.20 Company Indemnified Parties Party Section 8.2(a)(ii6.05(a) Contracts Company Permits Section 4.8(a3.12(a) Covered Party (PartiesCompany Preferred Stock Section 3.03(a) Company Registered IP Section 8.2(a)(ii3.17(a) Damages Company RSU Section 8.2(a)(i2.04(d) Company SEC Documents Section 3.06(a) Company Stock Option Section 2.04(a) Company Stockholder Approval Section 3.04(a) Company Stockholders Meeting Section 3.04(b) Company Subsidiaries Section 3.02(a) Company Termination Fee Section 8.02(b) Company Voting Debt Section 3.03(e) Confidentiality Agreement Section 6.02 Continuing Employee Section 6.13(a) DGCL Recital A Dissenting Shares Section 2.1 Document Retention Period 2.03 Draft Financial Statements Section 2.12(f)(23.06(b) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 1.03 Equity Commitment Letter Recital F Equity Investor Recital F Escrow Account Section 4.13(a6.14 Escrow Agent Section 6.14 Escrow Agreement Recital G Escrow Deposit Section 6.14 ESPP Section 2.05 Excluded Shares Section 2.01(a) ERISA Affiliate Financing Section 4.13(a4.11(a) Finally Determined In-the-Money Company Stock Option Section 8.5(b2.04(a) First Milestone Material Contract Section 2.10(e3.15(b) First Milestone Payment Material Customer Section 3.19(a) Material Lease Section 3.16(b) Material Supplier Section 3.19(b) Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c6.05(b) Merger Recital A Merger Consideration Section 2.1 Merger Certificate Section 2.2 2.01(b) Merger Sub Preamble NASDAQ Section 3.05(a) Notice Period Section 5.02(g)(i) Outside Date Section 8.01(b)(i) Owned Real Property Section 3.16(a) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Termination Fee Section 8.02(c) Parties Preamble Paying Agent Section 8.2(a)(i2.02(a) parties Preamble Payee Payment Fund Section 8.5 Payor 2.02(a) Permits Section 8.5 Per Diem Taxes 3.12(a) Post-Closing Plans Section 8.7(a6.13(b) Proceeding Proxy Statement Section 4.17 Royalties 6.01(a) Regulatory Filings Section 2.10(h6.04(b) Second Milestone Representatives Section 2.10(f5.02(a) Second Milestone Payment Amount Shares Section 2.10(f2.01(a) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority SIAC Rules Section 2.12(b9.09(b) Specified Person Section 8.02(f) SSOs Section 3.17(i) Surviving Corporation Section 2.1 Third Milestone 1.01 Unvested RSU Section 2.10(g2.04(d) Third Milestone Payment Amount Vested Company Options Section 2.10(g2.04(a) Vested RSU Section 2.04(d)

Terms Defined Elsewhere. The For purposes of this Agreement each of the following is a list of additional terms (capitalized below) when used in this Agreement and a reference will have the meaning ascribed to such term in the Section hereof in which set forth opposite such term is definedterm: 401(k) Plan Section 6.4(d) ADS Cash Consideration Section 2.1(a) ADS Transaction Consideration Section 2.1(a) Affiliate Transaction Section 4.24 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.3(d) Ancillary Scheme Documentation Section 4.7 Books and Records 3.1(a)(ii) Anti-Takeover Laws Section 2.12(f)(24.22 Broker Fee Section 4.21 CARES Act Section 4.12(c) Claim Notice Cash Consideration Section 8.3(a2.1(a) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Code Section 2.4 Company Preamble Company Common Board Recitals Company Board Recommendation Section 4.2(b) Company Cash-Out Stock Option Section 2.8 2.2(a)(i) Company Disclosure Schedule Letter Article IV Company Expenses Schedule Equity Plan Section 2.13 2.2(a) Company Indemnified Parties Equity Plans Section 8.2(a)(ii2.2(a) Contracts Company ESPP Section 4.8(a2.2(a) Covered Party (PartiesCompany Material Contract Section 4.13(a) Company Organizational Documents Section 8.2(a)(ii4.1(c) Damages Company Real Property Section 8.2(a)(i4.11(b) DGCL Company Registered Intellectual Property Section 2.1 Document Retention Period 4.14(a) Company RSU Section 2.12(f)(22.2(a)(iii) Drug Regulatory Agency Company SEC Documents Section 4.25 4.6(a) Company Securities Section 4.3(e) Company Stock Option Section 2.2(a)(i) Company Systems Section 4.14(j) Company Underwater Option Section 2.2(a)(ii) Confidentiality Agreement Section 6.2(b) Converted Direct Shareholder Section 3.1(a)(xx) Court Documentation Section 3.1(a)(vii) Current Employee Section 6.4(a) CVRs Section 2.1(a) CVR Agreement Recitals DSP Section 4.20(j) Effective Time Section 2.2 1.3 ERISA Section 4.13(a4.17(d) ERISA Affiliate Excluded Benefits Section 4.13(a6.4(a) Finally Determined FCPA Section 8.5(b4.20(j) First Milestone FDA definition of Healthcare Laws Forms of Proxy Section 2.10(e3.1(a)(ii) First Milestone Payment Healthcare Correspondence Section 4.20(b) HHS Section 4.20(e) HSR Act Section 4.5 Indemnified Party Section 6.5(b) Intentional Breach Section 8.5(a) Labor Agreements Section 4.13(a)(ii) Maximum Amount Section 2.10(e6.5(c) Indemnifying Party Measurement Date Section 8.3(a4.3(a) Instrument Non-U.S. Plan Section 2.12(c4.17(h) Merger OECD definition of Good Laboratory Practices OECD Convention Section 2.1 Merger Certificate 4.20(j) OFAC definition of Sanctions Laws Other Required SEC Filing Section 2.2 Merger Sub Preamble 3.1(a)(iii) Outside Date Section 8.2(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Preamble Paying Agent Section 8.2(a)(i2.1(b) parties Payment Fund Section 2.1(b) Pre-Closing Period Section 6.1(a) Privacy Policies Section 4.20(l) Prohibited Payment Section 4.20(j) Proxy Statement Section 3.1(a)(i) Purchaser Preamble Payee Regulatory Authorizations Section 8.5 Payor 4.20(a) Rights Agent Recitals ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Section 8.5 Per Diem Taxes 4.10(e) Scheme Document Annex Section 8.7(a3.1(a)(i) Proceeding Securities Act Section 4.17 Royalties 4.6(a) Shareholder Litigation Section 2.10(h6.11 Transaction Consideration Section 2.1(a) Second Milestone Transaction Documentation Section 2.10(f3.1(a)(iv) Second Milestone Payment Amount Treasury Regulations Section 2.10(f2.4 UK Bribery Act Section 4.20(j) Stockholder Consent Voting and Support Agreements Recitals Stockholder Representative Preamble Super Majority WARN Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g4.19(c)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Acquisition Sub Preamble Adjustment Amount Section 2.13(d) Agreement Preamble Biogen Idec License Agreement of Merger Section 4.7 Biogen Idec Supply Agreement 2.3 Assumption Conditions Section 4.7 Books and Records 9.6(b) Business Intellectual Property Section 2.12(f)(23.17(b) Calculation Notice Section 2.13(b) Cap Section 9.3(a)(ii) Certificates Section 2.11(b) Claim Notice Section 8.3(a9.5(a) Closing Section 2.3 2.4 Closing Certificate Section 2.10 Closing Date Section 2.3 2.4 Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Preamble to ARTICLE III Company Expenses Schedule Representatives Section 2.13 Company Indemnified Parties 6.2(a) Confidentiality Agreement Section 8.2(a)(ii6.4(d) Contracts Copyrights Section 4.8(a3.17(a) Covered Party (PartiesDispute Notice Section 9.5(b) Dissenting Shares Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 2.12 Effective Time Section 2.2 2.3 El-Badry Section 9.2(a)(vii) Employee Plans Section 3.11(a) ERISA Section 4.13(a3.11(a) ERISA Affiliate Section 4.13(a3.11(a) Finally Determined Estimated Closing Cash Section 8.5(b2.10 Estimated Closing Indebtedness Section 2.10 Estimated Closing Transaction Fees Section 2.10 Estimated Working Capital Section 2.10 Exchange Section 2.1 Exchange Shares Section 2.1 FCPA Section 3.25(a) First Milestone Final Merger Consideration Section 2.10(e2.13(d) First Milestone Payment Amount Fundamental Representations Section 2.10(e) Indemnifying 9.1 General Survival Date Section 9.1 Indemnified Party Section 8.3(a9.3(b) Instrument Indemnitor Section 2.12(c9.3(b) Merger Infringes Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g3.17(d)

Terms Defined Elsewhere. The For purposes of this Agreement, each of the following is a list of additional terms (as capitalized below) when used in this Agreement and a reference will have the meaning ascribed to such term in the Section hereof in which set forth opposite such term is definedterm: Action Section 5.10(b) Agreement Preamble Biogen Idec License Agreement Alternative Financing Section 4.7 Biogen Idec Supply Agreement 5.16(c) Alternative Proposal Section 4.7 Books and Records 5.4(g) Appraisal Rights Section 2.12(f)(22.1(b) Claim Notice Book-Entry Shares Section 8.3(a2.2(a) Burdensome Condition Section 5.7(c) Cancelled Shares Section 2.1(a)(ii) Certificate of Merger ‎Section 1.3 Certificates Section 2.2(a) Change of Recommendation Section 5.4(c) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Code Section 2.2(b)(iii) Commitment Letter Section 4.6(a) Common Stock Section 2.1(a)(i) Company Preamble Company Common Stock Section 2.8 Board Recitals Company Disclosure Schedule Letter Article IV 3 Company Expenses Schedule PSU Consideration Section 2.13 2.3(c) Company Indemnified Recommendation Section 3.3 Company Registered IP Section 3.10(a) Company Related Parties ‎Section 7.3(d) Company RSU Consideration Section 8.2(a)(ii2.3(a) Contracts Company SEC Reports Section 4.8(a3.5(a) Covered Party (PartiesCompany Stockholder Approval Section 3.20 Company Stockholders’ Meeting ‎Section 5.5(b) Company Termination Fee Section 8.2(a)(ii7.3(a) Damages Confidentiality Agreement Section 8.2(a)(i5.3(b) Continuation Period Section 5.6(a) Data Breach Section 3.10(f) Data Protection Requirements Section 3.10(a) Definitive Agreements Section 5.16(a) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period Section 2.12(f)(22.1(b) Drug Regulatory Agency Section 4.25 ▇▇▇▇▇ Article 3 Effective Time Section 2.2 ERISA 1.3 Employee Census ‎Section 3.15(g) End Date ‎Section 7.1(b) Filed SEC Reports Article 3 Financing Section 4.13(a4.6(a) ERISA Affiliate Financing Amounts Section 4.13(a4.6(d) Finally Determined Indemnified Party Section 8.5(b5.10(b) First Milestone Intervening Event Section 2.10(e5.4(i) First Milestone Payment Intervening Event Notice Section 5.4(e) Intervening Event Notice Period Section 5.4(e) Leases Section 3.9(a) Legal Restraint ‎Section 6.1(b) Lenders Section 4.6(a) Made Available to Parent Section 8.12 Material Contract Section 3.11(a) Maximum Amount Section 2.10(e5.10(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c3.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 2.1(a)(i) Merger Sub Preamble New Plans Section 5.6(b) Old Plans Section 5.6(b) Owned Real Property Section 3.9(a) Parent Preamble Parent Approvals Section 4.2(b) Parent Disclosure Schedule Letter Article V 4 Parent Indemnified Material Adverse Effect ‎Section 4.1 Parent Related Parties ‎Section 7.3(d) Parent RSU Section 8.2(a)(i2.3(b) parties Preamble Payee Parent Termination Fee Section 8.5 Payor 7.3(b)(i) Paying Agent Section 8.5 Per Diem Taxes 2.2(a) Payment Fund Section 8.7(a2.2(a) Proceeding Permitted Change of Recommendation Section 4.17 Royalties 5.4(e) Permitted Termination Section 2.10(h5.16(b) Second Milestone Prohibited Modifications Section 2.10(f5.16(b) Second Milestone Payment Amount Proposed Dissenting Shares Section 2.10(f2.1(b) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Representatives Section 2.12(b5.3(a) Share Section 2.1(a)(i) Subsidiary Shares Section 2.1(a)(i) Superior Proposal ‎Section 5.4(h) Superior Proposal Notice Section 5.4(d) Superior Proposal Notice Period ‎Section 5.4(c) Surviving Corporation Section 2.1 Third Milestone 1.1 Takeover Statute Section 2.10(g3.19 Tax Incentive ‎Section 3.15(g) Third Milestone Payment Amount Terminating Company PSU Section 2.10(g2.3(c) Terminating Company RSU Section 2.3(a) Termination Date Section 5.1(a)

Terms Defined Elsewhere. The For purposes of this Agreement, the following is a list of additional terms (as capitalized below) will have the following meanings when used in this Agreement and a reference to the Agreement: Action Section hereof in which such term is defined: 5.10(b) Agreement Preamble Biogen Idec License Agreement Appraisal Rights Section 4.7 Biogen Idec Supply Agreement 2.1(b) Board of Directors Recitals Book-Entry Shares Section 4.7 Books and Records 2.2(a) Cancelled Shares Section 2.12(f)(22.1(a)(ii) Claim Notice Certificate of Merger Section 8.3(a1.3 Certificates Section 2.2(a) Change of Recommendation Section 5.4(e) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Code Section 2.2(b)(iii) Common Stock Section 2.1(a)(i) Company Preamble Company Common Stock Disclosure Letter Article 3 Company Employees Section 2.8 5.6(a) Company Disclosure Schedule Article IV Post-Signing RSU Award Section 2.3(c) Company Expenses Schedule Section 2.13 Company Indemnified Related Parties Section 8.2(a)(ii7.3(a) Contracts Company SEC Reports Section 4.8(a3.5(a) Covered Party (PartiesCompany Stockholders’ Meeting Section 5.5(b) Company Termination Fee Section 8.2(a)(ii7.3(a) Damages Confidentiality Agreement Section 8.2(a)(i5.3(b) Development Real Property Section 3.9(e) DFARS Section 3.20(c) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period 2.1(b) EAR Section 2.12(f)(23.15(d) Drug Regulatory Agency Section 4.25 E▇▇▇▇ Article 3 Effective Time Section 2.2 ERISA 1.3 End Date Section 4.13(a7.1(b) ERISA Affiliate ESPP Section 4.13(a3.2(b)(i) Finally Determined Exchange Fund Section 8.5(b2.2(a) First Milestone Filed SEC Reports Article 3 Financing Amounts Section 2.10(e4.12 HSR Act Section 3.4 Indemnified Party Section 5.10(b) First Milestone Payment Intervening Event Notice Section 5.4(f) Leases Section 3.9(a) Legal Restraint Section 6.1(b) Major Customer Section 3.13(a) Major Supplier Section 3.13(b) Material Contract Section 3.11(a) Maximum Amount Section 2.10(e5.10(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c3.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 2.1(a)(i) Merger Sub Preamble New Plans Section 5.6(b) Old Plans Section 5.6(b) Owned Real Property Section 3.9(a) Parent Preamble Parent Approvals Section 4.2(b) Parent Disclosure Schedule Letter Article V 4 Parent Indemnified Material Adverse Effect Section 4.1 Parent Related Parties Section 8.2(a)(i7.3(a) parties Preamble Payee Parent RSU Award Section 8.5 Payor 2.3(c)(i) Paying Agent Section 8.5 Per Diem Taxes 2.2(a) Proposed Dissenting Shares Section 8.7(a2.1(b) Proceeding Recommendation Section 4.17 Royalties 3.3 Remedial Action Section 2.10(h5.7(b) Second Milestone Representatives Section 2.10(f5.3(a) Second Milestone Payment Amount Required Company Stockholder Vote Section 2.10(f3.23 Sexual Misconduct Allegation Section 3.18(c) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Share Section 2.12(b2.1(a)(i) Specified Approvals Section 3.4 Standards Organization Section 3.10(b) Superior Proposal Notice Section 5.4(e) Surviving Corporation Section 2.1 Third Milestone 1.1 Takeover Statute Section 2.10(g3.22 Termination Date Section 5.1(a) Third Milestone Payment Amount WARN Act Section 2.10(g3.18(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement Agreement, as indicated below: Term Location Acquired Companies Recitals Acquired Company Releasee Section 8.20(a) Acquired Interests Recitals Acquisition Transaction Section 5.21(b) Allocation Section 5.13(a)(ii) Antitrust Division Section 5.5(b) Applicable Debt Financing Provisions Section 8.11 Assigned Software Section 5.30 Back Office Operations Section 3.9(b) Balance Sheet Date Section 3.6 Bankruptcy and a reference to the Equity Principles Section hereof in which such term is defined: Agreement 3.2 Business Product Section 3.8(b) Buyer Preamble Biogen Idec License Agreement Buyer 401(k) Plan Section 4.7 Biogen Idec Supply Agreement 5.2(c)(iii) Buyer Benefit Plan Section 4.7 Books and Records 5.2(c)(i) Buyer Disclosing Party Section 2.12(f)(25.4(e) Claim Notice Buyer General Liability Policies Section 8.3(a5.24(a) Buyer Insureds Section 5.24(b) Buyer Parties Section 7.3(b) Buyer’s Allocation Section 5.13(a)(ii) Chosen Courts Section 8.3 Closing Section 2.3(a) Closing Cash Amounts Section 2.3 2.4(b) Closing Date Section 2.3 2.3(a) Closing Indebtedness Section 2.4(b) Closing Net Working Capital Section 2.4(b) Closing Transaction Expenses Section 2.4(b) Commitment Letters Section 4.7(a) Company Preamble Company Common Stock Recitals Confidential Business Information Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 5.4(b) Continuation Period Section 2.13 Company Indemnified 5.2(b)(i) Covered Parties Section 8.2(a)(ii5.14 Covered Persons Section 5.21(a) Contracts Current Representation Section 4.8(a8.17(a) Covered Debt Commitment Letter Section 4.7(a) Debt Fee Letter Section 4.7(a) Debt Financing Section 4.7(a) Designated LOA Employee Section 5.2(a)(i) Designated Person Section 8.17(a) Disagreement Notice Section 2.4(c) Disclosing Party (PartiesSection 5.4(c) Divestiture Actions Section 8.2(a)(ii5.5(c) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.3(a) Equity Commitment Letter Section 4.13(a4.7(a) ERISA Affiliate Equity Financing Section 4.13(a4.7(a) Finally Determined Estimated Closing Cash Amounts Section 8.5(b2.4(a)(i) First Milestone Estimated Closing Indebtedness Section 2.10(e2.4(a)(i) First Milestone Payment Amount Estimated Closing Statement Section 2.10(e2.4(a)(i) Indemnifying Party Estimated Net Working Capital Section 8.3(a2.4(a)(i) Instrument Estimated Transaction Expenses Section 2.12(c2.4(a)(i) Merger Excluded Businesses Section 1.1 Exclusivity Period Section 5.27 Final Cash Amounts Section 2.4(h) Final Closing Adjustment Section 2.4(i) Final Indebtedness Section 2.4(h) Final Net Working Capital Section 2.4(h) Final Purchase Price Section 2.4(i) Final Transaction Expenses Section 2.4(h) Financial Statements Section 3.6 Financing Section 4.7(a) Financing Related Parties Section 7.3(b) FTC Section 5.5(b) Governmental Filings Section 3.4(a) Guarantors Recitals Independent Accounting Firm Section 2.4(e) Initial Purchase Price Section 2.4(a)(ii) Insurance Policies Section 3.25 Lease Agreement Section 5.29 Legacy Policies Section 5.24(c) Limited Guarantee Recitals Material Contract Section 3.12(a) Minimum Cash Balance Section 5.25 Outside Date Section 7.1(b) Payoff Letters Section 2.4(a)(i) Permits Section 3.14(b) Post-Closing Representation Section 8.17(a) Pre-Closing State Income Tax Section 5.13(c) Preliminary Adjustment Statement Section 2.4(b) Privileged Communications Section 8.17(b) R&W Insurance Policy Section 5.18 Recovery Costs Section 7.3(b) Recovery Interest Section 7.3(b) Registered Business Intellectual Property Section 3.16(a) Resolution Period Section 2.4(e) Review Period Section 2.4(c) Sale Section 2.1 Merger Certificate Sales Tax Study Section 2.2 Merger Sub 5.13(k) Section 336(e) Elections Section 5.13(h)(iii)(1) Section 336(e) Forms Section 5.13(h)(iii)(2) Section 338(h)(10) Elections Section 5.13(h)(ii)(1) Section 338(h)(10) Forms Section 5.13(h)(ii)(2) Seller Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Seller Confidential Information Section 5.4(d) Seller Debt Release Documents Section 2.3(b)(vi) Seller General Liability Policies Section 5.24(b) Seller Guarantors Section 5.16(a) Seller Insureds Section 5.24(a) Seller Parties Section 8.2(a)(i7.3(b) parties Seller Releasee Section 8.20(b) Seller’s Allocation Notice Section 5.13(a)(ii) Service Credits Section 5.2(b)(ii) Signing Date Preamble Payee Sufficiency Assets Section 8.5 Payor 3.24 Supply/Distribution Agreement Section 8.5 Per Diem Taxes 5.27 Support Services Section 8.7(a5.10 Terminating Contracts Section 5.9(a) Proceeding Termination Fee Section 4.17 Royalties 7.3(a) Termination Payments Section 2.10(h7.3(a) Second Milestone THP Recitals Top Customers Section 2.10(f3.26(a) Second Milestone Payment Amount Top Suppliers Section 2.10(f3.26(b) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Transaction Accounting Principles Section 2.12(b1.1 Transaction Amounts Section 4.7(c) Surviving Corporation Transaction Invoices Section 2.1 Third Milestone 2.4(a)(i) Transferred Employee Section 2.10(g5.2(a)(i) Third Milestone Payment Amount Transitional Trademark License Period Section 2.10(g)5.11(a) Union Section 3.13(b) Unresolved Items Section 2.4(e) VDA Process Section 5.13(k) willful and material breach Section 7.2

Terms Defined Elsewhere. The For purposes of this Agreement, each of the following is a list of additional terms (as capitalized below) when used in this Agreement and a reference will have the meaning ascribed to such term in the Section hereof in which set forth opposite such term is definedterm: Absence of Legal Restraint Condition Exhibit A Acceptance Time Section 1.1(c) Agreement Preamble Biogen Idec License Alternative Proposal Section 5.4(f) Appraisal Rights Section 2.1(b) Benefits Continuation Period Section 5.5(a) Book-Entry Shares Section 2.2(a) Cancelled Shares Section 2.1(a)(ii) Capex Budget Section 5.1(b)(xvi) Certificate of Merger Section 1.5 Certificates Section 2.2(a) Change of Recommendation Section 5.4(c) Clean Team Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a5.3(b) Closing Section 2.3 1.4 Closing Date Section 2.3 1.4 Code Section 2.2(b)(iv) Collection Costs Section 7.3(b) Common Stock Recitals Company Preamble Company Common Stock Approvals Section 2.8 3.4 Company Board Recitals Company Disclosure Schedule Letter Article IV 3 Company Expenses Schedule Employees Section 2.13 5.5(a) Company Indemnified ESPP Section 3.2(b)(i) Company Recommendation Section 3.3 Company Registered IP Section 3.11(a) Company Related Parties Section 8.2(a)(ii7.3(c) Contracts Company SEC Reports Section 4.8(a3.6(a) Covered Party (PartiesCompany Termination Fee Section 7.3(a) Confidentiality Agreement Section 8.2(a)(ii5.3(b) Damages Continuing Directors Section 8.2(a)(i8.10 Depository Agent Section 2.2(a) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period 2.1(b) DTC Section 2.12(f)(22.2(b)(ii) Drug Regulatory Agency Section 4.25 ▇▇▇▇▇ Article 3 Effective Time Section 2.2 ERISA 1.5 End Date Section 4.13(a7.1(b) ERISA Affiliate ESPP Offering Period Section 4.13(a2.3(c) Finally Determined Existing Loan Documents Section 8.5(b2.4 Fair Value Section 8.14 FCPA Section 3.14(d) First Milestone FDA Application Integrity Policy Section 2.10(e3.16(g) First Milestone Payment Filed SEC Reports Article 3 Indemnified Party Section 5.9(a) Intervening Event Section 5.4(h) Intervening Event Notice Section 5.4(d) Intervening Event Notice Period Section 5.4(d) Leases Section 3.10(a) Legal Restraint Section 6.1(a) Material Contract Section 3.12(a) Maximum Amount Section 2.10(e5.9(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c3.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate 2.1(a)(i) Minimum Tender Condition Exhibit A New Plans Section 2.2 Merger Sub Preamble 5.5(b) Offer Recitals Offer Conditions Section 1.1(b) Offer Documents Section 1.1(e) Old Plans Section 5.5(b) Parent Preamble Parent Approvals Section 4.2(b) Parent Disclosure Schedule Letter Article V 4 Parent Indemnified Material Adverse Effect Section 4.1 Parent Related Parties Section 8.2(a)(i7.3(c) parties Preamble Payee Paying Agent Section 8.5 Payor 2.2(a) Payment Fund Section 8.5 Per Diem Taxes Section 8.7(a2.2(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Payoff Amount Section 2.10(f2.4 Payoff Letter Section 2.4 PMA Section 3.16(e) Stockholder Consent Regulatory Condition Exhibit A Remedy Action Section 5.6(a) Representatives Section 5.3(a) Schedule 14D-9 Section 1.2(b) Security Incident Section 3.11(i) Share Recitals Stockholder Representative Preamble Super Majority Superior Proposal Section 2.12(b5.4(g) Superior Proposal Notice Section 5.4(c) Superior Proposal Notice Period Section 5.4(c) Surviving Corporation Section 2.1 Third Milestone 1.1 Takeover Statute Section 2.10(g3.21 Termination Condition Exhibit A Termination Date Section 5.1(a) Third Milestone Payment Amount Trade Authorizations Section 2.10(g3.14(f)

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: ACA ‎Section 4.15(c) Additional Buyer Filings ‎Section 8.10(f) Affiliated Transactions ‎Section 4.20 Aggregate Consideration ‎Section 10.1(e) Agreement Preamble Biogen Idec License Agreement Allocation ‎Section 10.1(e) Alternative Financing Section 4.7 Biogen Idec Supply Agreement 8.13(a)(iv) Antitrust Laws ‎Section 8.8(c) Assets ‎Section 4.19 Audited Financial Statements ‎Section 4.4(a)(i) Blocker Affiliated Transactions ‎Section 5.9 Blocker Bring-Down Certificate Section 4.7 Books and Records 11.2(d) Blocker Certificates of Merger ‎Section 2.2(b) Blocker Effective Time ‎Section 2.2(b) Blocker Letter of Transmittal ‎Section 3.4(a) Blocker Merger Closing ‎Section 2.2(a) Blocker Merger Sub 1 Preamble Blocker Merger Sub 2 Preamble Blocker Merger Sub 3 Preamble Blocker Merger Sub 4 Preamble Blocker Merger Sub 5 Preamble Blocker Merger Sub 6 Preamble Blocker Merger Subs Preamble Blocker Mergers Recitals Blocker Owned Company Equity Interests ‎Section 5.4(b) Blockers Preamble Buyer Preamble Buyer Balance Sheet ‎Section 6.11(c) Buyer Bring-Down Certificate Section 2.12(f)(211.3(c) Claim Notice Buyer Certificate of Merger ‎Section 2.2(c) Buyer Certificates of Merger ‎Section 2.2(c) Buyer Contribution Amount ‎Section 3.2(e)(i) Buyer Effective Time ‎Section 2.2(c) Buyer Merger Closing ‎Section 2.2(a) Buyer Mergers Recitals Buyer Parties Preamble Buyer Preference Shares ‎Section 6.3(a) Buyer Public Securities ‎Section 6.9 Buyer SEC Documents ‎Section 6.8(a) Buyer Warrants ‎Section 6.3(a) Cancelled Equity Interests ‎Section 3.1(d) Cancelled Cash Portion Section 8.3(a3.1(c)(iii)(B) Cancelled Option Value Section 3.1(c)(iii)(B) CBA Section 4.9(a)(i) Certificates of Merger ‎Section 2.2(d) Closing Section 2.3 ‎Section 2.2(a) Closing Cash ‎Section 3.5(a) Closing Date ‎Section 2.2(a) Closing Form 8-K ‎Section 8.10(g) Closing Net Working Capital ‎Section 3.5(a) Closing Press Release ‎Section 8.10(g) Closing Statement ‎Section 3.5(a) Closing Transaction Expenses ‎Section 3.5(a) Commitment Letter Section 2.3 8.13(a)(i) Company Preamble Company Common Stock A&R LLCA Recitals Company Bring-Down Certificate Section 2.8 11.2(d) Company Disclosure Schedule Article IV Certificate of Merger ‎Section 2.2(d) Company Expenses Schedule Section 2.13 Equity Interests ‎Section 4.3(a) Company Indemnified Parties Section 8.2(a)(iiMerger ‎Section 2.2(a) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Company Merger Closing Section 2.2 ERISA Section 4.13(a(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Company Merger Sub Preamble Parent Company Optionholder Letter of Transmittal ‎Section 3.4(a) Company Unitholder Letter of Transmittal ‎Section 3.4(a) Competing Buyer ‎Section 8.23 Contribution Common Units Section 3.2(e)(i)(A) Control ‎Section 1.1 D&O Provisions ‎Section 8.14(a) Data Room ‎Section 13.5 Debt Financing Section 8.13(a)(i) Debt Financing Sources Section 8.13(a)(i) Debt Payoff Amount ‎Section 3.2(e)(i)(A) DGCL Recital Disclosing Party ‎Section 1.1 Dispute Notice ‎Section 3.5(b) DLLCA Recitals Domestication Recitals E2open Intermediate ‎Section 4.4(e) Effective Date Preamble Parent Disclosure Schedule Article V Parent Effective Time ‎Section 2.2(d) EALP Section 1.1 EIP ‎Section 8.4 EILP Section 1.1 ▇▇▇▇▇▇▇ Catch-Up Amount 3.2(e)(i)(E) ▇▇▇▇▇▇▇ Eagle Blocker Preamble ▇▇▇▇▇▇▇ Merger Recitals ▇▇▇▇▇▇▇ Note Transfer Section 3.2(f) ▇▇▇▇▇▇▇ Reorganization Transferee Section 8.26 Environmental Permits ‎Section 4.17 Equity Financing ‎Section 1.1 Equityholder Materials ‎Section 3.4(b) Equityholder Representative Preamble Estimated Closing Blocker Indebtedness Section 3.2(b)(i) Estimated Closing Statement ‎Section 3.2(b)(ii) Estimated Merger Consideration ‎Section 3.2(b)(ii) Final Allocation ‎Section 10.1(e) Final Closing Blocker Indebtedness Section 3.5(a) Final Closing Company Indebtedness ‎Section 3.5(a) Final Tax Basis Balance Sheet ‎Section 10.1(e) Financial Statements ‎Section 4.4(a) Foreign Plan ‎Section 4.15(f) Forward Purchase Agreement Recitals Forward Purchase Amount Recitals ▇▇▇▇▇ Payoff Letter ‎Section 3.2(e)(ii)(D) Indemnified Parties Persons ‎Section 8.14(a) Insight Agreement Section 8.2(a)(i3.6(m) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Insight Catch-Up Amount Section 2.10(f3.2(e)(i)(E) Stockholder Consent Insight Cayman Blocker Preamble Insight Cayman Merger Recitals Stockholder Representative Insight Delaware Blocker Preamble Super Majority Insight Delaware Merger Recitals Insight GBCF Cayman Blocker Preamble Insight GBCF Cayman Merger Preamble Insight GBCF Delaware Blocker Preamble Insight GBCF Delaware Merger Recitals Insight Blocker Letter Agreement Section 2.12(b3.7(f) Insight Letter Agreement Section 3.6(m) Insurance Policies ‎Section 4.15(b) Intended Tax Treatment Section 10.1(e) Internal Controls ‎Section 4.4(c) Investor Rights Agreement Recitals IRS ‎Section 4.15(a) LLCA Amendment and Restatement Section 3.1(e) Lock-Up Agreement Recitals Material Contract ‎Section 4.9(b) Material Customer ‎Section 4.9(c) Material Leases ‎Section 4.7 Maximum Payable Amount Section 8.15(d) Merger Consideration ‎Section 3.2(a) Mergers Recitals NBOKS Recitals NBOKS Side Letter Recitals New Commitment Letter Section 8.13(a)(iv) Non-Party Affiliate ‎Section 13.14 Outside Date ‎Section 12.1(c) Parties Preamble Party Preamble PCAOB Financial Statements ‎Section 8.10(h) PDI Blocker Preamble PDI Merger Recitals Permits ‎Section 4.17(b) Permitted Equity Financing Proceeds Section 8.15(c) PIPE Investment Recitals PIPE Investors Recitals Pre-Closing Period ‎Section 7.1 Pre-Closing Reorganization Section 8.26 Premium Cap ‎Section 8.14(b)(ii) Recipient ‎Section 1.1 Resolution Period ‎Section 3.5(b) Review Period ‎Section 3.5(b) Sale ‎Section 10.1(e) Sellers Prepared Returns ‎Section 10.1(a) Signing Form 8-K ‎Section 8.10(b) Signing Press Release ‎Section 8.10(b) Sponsor Side Letter Recitals Subscription Agreements Recitals Support Agreement Section 8.12 Surviving Blocker Section 2.1(g) Surviving Corporation Section 2.1 Third Milestone Section 2.10(gBlocker Interests ‎Section 3.1(a)(i) Third Milestone Payment Surviving Buyer ‎Section 2.1(h) Surviving Company ‎Section 2.1(i) Surviving ▇▇▇▇▇▇▇ Eagle Blocker ‎Section 2.1(f) Surviving Insight Cayman Blocker ‎Section 2.1(a) Surviving Insight Delaware Blocker ‎Section 2.1(c) Surviving Insight GBCF Cayman Blocker ‎Section 2.1(d) Surviving Insight GBCF Delaware Blocker ‎Section 2.1(e) Surviving PDI Blocker ‎Section 2.1(g) SVB Payoff Amount Section 2.10(g)3.2(e)(i)(B) SVB Payoff Letter ‎Section 3.2(e)(i)(A) Tail Policy ‎Section 8.14(b)(ii) Tax Accounting Firm ‎Section 10.1(e) Tax Basis Balance Sheet ‎Section 10.1(e) Tax Contest Section 10.1(i) Tax Positions ‎Section 10.1(g) Tax Receivable Agreement Recitals Total Individual Blocker Merger Consideration Section 3.1(a)(ii) Total Individual Company Optionholder Merger Consideration Section 3.1(c)(iii) Total Individual Company Class A Unitholder Merger Consideration ‎Section 3.1(c)(ii) Total Individual Company Class B Unitholder Merger Consideration Section 3.1(c)(iii) Trade Controls ‎Section 4.21(a) Transaction Expenses Amount ‎Section 3.2(e)(i)(B) Trust Amount ‎Section 6.7 Trust Distributions ‎Section 13.9 Unaudited Balance Sheet ‎Section 4.4(a)(ii) Unaudited Financial Statements ‎Section 4.4(a)(ii) Valuation Firm ‎Section 3.5(b) Waived 280G Benefits ‎Section 8.17

Terms Defined Elsewhere. The For purposes of this Agreement, the following is a list of additional terms (as capitalized below) will have the following meanings when used in this Agreement and a reference to the Agreement: Action Section hereof in which such term is defined: 5.10(b) Agreement Preamble Biogen Idec License Agreement Appraisal Rights Section 4.7 Biogen Idec Supply Agreement 2.1(b) Board of Directors Recitals Book-Entry Shares Section 4.7 Books and Records 2.2(a) Cancelled Shares Section 2.12(f)(22.1(a)(ii) Claim Notice Certificate of Merger Section 8.3(a1.3 Certificates Section 2.2(a) Change of Recommendation Section 5.4(e) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Code Section 2.2(b)(iii) Common Stock Section 2.1(a)(i) Company Preamble Company Common Stock Disclosure Letter Article 3 Company Employees Section 2.8 5.6(a) Company Disclosure Schedule Article IV Post-Signing RSU Award Section 2.3(c) Company Expenses Schedule Section 2.13 Company Indemnified Related Parties Section 8.2(a)(ii7.3(a) Contracts Company SEC Reports Section 4.8(a3.5(a) Covered Party (PartiesCompany Stockholders’ Meeting Section 5.5(b) Company Termination Fee Section 8.2(a)(ii7.3(a) Damages Confidentiality Agreement Section 8.2(a)(i5.3(b) Development Real Property Section 3.9(e) DFARS Section 3.20(c) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period 2.1(b) EAR Section 2.12(f)(23.15(d) Drug Regulatory Agency Section 4.25 ▇▇▇▇▇ Article 3 Effective Time Section 2.2 ERISA 1.3 End Date Section 4.13(a7.1(b) ERISA Affiliate ESPP Section 4.13(a3.2(b)(i) Finally Determined Exchange Fund Section 8.5(b2.2(a) First Milestone Filed SEC Reports Article 3 Financing Amounts Section 2.10(e4.12 HSR Act Section 3.4 Indemnified Party Section 5.10(b) First Milestone Payment Intervening Event Notice Section 5.4(f) Leases Section 3.9(a) Legal Restraint Section 6.1(b) Major Customer Section 3.13(a) Major Supplier Section 3.13(b) Material Contract Section 3.11(a) Maximum Amount Section 2.10(e5.10(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c3.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 2.1(a)(i) Merger Sub Preamble New Plans Section 5.6(b) Old Plans Section 5.6(b) Owned Real Property Section 3.9(a) Parent Preamble Parent Approvals Section 4.2(b) Parent Disclosure Schedule Letter Article V 4 Parent Indemnified Material Adverse Effect Section 4.1 Parent Related Parties Section 8.2(a)(i7.3(a) parties Preamble Payee Parent RSU Award Section 8.5 Payor 2.3(c)(i) Paying Agent Section 8.5 Per Diem Taxes 2.2(a) Proposed Dissenting Shares Section 8.7(a2.1(b) Proceeding Recommendation Section 4.17 Royalties 3.3 Remedial Action Section 2.10(h5.7(b) Second Milestone Representatives Section 2.10(f5.3(a) Second Milestone Payment Amount Required Company Stockholder Vote Section 2.10(f3.23 Sexual Misconduct Allegation Section 3.18(c) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Share Section 2.12(b2.1(a)(i) Specified Approvals Section 3.4 Standards Organization Section 3.10(b) Superior Proposal Notice Section 5.4(e) Surviving Corporation Section 2.1 Third Milestone 1.1 Takeover Statute Section 2.10(g3.22 Termination Date Section 5.1(a) Third Milestone Payment Amount WARN Act Section 2.10(g3.18(a)

Terms Defined Elsewhere. The For purposes of this Agreement, the following is a list of additional terms used have the meanings set forth in this Agreement and a reference to the Sections indicated: Term Section hereof in which such term is defined: 2017 Financial Statements Section 5.13(a) Acquisition Transaction Section 5.9 Agreement Preamble Biogen Idec License Agreement Agreements and Instruments Section 4.7 Biogen Idec Supply Agreement 4.12 Allocation Statement Section 4.7 Books and Records 2.7(a) Annual Financial Statements Section 2.12(f)(23.6 Antitrust Laws Section 5.4(b) Claim Notice Balance Sheet Section 8.3(a3.6 Balance Sheet Date Section 3.6 Basket Section 8.5(a) Cash Consideration Amount Section 2.2(a) Closing Section 7.4 Closing Cash Consideration Section 2.3 Closing Date Section 7.4 Closing Net Working Capital Section 2.4(a) Closing Statement Section 2.4(a) Company Released Parties Section 5.10(a) Cumulative Revenue Make Up Amount Section 2.5(a) Dispute Notice Section 2.4(b) Disputed Amount Section 2.6(b) Earnout Recipients Section 2.5(d) Earnout Statement Section 2.5 Employee Benefit Plans Section 3.14(a) Equity Interests Recitals Estimated Closing Statement Section 2.3 Company Estimated Net Working Capital Section 2.3 FCPA Section 3.17(c) Financial Statements Section 3.6 Fraud Claims Section 8.1(b) ▇. ▇▇▇▇▇▇ Guaranties Section 5.14 HSR Act Section 3.5(b) Indemnification Claim Section 8.4(a) Indemnity Cap Section 8.5(d) Insurance Policies Section 3.21 Interim Financial Statements Section 3.6 Leased Real Property Section 3.10(a) Losses Section 8.2(a) Material Contracts Section 3.13(a) Material Customers Section 3.24(a) Material Vendors Section 3.24(a) Non-Disclosure Agreement Section 5.6(a) NYSE Section 4.13 Objection Notice Section 2.5(c) Party and Parties Preamble Company Payoff Letters Section 7.1(i) Personal Property Leases Section 3.11 Purchaser Preamble Purchaser Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.2(a) Purchaser Documents Section 2.13 Company 4.2 Purchaser Financial Statements Section 4.10 Purchaser Indemnified Parties Section 8.2(a)(ii8.2(a) Contracts Purchaser Plans Section 4.8(a6.1(b) Covered Party (PartiesPurchaser Preferred Stock Section 4.9(a) Purchaser SEC Documents Section 8.2(a)(ii4.11(a) Damages R&W Policy Premium Section 8.2(a)(i8.10 Real Property Leases Section 3.10(a) DGCL 93 Required Quarter Financial Statements Section 2.1 Document Retention Period 5.13(a) Rights-of-Way Section 2.12(f)(23.10(a) Drug Regulatory Agency SEC Section 4.25 Effective Time 4.10 Seller Documents Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent 3.2 Seller Indemnified Parties Section 8.2(a)(i8.3 Sellers Representative Section 9.1(a) parties Sellers Preamble Payee Specified Creditors Section 8.5 Payor 2.3(b) Specified Indebtedness Section 8.5 Per Diem Taxes 2.3(b) Specified Indebtedness Statement Section 8.7(a2.3(b) Proceeding Tax Matter Section 4.17 Royalties 9.2(d) Termination Date Section 2.10(h7.5(a) Second Milestone Transaction Consideration Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)2.2

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: Acceptable Confidentiality Agreement and a reference to the Section hereof in which such term is defined: 7.4(b) Acquisition Agreement Section 7.4(a) Agreement Preamble Biogen Idec License Agreement Book-Entry Share Section 4.7 Biogen Idec Supply Agreement 3.1(a)(ii) Certificate Section 4.7 Books and Records 3.1(a)(ii) Certificate of Limited Partnership Section 2.12(f)(24.1(c) Claim Notice Certificate of Partnership Merger Section 8.3(a2.1(c)(ii) Change in Company Recommendation Section 7.4(b)(iii) Change in Parent Recommendation Section 7.4(b)(iii) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Code Recitals Company Preamble Company 401(k) Plan Section 4.14(b) Company Articles of Merger Section 2.1(a)(ii) Company Board Designee Section 7.22 Company Bylaws Section 4.1(c) Company Charter Section 4.1(c) Company Common Stock Recitals Company Development Properties Section 2.8 4.12(h) Company Development Property Section 4.12(h) Company Disclosure Schedule Article IV Company Expenses Schedule Employee Programs Section 2.13 4.14(a) Company Equity Award Section 4.3(c) Company Governing Documents Section 4.1(c) Company Merger Section 2.1(a)(i) Company Merger Certificates Section 2.1(a)(ii) Company Merger Effective Time Section 2.1(a)(ii) Company Parties Preamble Company Preferred Stock Section 4.3(a) Company Properties Section 4.12(a) Company Recommendation Section 4.2(b) Company SEC Reports Section 4.8(a) Company Stockholder Approval Section 4.18 Company Stockholder Meeting Section 7.1(c) Company Subsidiaries Section 4.1(b) Company Subsidiary Section 4.1(b) Company Tax Protection Agreement Section 6.1(w) Consent Solicitations Section 7.20(b) Continuing Employee Section 7.8(a) Continuing Employees Section 7.8(a) Contribution Section 2.1(b)(i) Contribution and Issuance Effective Time Section 2.1(b)(ii) Debt Offer Documents Section 7.20(b) DLLCA Section 2.1(a)(i) Drop Dead Date Section 9.1(b)(iv) DSOS Section 2.1(a)(ii) Encumbrances Section 4.12(a) Exchange Agent Section 3.3(a) Exchange Fund Section 3.3(a) Exchange Ratio Section 3.1(a)(ii) Form S-4 Section 4.6 Fractional Share Consideration Section 3.1(a)(ii) G▇▇▇▇▇▇ S▇▇▇▇ Section 5.14 HCERA Section 4.14(i) Health Plan Section 4.14(i) Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e7.5(a) Indemnifying Party Section 8.3(a7.5(a) Instrument Indiana Secretary Section 2.12(c2.1(a)(ii) Interim Period Section 6.1 Intervening Event Notice Period Section 7.4(b)(v) Issuance Section 2.1(b)(i) Letter of Transmittal Section 3.3(c) Maryland Court Section 10.7(b) Maximum Premium Section 7.5(c) Merger Consideration Section 2.1 Merger Certificate 3.1(a)(ii) Mergers Section 2.2 Merger Sub 2.1(c)(i) New OP Units Section 3.1(b)(iii) Note Offers and Consent Solicitations Section 7.20(b) Notice Period Section 7.4(b)(iv) Offers to Exchange Section 7.20(b) Offers to Purchase Section 7.20(b) OP Unit Form S-4 Section 7.1(a) Other Filings Section 7.2 Parent Preamble Parent Preamble Bylaws Section 5.1(d) Parent Charter Section 5.1(d) Parent Common Stock Issuance Section 5.2(a) Parent Development Property Section 5.11(e) Parent Disclosure Schedule Article V Parent Indemnified Governing Documents Section 5.1(d) Parent OP Preamble Parent OP Certificate of Limited Partnership Section 5.1(d) Parent OP Governing Documents Section 5.1(d) Parent Parties Preamble Parent Partnership Agreement Section 8.2(a)(i5.1(d) parties Parent Preferred Stock Section 5.3(a) Parent Properties Section 5.11(a) Parent Recommendation Section 5.2(b) Parent SEC Reports Section 5.7(a) Parent Stockholder Approval Section 5.15 Parent Stockholder Meeting Section 7.1(c) Parent Subsidiary Section 5.1(c) Parent Tax Protection Agreement Section 6.2(j) Parent-Approved Transaction Section 7.18 Parties Preamble Payee Partnership Preamble Partnership Agreement Section 8.5 Payor 4.1(c) Partnership Governing Documents Section 8.5 Per Diem 4.1(c) Partnership Merger Section 2.1(c)(i) Partnership Merger Certificates Section 2.1(c)(ii) Partnership Merger Consideration Section 3.1(b)(iii) Partnership Merger Effective Time Section 2.1(c)(ii) Partnership OP Unit Recitals Party Preamble Permit Section 4.7 PPACA Section 4.14(i) Prologis Merger Sub Preamble Prologis OP Merger Sub Preamble Proxy Statement/Prospectus Section 3.3(a) Qualified REIT Subsidiary Section 4.11(f) Qualifying Income Section 9.4(a) Registered Intellectual Property Section 4.21(a) REIT Section 4.11(b) REIT Dividend Section 7.17(b) S▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.8(a) Securities Laws Section 4.8(a) Superior Proposal Notice Section 7.4(b)(iv) Surviving Entity Section 2.1(a)(i) Takeover Statutes Section 4.25 Tax Protection Agreement Section 4.11(m) Taxable REIT Subsidiary Section 4.11(f) Transfer Taxes Section 8.7(a7.9(b) Proceeding UBOAPA Section 4.17 Royalties 2.1(a)(i) UBOTA Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g2.1(a)(i)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.15 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.4(a)(ii)(E) Bankruptcy and Equity Exception Section 4.7 Books and Records 4.3(a) Capitalization Date Section 2.12(f)(24.2(a) Claim Notice Cash Equity. Section 8.3(a5.6(b) Certificate of Merger Section 2.3 Certificates Section 3.2(b) Closing Section 2.3 2.2 Closing Date Date. Section 2.3 2.2 Company Preamble Company Common Adverse Recommendation Change Section 6.4(c)(v) Company Board Recommendation Recitals Company Financial Advisor Section 4.3(b) Company Financial Statements Section 4.7(b) Company Material Contract. Section 4.14(a) Company Plans Section 4.10(a) Company Preferred Stock Section 2.8 4.2(a) Company Disclosure Schedule Article IV Recommendation Section 4.3(b) Company Expenses Schedule Registered Intellectual Property Section 2.13 4.17(a) Company Representatives Section 6.3 Company SEC Filings Section 4.7(a) Company Stockholders Recitals Company Stockholders Meeting Section 6.2(d)(i) Company Subsidiary Section 4.1 Continuing Employee Section 6.10(a) Current Premium Amount Section 6.12(b) Debt Financing Commitments. Section 5.6(a) Debt Financing Sources Section 9.9 Debt Financing. Section 5.6(a) Determination Notice Section 6.4(d)(i)(D) DGCL Recitals Dissenting Shares Section 3.1(a) Dissenting Stockholders Section 3.1(a) Effective Time Section 2.3 End Date Section 8.1(b)(i) Equity Financing Commitments Section 5.6(b) ERISA Section 4.10(a) Exchange Fund Section 3.2(a) FCPA Section 4.5(d) FDA Section 1.1(ee) Fee Letters. Section 5.6(a) Financing Commitments Section 5.6(b) Governmental Plan Section 4.10(a) Health Care Permits Section 4.6(c) HIPAA Section 1.1(dd) Improvements Section 4.20(d) Incremental Debt Financing Cooperation Section 2.3 Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Intervening Event Change of Recommendation Section 4.8(a6.4(d)(ii) Covered Party (PartiesInvestments Section 4.2(d) IRS Section 8.2(a)(ii4.10(b) Damages Lenders Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c5.6(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 3.1(a) Merger Sub Preamble Notice Period Section 6.4(d)(i)(D) Parent Preamble Parent Disclosure Schedule Article V Expenses Section 8.2(b)(iv) Parent Indemnified Parties Representatives Section 8.2(a)(i6.3 Parties. Preamble Party Preamble Paying Agent Section 3.2(a) parties Preamble Payee Proxy Statement Section 8.5 Payor 6.2(a) Purchaser Plans Section 8.5 Per Diem Taxes 6.10(c) Record Date Section 8.7(a6.2(d)(ii) Proceeding Replacement Financing Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment 2.3 Required Amount Section 2.10(f5.6(d) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Approval Section 2.12(b4.3(a) Surviving Corporation Section 2.1 Third Milestone Tail Period Section 2.10(g6.12(a) Third Milestone Payment Amount Takeover Provision Section 2.10(g)4.22(a) Top Customers Section 4.12 Top Suppliers Section 4.12 Transaction Litigation Section 6.7

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement: 401(k) Termination Date Section hereof in which such term is defined: 7.7(c) Adjusted Option Section 3.4(b) Adjusted RS Award Section 3.4(e) Adjusted RSU Award Section 3.4(d) Agreement Preamble Biogen Idec License Agreement Base Amount Section 4.7 Biogen Idec Supply Agreement 7.4(c) Book-Entry Shares Section 4.7 Books and Records 3.2(b)(ii) Certificate of Merger Section 2.12(f)(22.3 Certificates Section 3.2(b)(i) Claim Notice Change of Recommendation Section 8.3(a6.3(a) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Acquisition Agreement Section 6.3(a) Company Board of Directors Recitals Company Board Recommendation Recitals Company Capitalization Date Section 4.2(a) Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Letter Article IV Company Expenses Schedule Notes Section 2.13 7.14(b) Company Permits Section 4.9(b) Company Preferred Stock Section 4.2(a) Company SEC Documents Section 4.5(a) Company Stockholder Approval Section 4.3(a) Company Stockholders Recitals Company Stockholders’ Meeting Section 7.12(b) Continuing Employees Section 7.7(a) Converted Shares Section 3.1(b) Copyrights Section 1.1 Credit Facility Terminations Section 7.14(a) Current ESPP Offering Period Section 3.4(f) Debt Commitment Letter Section 5.6(a) DGCL Recitals Dissenting Shares Section 3.3(a) DOJ Section 7.2(b) Effective Time Section 2.3 Enforceability Limitations Section 4.3(b) Financing Section 5.6(a) Financing Entities Section 1.1 FTC Section 7.2(b) GAAP Section 4.5(b) HIPAA Section 1.1 Indemnified Parties Section 8.2(a)(ii7.4(a) Indenture Section 7.14(b) Integration Committee Section 7.1(c) Integration Plan Section 7.1(c) Intervening Event Section 6.3(d) IP Contracts Section 4.8(a4.14(h) Covered Party (PartiesMaterial Contracts Section 4.17(a) Material Customer Section 8.2(a)(ii4.19(a) Damages Material Customer Agreement Section 8.2(a)(i4.19(a) DGCL Material Government Bid Section 2.1 Document Retention Period 4.17(c) Material Reseller Section 2.12(f)(24.19(c) Drug Regulatory Agency Material Reseller Agreement Section 4.25 Effective Time 4.19(c) Material Supplier Section 2.2 ERISA 4.19(b) Material Supplier Agreement Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c4.19(b) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 3.1(a) Merger Sub Preamble Merger Sub Shares Section 3.1(c) New Plans Section 7.7(b) OFAC Section 4.9(e) Old Plans Section 7.7(b) Outside Date Section 9.1(d) Owned Real Property Section 4.16(a) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Governing Documents Section 5.1 Parties Preamble Party Preamble Patents Section 1.1 Paying Agent Section 3.2(a) Payment Fund Section 3.2(a) Payoff Letter Section 7.14(a) Proxy Statement Section 7.12(a) Qatalyst Section 4.22 Quarterly Dividend Section 6.1(b)(ii) Relevant Matters Section 10.9(a) Remaining Shares Section 3.1(b) Restricted Parties Section 8.2(a)(i4.9(g) parties Preamble Payee Sale Section 8.5 Payor 7.16(a) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b4.5(a) Surviving Corporation Company Section 2.1 Third Milestone Surviving Company Stock Section 2.10(g3.1(b) Third Milestone Payment Amount Termination Fee Section 2.10(g9.2(b)(i) Trade Secrets Section 1.1 Transactions Recitals Voting Agreement Recitals willful breach Section 9.2(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 510(k) Section hereof in which such term is defined: 5.6(b) Acceptance Time Section 2.4(a) Action Section 5.15 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 7.5(c)(ii) Bankruptcy Exception Section 4.7 Books and Records 5.13(b) Board Appointment Date Section 2.12(f)(22.4(a) Claim Notice Certificate of Merger Section 8.3(a3.3 Certificates Section 4.2(b) Closing Section 2.3 3.2 Closing Date Section 2.3 3.2 Company Preamble Company Adverse Recommendation Change Section 7.5(c)(i) Company Board Recommendation Section 2.3(a)(iv) Company Common Stock Recitals Company Disclosing Party Section 2.8 1.1 Company Disclosure Schedule Article IV Documents Section 5.10(a) Company Expenses Schedule Financial Advisor Section 2.13 5.3(c) Company Indemnified Parties Financial Statements Section 8.2(a)(ii5.7(b) Contracts Company Intellectual Property Section 4.8(a5.17(b) Covered Party (PartiesCompany Material Contract Section 5.13(a) Company Person Section 5.21(b) Company Plan(s) Section 8.2(a)(ii5.11(a) Damages Company Preferred Stock Section 8.2(a)(i5.2(a) Company Related Party Section 5.21(b) Company Representatives Section 7.4(a) Company SEC Filings Section 5.7(a) Company Stockholder Approval Section 5.3(b) Company Stockholders’ Meeting Section 7.2(a) Company Subsidiary Section 5.1 Compensation Committee Section 5.24 Continuing Directors Section 2.4(a) DGCL Section 2.1 Document Retention Period 3.1 Dissenting Shares Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 4.3 Effective Time Section 2.2 3.3 Employment Compensation Arrangement Section 5.24 End Date Section 9.1(b) ERISA Section 4.13(a5.11(a) ERISA Affiliate Section 4.13(a5.11(a) Finally Determined Exchange Fund Section 8.5(b4.2(a) First Milestone FDA Section 2.10(e5.6(a) First Milestone Payment Amount FDCA Section 2.10(e5.6(a) Indemnifying Party Improvements Section 8.3(a5.20(b) Instrument Indemnified Parties Section 2.12(c7.12(a) Independent Directors Section 2.4(b) Investments Section 5.2(d) IRS Section 5.11(b) JV Partner Section 5.21(b) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 4.1(a) Merger Sub Preamble Minimum Condition Section 2.1(b) Notice Period Section 7.5(d)(iii) Offer Recitals Offer Documents Section 2.1(g) Offer Price Recitals Parent Preamble Parent Disclosure Expenses Section 9.4(c) Parent Plans Section 7.18(a) Parent Share Price Section 1.1 Parent Representatives Section 7.4(a) Party Preamble Paying Agent Section 4.2(a) Proxy Statement Section 7.2(b) Registered Company Intellectual Property Section 5.17(a) Reimbursable Expenses Section 9.4(c) Related Party Financing Section 5.21(b) Schedule Article V Parent Indemnified Parties TO Section 8.2(a)(i2.1(g) parties Preamble Payee Schedule 14D-9 Section 8.5 Payor 2.3(b) Software Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent 1.1 Support Agreement Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone 3.1 Tail Period Section 2.10(g7.12(c) Third Milestone Payment Amount Takeover Provisions Section 2.10(g)2.3(a)(iii) Top-Up Option Section 2.2(a) Top-Up Option Shares Section 2.2(d) Transaction Litigation Section 7.8

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 401(k) Plan Section hereof in which such term is defined: 5.07(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 5.03(d)(i) Book-Entry Shares Section 4.7 Books and Records 2.02(b) Capitalization Date Section 2.12(f)(23.02(a) Claim Notice Certificate of Merger Section 8.3(a1.02 Certificates Section 2.02(b) Change of Board Recommendation Section 5.03(a)(iv) Closing Section 2.3 1.02 Closing Date Section 2.3 1.02 Company Preamble Company Common Stock Section 2.8 Board Recitals Company Board Recommendation Recitals Company Disclosure Schedule Article IV ARTICLE III Company Expenses Schedule Employees Section 2.13 5.07(a) Company Indemnified Parties Financial Statements Section 8.2(a)(ii3.07(a) Contracts Company Material Contract Section 4.8(a3.13(a) Covered Party (PartiesCompany Permits Section 3.05(a) Company Preferred Stock Section 8.2(a)(ii3.02(a) Damages Company Representatives Section 8.2(a)(i5.02(a) Company SEC Documents Section 3.06(a) Company Stockholder Approval Section 3.21 Confidentiality Agreement Section 5.02(c) D&O Insurance Section 5.08(c) DGCL Recitals Dispute Section 2.1 Document Retention Period 3.15(i) Dissenting Shares Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 2.03 Effective Time Section 2.2 ERISA 1.02 Electronic Delivery Section 4.13(a8.13 Employment Practices Section 3.12(a) ERISA Affiliate Equity Plan Documents Section 4.13(a2.04(b) Finally Determined Equity Plan Stock Section 8.5(b2.04(b) First Milestone Exon-▇▇▇▇▇▇ Filing Section 2.10(e5.04(c) First Milestone Payment Export Approvals Section 3.05(e) Guarantee Section 8.15(c) Guaranteed Obligations Section 8.15(a) Guarantor Section 8.15(a) Insurance Policies Section 3.17 Intervening Event Notice Period Section 5.03(e)(i) Lease Agreement Section 3.18(c) Leased Real Property Section 3.18(c) LGPL Section 3.15(f) Maximum Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c5.08(c) Merger Section 2.1 Recitals Merger Certificate Section 2.2 Consideration Recitals Merger Sub Preamble Most Recent Balance Sheet Section 3.09(a)(i) New Plans Section 5.07(a) Parent Preamble Parent Disclosure Schedule Article V 401(k) Plan Section 5.07(c) Parent Indemnified Parties Representatives Section 8.2(a)(i5.02(a) parties Preamble Payee Parent Subsidiary Section 8.5 Payor 4.03(a) Parent Welfare Plan Section 8.5 Per Diem Taxes 5.07(a) Paying Agent Section 8.7(a2.02(a) Proceeding Proxy Statement Section 4.17 Royalties 1.03(a) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 2.10(h3.06(a) Second Milestone Section 2.10(f16 Section 5.10 Shares Recitals Significant Customer Section 3.23 Special Meeting Section 1.03(e) Second Milestone Payment Amount Superior Proposal Notice Period Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b5.03(d)(i) Surviving Corporation Recitals Takeover Law Section 2.1 Third Milestone 3.03(b) Termination Fee Section 2.10(g7.02(b) Third Milestone Payment Amount Unvested Cash Section 2.10(g2.04(b) WARN Act Section 3.12(e) Worker List Section 3.12(g)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: AAA Section 9.3(b) Adjustment Event Section 2.6 Aggregate Company Consideration Section 2.2(b) Aggregate N.Z. Consideration Section 2.1(b) Aggregate U.S. Consideration Section 2.1(a) Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 9.3(b) Australian Business Number Section 4.7 Books and Records 4.12(a) Australian Company Preamble Australian Indemnification Obligations Section 2.12(f)(29.2(a)(i) Blue Sky Laws Section 4.17 Cash Consideration Section 2.4(b) Cash Percentage Section 2.4(a) CERCLA Section 4.13 Claim Notice Section 8.3(a9.3(a) Closing Section 2.3 3.1 Closing Date Section 2.3 3.1 Company Preamble Cap Section 9.5(b) Company Common Stock Marks Section 2.8 4.20(b) Company Disclosure Schedule Article IV Patents Section 4.20(c) Company Expenses Schedule Percentage Interest Section 2.13 2.2(b) Company Registered Copyrights Section 4.20(d) Company Registered IP Section 4.20(g) Company Shareholders Recitals Company Shares Recitals Company Software Section 4.20(l) Copyrights Section 4.20(a) Damages Section 9.2(a) Disposition Section 6.9 Dispute Notice Section 9.3(b) Double Taxation Agreement Section 4.12(a) Effective Period Section 6.2(d) Employee Loans Section 4.8(a) Escrow Account Section 2.5 Escrow Agent Section 2.5 Escrow Amount Section 2.5 Escrow Shares Section 2.5 Escrow Value Section 9.6 Foreign Status Certificate Section 3.2(n) GST Section 4.12(a) Hazardous Materials Section 4.13 Holder Section 6.2(f)(iii) Inbound License Agreements Section 4.20(i) Indemnified Parties Party Section 8.2(a)(ii9.3(a) Indemnitor Section 9.3(a) Intellectual Property Section 4.20(a) Lock-up Section 6.9 Lock-up Period Section 6.9 Marks Section 4.20(a) Mask Works Section 4.20(a) Material Contracts Section 4.8(a) Covered Net Cash Deficit Section 2.7(b) Net Cash Estimate Section 2.7(a) N.Z. Company Preamble N.Z. Purchase Price Section 2.1(d) N.Z. Shareholders Recitals N.Z. Shares Recitals Net Cash Estimate Section 2.7(a) OSR Section 6.14 Outside Date Section 8.1(b) Parent Preamble Parent SEC Documents Section 5.5 Patents Section 4.20(a) Personal Element Section 4.20(p) Privacy Policies Section 4.20(p) Proceeding Section 4.18 Purchaser Preamble Purchaser Indemnified Parties Section 9.2(a) Real Property Section 4.5(c) Registration Indemnified Party (PartiesSection 6.2(g)(iii) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Registration Indemnifying Party Section 8.3(a6.2(g)(iii) Instrument Registration Statement Section 2.12(c6.2(a) Merger Share Consideration Section 2.1 Merger Certificate 2.4(b) Share Percentage Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent 2.4(a) Shareholder Indemnified Parties Section 8.2(a)(i9.2(b) parties Preamble Payee Shares Section 8.5 Payor 2.3 Software Section 8.5 Per Diem 4.20(l) Tax Section 4.12(a) Tax Return Section 4.12(a) Taxable Section 4.12(a) Taxes Section 8.7(a4.12(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Threshold Amount Section 2.10(f9.5(a) Stockholder Consent Trade Secrets Section 4.20(a) Transaction Fees Section 10.12 U.S. Company Preamble U.S. Purchase Price Section 2.1(b) U.S. Shareholder Recitals Stockholder Representative Preamble Super Majority U.S. Shares Recitals Unique Identifying Number Section 2.12(b4.20(p) Surviving Corporation Unstamped Transfers Section 2.1 Third Milestone 6.14 User Data Section 2.10(g4.20(p) Third Milestone Payment Amount Violation Section 2.10(g6.2(g)(i)

Terms Defined Elsewhere. The For purposes of this Agreement, each of the following is a list of additional terms (as capitalized below) when used in this Agreement and a reference will have the meaning ascribed to such term in the Section hereof in which set forth opposite such term is definedterm: Action Section 5.10(b) Agreement Preamble Biogen Idec License Agreement Alternative Financing Section 4.7 Biogen Idec Supply Agreement 5.16(c) Alternative Proposal Section 4.7 Books and Records 5.4(g) Appraisal Rights Section 2.12(f)(22.1(b) Claim Notice Book-Entry Shares Section 8.3(a2.2(a) Burdensome Condition Section 5.7(c) Cancelled Shares Section 2.1(a)(ii) Certificate of Merger Section 1.3 Certificates Section 2.2(a) Change of Recommendation Section 5.4(c) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Code Section 2.2(b)(iii) Commitment Letter Section 4.6(a) Common Stock Section 2.1(a)(i) Company Preamble Company Common Stock Section 2.8 Board Recitals Company Disclosure Schedule Letter Article IV 3 Company Expenses Schedule PSU Consideration Section 2.13 2.3(c) Company Indemnified Recommendation Section 3.3 Company Registered IP Section 3.10(a) Company Related Parties Section 8.2(a)(ii7.3(d) Contracts Company RSU Consideration Section 4.8(a2.3(a) Covered Party (PartiesCompany SEC Reports Section 3.5(a) Company Stockholder Approval Section 8.2(a)(ii3.20 Company Stockholders’ Meeting Section 5.5(b) Damages Company Termination Fee Section 8.2(a)(i7.3(a) Confidentiality Agreement Section 5.3(b) Continuation Period Section 5.6(a) Data Breach Section 3.10(a) Data Protection Requirements Section 3.10(f) Definitive Agreements Section 5.16(a) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period Section 2.12(f)(22.1(b) Drug Regulatory Agency Section 4.25 ▇▇▇▇▇ Article 3 Effective Time Section 2.2 ERISA 1.3 Employee Census Section 4.13(a3.15(g) ERISA Affiliate End Date Section 4.13(a7.1(b) Finally Determined Filed SEC Reports Article 3 Financing Section 8.5(b4.6(a) First Milestone Financing Amounts Section 2.10(e4.6(d) First Milestone Payment Indemnified Party Section 5.10(b) Intervening Event Section 5.4(i) Intervening Event Notice Section 5.4(e) Intervening Event Notice Period Section 5.4(e) Leases Section 3.9(a) Legal Restraint Section 6.1(b) Lenders Section 4.6(a) Made Available to Parent Section 8.12 Material Contract Section 3.11(a) Maximum Amount Section 2.10(e5.10(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c3.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 2.1(a)(i) Merger Sub Preamble New Plans Section 5.6(b) Old Plans Section 5.6(b) Owned Real Property Section 3.9(a) Parent Preamble Parent Approvals Section 4.2(b) Parent Disclosure Schedule Letter Article V 4 Parent Indemnified Material Adverse Effect Section 4.1 Parent Related Parties Section 8.2(a)(i7.3(d) parties Preamble Payee Parent RSU Section 8.5 Payor 2.3(b) Parent Termination Fee Section 8.5 Per Diem Taxes 7.3(b)(i) Paying Agent Section 8.7(a2.2(a) Proceeding Payment Fund Section 4.17 Royalties 2.2(a) Permitted Change of Recommendation Section 2.10(h5.4(e) Second Milestone Permitted Termination Section 2.10(f5.16(b) Second Milestone Payment Amount Prohibited Modifications Section 2.10(f5.16(b) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Proposed Dissenting Shares Section 2.12(b2.1(b) Representatives Section 5.3(a) Share Section 2.1(a)(i) Subsidiary Shares Section 2.1(a)(i) Superior Proposal Section 5.4(h) Superior Proposal Notice Section 5.4(d) Superior Proposal Notice Period Section 5.4(c) Surviving Corporation Section 2.1 Third Milestone 1.1 Takeover Statute Section 2.10(g3.19 Tax Incentive Section 3.15(g) Third Milestone Payment Amount Terminating Company PSU Section 2.10(g2.3(c) Terminating Company RSU Section 2.3(a) Termination Date Section 5.1(a)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Act Section 2.1(b) Affected Employees Section 6.7(a) Agreement Preamble Biogen Idec License Agreement Date Preamble Benefit Plans Section 4.7 Biogen Idec Supply Agreement 3.16(a) Burdensome Action Section 4.7 Books and Records Section 2.12(f)(26.4(c) Claim Calculation Notice Section 8.3(a2.5(b) Closing Section 2.3 2.3(a) Closing Date Section 2.3 2.3(a) Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Preamble to Article IV 3 Company Expenses Schedule Sale Transaction Section 2.13 6.3(a) Company Indemnified Trade Secrets Section 3.12(c) Competing Business Section 6.15(a) Confidential Information Section 6.2(e) Continuation Period Section 6.7(a) Contracting Parties Section 8.2(a)(ii11.10 Contribution Recitals Conversion Recitals Credit Agreement Section 2.3(c)(iv) Contracts Debt Financing Section 4.8(a) Covered Party (Parties) 5.6 Debt Financing Commitment Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention 5.6 Dispute Period Section 2.12(f)(210.5(b) Drug Regulatory Agency DOJ Section 4.25 Effective Time 6.4(b) Enforceability Exceptions Section 2.2 3.3 ERISA Section 4.13(a3.16(a) ERISA Affiliate Estimated Cash Section 4.13(a2.3(a)(iii) Finally Determined Estimated Closing Statement Section 8.5(b2.3(a) First Milestone Estimated Indebtedness Section 2.10(e2.3(a)(ii) First Milestone Payment Amount Estimated Non-Cash Working Capital Section 2.10(e2.3(a)(i) Estimated Transaction Expenses Section 2.3(a)(iv) Final Election Allocation Section 8.3 FTC Section 6.4(b) Holdco Preamble Indemnified Party Section 10.5(a) Indemnifying Party Section 8.3(a10.5(a) Instrument Initial Calculations Section 2.12(c2.5(a) Merger Interests Recitals IT Systems Section 2.1 Merger Certificate 3.12(f) Leased Real Property Section 2.2 Merger Sub Preamble 3.22(b) Licensed Company Intellectual Property Section 3.12(b) Material Breach Section 9.2 Material Contracts Section 3.14(a) Non-Disclosure Agreement Section 6.2(d) Nonparty Affiliates Section 11.10 Notice Section 10.5(a) OFAC Section 3.9(b) Outside Date Section 9.1(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i10.2 Parties Preamble Party Preamble Personal Information Section 3.25 Pre-Closing Period Section 8.4(a) parties Privacy Laws Section 3.25 Proposed Election Allocation Section 8.3 Purchaser Preamble Payee Purchaser Related Parties Section 8.5 Payor 9.3(b) Purchaser Related Party Section 8.5 Per Diem 9.3(b) Real Property Leases Section 3.22(b) Registered Company Intellectual Property Section 3.12(a) Released Parties Section 10.9 Releasing Parties Section 10.9 Reorganization Recitals Restricted Commitment Amendments Section 6.13(a) Restricted Period Section 6.15(a) Reverse Termination Fee Section 9.3(a) Seller Preamble Seller Indemnified Parties Section 10.3 Seller Indemnifying Parties Section 10.2 Seller Indemnifying Party Section 10.2 Seller Parties Preamble Settlement Accountants Section 2.5(c) Straddle Period Section 8.4(a) -19- Telecommunications Providers Section 6.15(a) Third-Party Claim Section 10.5(a) Transfer Taxes Section 8.7(a) Proceeding 8.6 Transferred Employees Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g2.3(e)

Terms Defined Elsewhere. The Each of the following terms is a list defined in the Section of additional terms used in this Agreement and a reference to the Section hereof in which set forth opposite such term is definedbelow: Agreement "Acceptable Confidentiality Agreement" Section 5.3(j)(i) "Agreement" Preamble Biogen Idec License Agreement "Amended and Restated Agreement" Preamble "Amended and Restated Voting Agreement" Recitals "Amendment No. 1" Preamble "Bankruptcy and Equity Exception" Section 4.7 Biogen Idec Supply Agreement 3.3(a) "Book-Entry Shares" Section 4.7 Books and Records 2.2(a) "Certificate of Merger" Section 2.12(f)(21.3 "Certificates" Section 2.2(a) Claim Notice "Change of Recommendation" Section 8.3(a5.3(d) "Closing" Section 1.2 "Closing Date" Section 2.3 Closing Date 1.2 "Company" Preamble "Company 401(k) Plans" Section 2.3 6.7(c) "Company Preamble Acquisition Agreement" Section 5.3(d) "Company Benefit Plans" Section 3.9(a) "Company Board" Section 3.3(a) "Company Board Recommendation" Section 3.3(a) "Company Capitalization Date" Section 3.2(a) "Company Common Stock Section 2.8 Stock" Recitals "Company Disclosure Schedule Letter" Article IV III "Company Expenses Schedule Equity Awards" Section 2.13 2.4(e) "Company Leased Real Property" Section 3.17(b) "Company Overlap Product" Section 6.2(c) "Company Permits" Section 3.7(b) "Company Preferred Stock" Section 3.2(a) "Company Remedial Action" Section 6.2(c) "Company Restricted Share Awards" Section 2.4(c) "Company RSU Awards" Section 2.4(b) "Company SEC Documents" Section 3.4(a) "Company Stock Option" Section 2.4(a) "Competing Proposal" Section 5.3(j)(i) "Continuing Employee" Section 6.7(a) "D&O Insurance Policy" Section 6.4 "DGCL" Section 1.1 "Dissenting Share" Section 2.3(a) "DOJ" Section 6.2(b) "Effective Time" Section 1.3 "Exchange Agent" Section 2.2(a) "Exchange Fund" Section 2.2(a) "Execution Date" Preamble "FDA Laws" Section 3.13(a) "Federal Health Care Programs" Section 3.13(j) "FTC" Section 6.2(b) "GAAP" Section 3.4(b) "GLP" Section 3.13(c) "HIPAA" Section 3.13(i) "IND" Section 3.13(d) "Indemnified Parties Parties" Section 8.2(a)(ii6.4 "Material Contracts" Section 3.20(a) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)"Merger" Recitals

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Section hereof in which such term is definedAgreement, as indicated below: Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 10.08(b) Base Premium Section 4.7 Books and Records 7.04(d) Change in Recommendation Section 2.12(f)(2) Claim Notice Section 8.3(a6.02(f) Closing Section 2.3 2.02 Closing Date Section 2.3 2.02 Company Preamble Company Common Stock Board Recitals Company Equity Interests Section 2.8 4.02(a) Company Disclosure Schedule Article IV Group Section 9.02(d) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.02(b) Competing Proposal Section 8.2(a)(ii6.02(e) Contracts Competition Laws Section 4.8(a4.05 Covered Persons Section 7.04(a) Covered Party (Parties) Deposit Agreement Section 8.2(a)(ii) Damages 3.05 Depositary Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 3.05 Effective Time Section 2.2 ERISA 2.03 Enforceability Exceptions Section 4.13(a4.03 GAAP Section 4.06(b) ERISA Affiliate Governmental Entity Section 4.13(a4.05 HKIAC Section 10.08(b) Finally Determined HKIAC Rules Section 8.5(b10.08(b) First Milestone Indemnification Agreements Section 2.10(e7.04(a) First Milestone Payment Amount Intervening Event Section 2.10(e6.02(h) Indemnifying Party Intervening Event Termination Section 8.3(a6.02(h) Instrument Legal Proceeding Section 2.12(c5.06 Limited Guarantee Recitals Merger Recitals Merger Consideration Section 3.02(a) Merger Consideration Fund Section 2.1 Merger Certificate Section 2.2 3.02(a) Merger Sub Preamble NASDAQ Section 4.02(a) Non-Required Remedy Section 7.02(e) Option Consideration Section 3.03(a) Parent Preamble Parent Disclosure Group Section 9.02(d) Parent Termination Fee Section 9.02(c) Parties Preamble Party Preamble Paying Agent Section 3.02(a) Per ADS Merger Consideration Section 3.01(b) Per Share Merger Consideration Section 3.01(a) Plan of Merger Section 2.03 Record ADS Holders Section 6.03(c) Record Date Section 6.03(c) Rollover Agreement Recitals Rollover Shareholders Recitals RSU Consideration Section 3.03(c) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.06(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.03(a) parties Preamble Payee SEC Documents Section 8.5 Payor 4.06(a) Securities Act Section 8.5 Per Diem Taxes 4.06(a) Special Committee Recitals Superior Proposal Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b6.02(g) Surviving Corporation Company Section 2.1 Third Milestone 2.01 Takeover Statute Section 2.10(g) Third Milestone Payment Amount 7.05 Transaction Litigation Section 2.10(g7.07 Transactions Recitals Uncertificated Shares Section 3.02(b)(i)

Terms Defined Elsewhere. The Each of the following terms is a list of additional terms used defined in this Agreement and a reference to the Section hereof in which set forth opposite such term is definedterm: Affected Employee Section 7.2(b) Agreement Preamble Biogen Idec License Agreement Alternative Debt Financing Section 4.7 Biogen Idec Supply Agreement 7.11(b) ANA Section 4.7 Books and Records 6.7(a) Ancillary Scheme Documentation Section 2.12(f)(23.1(b) Claim Notice AQN Recitals ASHUSA Section 8.3(a6.7(a) ASUSHI Section 6.7(a) Benefits Continuation Period Section 7.2(b) Bidco Preamble Bidco Board Recitals Bidco Organizational Documents Section 5.5 Bidco Related Parties Section 9.3(e) Capitalization Date Section 4.8(a) CFO Certificates Section 7.12(a)(xi) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 6.2(a) Company Disclosure Schedule Article IV Approval Time Section 6.2(b) Company Expenses Schedule Board Recitals Company Group Securities Section 2.13 4.8(e) Company Indemnified Material Contract Section 4.19(a) Company Material Contracts Section 4.19(a) Company Organizational Documents Section 4.3 Company Payment Fund Section 2.1(b) Company Permits Section 4.12 Company Related Parties Section 8.2(a)(ii9.3(e) Contracts Company RSU Consideration Section 4.8(a2.3(b) Covered Party (PartiesCompany SEC Documents Section 4.9(a) Company Securities Section 8.2(a)(ii4.8(d) Damages Company Share Option Consideration Section 8.2(a)(i2.3(a) DGCL Company Termination Fee Section 2.1 Document Retention Period 9.3(a) Cost Exceptions Section 2.12(f)(27.12(b) Drug Regulatory Agency Counsel Section 4.25 3.1(h) Court Documentation Section 3.1(e) Court Order Section 1.3 Credit Agreement Payoff Letters Section 6.5 Data Privacy Obligations Section 4.21(a) Debt Commitment Letter Section 5.7(b) Debt Financing Section 5.7(b) Definitive Debt Financing Agreements Section 7.11(a) Effective Time Section 2.2 ERISA 1.3 End Date Section 4.13(a9.1(b)(i) ERISA Affiliate Enforceability Exceptions Section 4.13(a4.5 Enforcement Cap Section 9.3(c) Finally Determined Enforcement Expenses Section 8.5(b9.3(c) First Milestone Equity Commitment Letter Section 2.10(e5.7(a) First Milestone Payment Amount Equity Financing Section 2.10(e5.7(a) Indemnifying Financing Section 5.7(b) Financing Conditions Section 5.7(c) Financing Costs Section 7.12(b) Financing Documents Section 5.7(b) Financing Letters Section 5.7(b) Forms of Proxy Section 3.1(b) Guaranty Recitals IP Licenses Section 4.17(c) New Company Plans Section 7.2(c) New Debt Financing Letters Section 7.11(b) Parties Preamble Party Preamble Paying Agent Section 8.3(a2.1(b) Instrument Per Share Consideration Recitals Remedy Action Section 2.12(c7.1(d) Merger Required Amounts Section 2.1 Merger Certificate 5.7(f) Restructuring Transactions Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties 6.7(a) Risk Management Policy Section 8.2(a)(i4.23 Scheme Documentation Section 3.1(c) parties Preamble Payee Support Agreement Recitals Transaction Recitals Transaction Litigation Section 8.5 Payor Section 8.5 Per Diem 6.3 Transfer Taxes Section 8.7(a10.4 THIS VOTING AND TRANSACTION SUPPORT AGREEMENT (this “Agreement”) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(gis made and entered into as of May __, 2024, by and among California Buyer Limited, a private limited company incorporated in England and Wales (“Bidco”), Atlantica Sustainable Infrastructure plc, a public limited company incorporated in England and Wales (the “Company”), Algonquin Power & Utilities Corp., a company incorporated under the federal laws of Canada (“Algonquin”), Liberty (AY Holdings), B.V., a corporation incorporated under the laws of the Netherlands (“AY Holdings”, and together with Algonquin, the “Shareholders” and each a “Shareholder”), direct and indirect shareholders of the Company. Capitalized terms used but not defined herein have the respective meanings given to them in the Transaction Agreement (as defined below).

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acceptance Time Section hereof in which such term is defined: 2.4(a) Action Section 5.14 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 7.5(c)(ii) Articles of Merger Section 4.7 Books and Records 3.3 Bankruptcy Exception Section 2.12(f)(25.12(b) Claim Notice Board Appointment Date Section 8.3(a2.4(a) Certificates Section 4.2(b) Closing Section 2.3 3.2 Closing Date Section 2.3 3.2 COI Section 5.13(a)(vi) Company Preamble Company Adverse Recommendation Change Section 7.5(c)(i) Company Board Recommendation Section 2.3(a)(iv) Company Common Stock Recitals Company Disclosing Party Section 2.8 1.1(cc) Company Disclosure Schedule Article IV Documents Section 7.20(a) Company Expenses Schedule Financial Advisor Section 2.13 5.3(c) Company Indemnified Parties Financial Statements Section 8.2(a)(ii5.6(b) Contracts Company Intellectual Property Section 4.8(a5.16(b) Covered Party (PartiesCompany Material Contract Section 5.12(a) Company Plan(s) Section 8.2(a)(ii5.10(a) Damages Company Preferred Stock Section 8.2(a)(i5.2(a) DGCL Company Representatives Section 2.1 Document Retention Period 7.4(a) Company SEC Filings Section 2.12(f)(25.6(a) Drug Regulatory Agency Company Stockholder Approval Section 4.25 5.3(b) Company Stockholders’ Meeting Section 7.2(a) Company Subsidiary Section 5.1 Compensation Committee Section 5.25 Continuing Directors Section 2.4(a) Effective Time Section 2.2 3.3 Employment Compensation Arrangement Section 5.25 End Date Section 9.1(b) ERISA Section 4.13(a5.10(a) ERISA Affiliate Section 4.13(a5.10(a) Finally Determined Exchange Fund Section 8.5(b4.2(a) First Milestone Indemnified Parties Section 2.10(e7.12(a) First Milestone Payment Amount Independent Directors Section 2.10(e2.4(b) Indemnifying Party Investments Section 8.3(a5.2(d) Instrument IRS Section 2.12(c5.10(b) JV Partner Section 1.1(o) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 4.1(a) Merger Sub Preamble Minimum Condition Section 2.1(b) Notice Period Section 7.5(d)(iii) Offer Recitals Offer Documents Section 2.1(g) Offer Price Recitals Parent Preamble Parent Disclosure Expenses Section 9.4(c) Parent Plans Section 7.18(a) Parent Representatives Section 7.4(a) Party Preamble Paying Agent Section 4.2(a) Proxy Statement Section 7.2(b) Purchaser Welfare Benefit Plans Section 7.18(c) Reimbursable Expenses Section 9.4(c) SCC Section 3.3 Schedule Article V Parent Indemnified Parties TO Section 8.2(a)(i2.1(g) parties Preamble Payee Schedule 14D-9 Section 8.5 Payor 2.3(b) Software Section 8.5 Per Diem Taxes Section 8.7(a1.1(kk) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Support Agreement Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone 3.1 Tail Period Section 2.10(g7.12(c) Third Milestone Payment Amount Takeover Provisions Section 2.10(g2.3(a)(iii) Top-Up Option Section 2.2(a) Top-Up Option Shares Section 2.2(d) VSCA Section 2.2(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement: 2024 Notes Section 1.1 2024 Notes Indenture Section 1.1 2029 Notes Indenture Section 1.1 401(k) Termination Date Section 7.7(c) ABL Agreement and a reference to the Section hereof in which such term is defined: 1.1 ABL Amendment Section 1.1 Agreement Preamble Biogen Idec License Agreement Antitrust Remedial Action Section 4.7 Biogen Idec Supply Agreement 7.2(a) Base Amount Section 4.7 Books and Records 7.4(c) Book-Entry Shares Section 2.12(f)(23.2(b)(ii) Claim Notice Cancelled Shares Section 8.3(a3.1(b) Certificate of Merger Section 2.3 Certificates Section 3.2(b)(i) Change of Recommendation Section 6.3(b) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Collective Bargaining Agreements Section 4.11(a) Company Preamble Company Acquisition Agreement Section 6.3(b) Company Board of Directors Recitals Company Board Recommendation Recitals Company Capitalization Date Section 4.2(a) Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Letter Article IV Company Expenses Schedule Leases Section 2.13 4.16(b) Company Permits Section 4.9(b) Company Preferred Stock Section 4.2(a) Company SEC Documents Section 4.5(a) Company Stockholder Approval Section 4.3(a) Company Stockholders Recitals Company Stockholders’ Meeting Section 7.12(b) Continuing Employees Section 7.7(a) Converted Shares Section 3.1(b) Copyrights Section 1.1 Credit Facility Terminations Section 7.14(a) Delayed Draw Term Loan Agreement Section 1.1 DGCL Recitals Discharge Section 7.14(b) Dissenting Shares Section 3.3(a) DOJ Section 7.2(b) Effective Time Section 2.3 Enforceability Limitations Section 4.3(b) Equity Award Consideration Section 3.4(a) Existing ABL Agreement Section 1.1 Financing Entities Section 1.1 FTC Section 7.2(b) GAAP Section 4.5(b) Indemnified Parties Section 8.2(a)(ii7.4(a) Intervening Event Section 6.3(e) Leased Real Property Section 4.16(b) Material Contracts Section 4.8(a4.17(a) Covered Party (PartiesMaterial Customer Section 4.19(a) Material Customer Agreement Section 8.2(a)(ii4.19(a) Damages Material Supplier Section 8.2(a)(i4.19(b) DGCL Material Supplier Agreement Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c4.19(b) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 3.1(a) Merger Sub Preamble Merger Sub Shares Section 3.1(c) New Plans Section 7.7(b) OFAC Section 4.9(e) Old Plans Section 7.7(b) Outside Date Section 9.1(d) Owned Real Property Section 4.16(a) Parent Preamble Parent Disclosure Schedule Article V Governing Documents Section 5.1 Parent Indemnified Termination Fee Section 9.2(c) Parties Preamble Party Preamble Patents Section 1.1 Paying Agent Section 3.2(a) Payment Fund Section 3.2(a) Payoff Letter Section 7.14(a) Proxy Statement Section 7.12(a) Real Property Section 4.16(b) Relevant Matters Section 10.9(a) Restricted Parties Section 8.2(a)(i4.9(f) parties Preamble Payee ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b4.5(a) Surviving Corporation Company Section 2.1 Third Milestone Surviving Company Stock Section 2.10(g3.1(b) Third Milestone Payment Amount Term Loan B Credit Agreement Section 2.10(g)1.1 Trade Secrets Section 1.1 Transactions Recitals USB Section 1.1 willful breach Section 9.2(a) ARTICLE II

Terms Defined Elsewhere. The following is a list of additional table sets forth the terms used that are defined elsewhere in this Agreement: Acquisition Proposal Section 7.3(a)(ii) Affiliate Termination Agreement and a reference to the Section hereof in which such term is defined: Recitals Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply 5.3(a) Book-Entry Shares Section 2.2(b)(ii) Cancelled Shares Section 2.1(b) Capitalization Date Section 3.2(d) CEO Separation Agreement Recitals Certificate of Merger Section 4.7 Books and Records 1.2 Certificates Section 2.12(f)(22.2(b)(i) Claim Notice Chosen Courts Section 8.3(a8.15(b) Class A Common Stock Recitals Class B Non-Voting Common Stock Section 3.2(a) Class V Common Stock Section 3.2(a) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 COBRA Section 3.12(h) Company Preamble Company Common Stock Benefit Plan Section 2.8 3.12(a) Company Board Recitals Company Board Recommendation Section 3.3(b) Company Board Recommendation Change Section 5.3(c) Company Bylaws Section 3.1 Company Charter Section 3.1 Company Disclosure Schedule Article IV 3 Company Expenses Schedule Lease Agreement Section 2.13 3.15(b) Company Indemnified Material Contract Section 3.17(a) Company Option Section 2.4(a) Company Parties Section 8.2(a)(ii7.3(b) Contracts Company Registered Intellectual Property Section 4.8(a3.18(a) Covered Party (PartiesCompany RSU Consideration Section 2.4(b) Company RSUs Section 8.2(a)(ii2.4(b) Damages Company SEC Documents Section 8.2(a)(i3.5(a) DGCL Company SEC Financial Statements Section 2.1 Document Retention 3.5(c) Company Stockholder Approval Section 3.3(d) Company Stockholder Meeting Section 5.4(c) Company Stockholders Recitals Company Systems Section 3.18(f) Company-Leased Real Property Section 3.15(b) Company-Owned Real Property Section 3.15(a) Confidential Information Section 3.18(d) Confidentiality Agreement Section 5.2(b) Continuing Employee Section 5.16(a) Data Partners Section 3.19 Debt Financing Section 5.5(a) Delisting Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)5.13

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.09 Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 10.08(b) Base Premium Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a7.04(d) Closing Section 2.3 2.02 Closing Date Section 2.3 2.02 Company Preamble Company Common Stock Board Recitals Company Equity Interests Section 2.8 4.02(a) Company Disclosure Schedule Article IV Group Section 9.02(d) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.02(b) Competing Proposal Section 8.2(a)(ii) Contracts Section 4.8(a6.02(d) Covered Party (PartiesPersons Section 7.04(a) Deposit Agreement Section 8.2(a)(ii3.05 Depositary Section 3.05 Dissent Notice Section 3.06(d) Damages Dissent Right Section 8.2(a)(i3.06(d) DGCL Dissenting Shareholders Section 2.1 Document Retention Period 3.06(a) Dissenting Shares Section 2.12(f)(23.06(a) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.03 Enforceability Exceptions Section 4.13(a4.03 Equity Commitment Letter Section 5.05(a) ERISA Affiliate Equity Commitment Letters Section 4.13(a5.05(a) Finally Determined Equity Financing Section 8.5(b5.05(a) First Milestone GAAP Section 2.10(e4.06(b) First Milestone Payment Amount Governmental Entity Section 2.10(e4.05 HKIAC Section 10.08(b) Indemnifying Party HKIAC Rules Section 8.3(a10.08(b) Instrument Indemnification Agreements Section 2.12(c7.04(a) Intervening Event Section 6.02(h) Intervening Event Termination Section 6.02(h) Legal Proceeding Section 5.06 Limited Guarantee Recitals Merger Recitals Merger Consideration Section 3.02(a) Merger Consideration Fund Section 2.1 Merger Certificate Section 2.2 3.02(a) Merger Sub Preamble Non-Required Remedy Section 7.02(d) NYSE Section 4.02(a) OTC Market Section 4.02(a) Parent Preamble Parent Disclosure Group Section 9.02(d) Parent Termination Fee Section 9.02(c) Parties Preamble Party Preamble Paying Agent Section 3.02(a) Per ADS Merger Consideration Section 3.01(b) Per Share Merger Consideration Section 3.01(a) Plan of Merger Section 2.03 Record ADS Holders Section 6.03(c) Record Date Section 6.03(c) Rollover Agreements Recitals Rollover Shareholders Recitals ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.06(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.03(a) parties Preamble Payee SEC Documents Section 8.5 Payor 4.06(a) Securities Act Section 8.5 Per Diem Taxes 4.06(a) Share Certificates Section 8.7(a3.02(b)(i) Proceeding Special Committee Recitals Superior Proposal Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b6.02(f) Surviving Corporation Company Section 2.1 Third Milestone 2.01 Takeover Statute Section 2.10(g) Third Milestone Payment Amount 7.05 Transaction Litigation Section 2.10(g7.07 Transactions Recitals Uncertificated Shares Section 3.02(b)(i)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: Acceptable Confidentiality Agreement and a reference to the Section hereof in which such term is defined: 7.4(b) Acquisition Agreement Section 7.4(a) Agreement Preamble Biogen Idec License Agreement Book-Entry Share Section 4.7 Biogen Idec Supply Agreement 3.1(a)(ii) Certificate Section 4.7 Books and Records 3.1(a)(ii) Certificate of Limited Partnership Section 2.12(f)(24.1(c) Claim Notice Certificate of Partnership Merger Section 8.3(a2.1(c)(ii) Change in Company Recommendation Section 7.4(b)(iii) Change in Parent Recommendation Section 7.4(b)(iii) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Code Recitals Company Preamble Company 401(k) Plan Section 4.14(b) Company Articles of Merger Section 2.1(a)(ii) Company Board Designee Section 7.22 Company Bylaws Section 4.1(c) Company Charter Section 4.1(c) Company Common Stock Recitals Company Development Properties Section 2.8 4.12(h) Company Development Property Section 4.12(h) Company Disclosure Schedule Article IV Company Expenses Schedule Employee Programs Section 2.13 4.14(a) Company Equity Award Section 4.3(c) Company Governing Documents Section 4.1(c) Company Merger Section 2.1(a)(i) Company Merger Certificates Section 2.1(a)(ii) Company Merger Effective Time Section 2.1(a)(ii) Company Parties Preamble Company Preferred Stock Section 4.3(a) Company Properties Section 4.12(a) Company Recommendation Section 4.2(b) Company SEC Reports Section 4.8(a) Company Stockholder Approval Section 4.18 Company Stockholder Meeting Section 7.1(c) Company Subsidiaries Section 4.1(b) Company Subsidiary Section 4.1(b) Company Tax Protection Agreement Section 6.1(w) Consent Solicitations Section 7.20(b) Continuing Employee Section 7.8(a) Continuing Employees Section 7.8(a) Contribution Section 2.1(b)(i) Contribution and Issuance Effective Time Section 2.1(b)(ii) Debt Offer Documents Section 7.20(b) DLLCA Section 2.1(a)(i) Drop Dead Date Section 9.1(b)(iv) DSOS Section 2.1(a)(ii) Encumbrances Section 4.12(a) Exchange Agent Section 3.3(a) Exchange Fund Section 3.3(a) Exchange Ratio Section 3.1(a)(ii) Form S-4 Section 4.6 Fractional Share Consideration Section 3.1(a)(ii) ▇▇▇▇▇▇▇ ▇▇▇▇▇ Section 5.14 HCERA Section 4.14(i) Health Plan Section 4.14(i) Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e7.5(a) Indemnifying Party Section 8.3(a7.5(a) Instrument Indiana Secretary Section 2.12(c2.1(a)(ii) Interim Period Section 6.1 Intervening Event Notice Period Section 7.4(b)(v) Issuance Section 2.1(b)(i) Letter of Transmittal Section 3.3(c) Maryland Court Section 10.7(b) Maximum Premium Section 7.5(c) Merger Consideration Section 2.1 Merger Certificate 3.1(a)(ii) Mergers Section 2.2 Merger Sub 2.1(c)(i) New OP Units Section 3.1(b)(iii) Note Offers and Consent Solicitations Section 7.20(b) Notice Period Section 7.4(b)(iv) Offers to Exchange Section 7.20(b) Offers to Purchase Section 7.20(b) OP Unit Form S-4 Section 7.1(a) Other Filings Section 7.2 Parent Preamble Parent Preamble Bylaws Section 5.1(d) Parent Charter Section 5.1(d) Parent Common Stock Issuance Section 5.2(a) Parent Development Property Section 5.11(e) Parent Disclosure Schedule Article V Parent Indemnified Governing Documents Section 5.1(d) Parent OP Preamble Parent OP Certificate of Limited Partnership Section 5.1(d) Parent OP Governing Documents Section 5.1(d) Parent Parties Preamble Parent Partnership Agreement Section 8.2(a)(i5.1(d) parties Parent Preferred Stock Section 5.3(a) Parent Properties Section 5.11(a) Parent Recommendation Section 5.2(b) Parent SEC Reports Section 5.7(a) Parent Stockholder Approval Section 5.15 Parent Stockholder Meeting Section 7.1(c) Parent Subsidiary Section 5.1(c) Parent Tax Protection Agreement Section 6.2(j) Parent-Approved Transaction Section 7.18 Parties Preamble Payee Partnership Preamble Partnership Agreement Section 8.5 Payor 4.1(c) Partnership Governing Documents Section 8.5 Per Diem 4.1(c) Partnership Merger Section 2.1(c)(i) Partnership Merger Certificates Section 2.1(c)(ii) Partnership Merger Consideration Section 3.1(b)(iii) Partnership Merger Effective Time Section 2.1(c)(ii) Partnership OP Unit Recitals Party Preamble Permit Section 4.7 PPACA Section 4.14(i) Prologis Merger Sub Preamble Prologis OP Merger Sub Preamble Proxy Statement/Prospectus Section 3.3(a) Qualified REIT Subsidiary Section 4.11(f) Qualifying Income Section 9.4(a) Registered Intellectual Property Section 4.21(a) REIT Section 4.11(b) REIT Dividend Section 7.17(b) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.8(a) Securities Laws Section 4.8(a) Superior Proposal Notice Section 7.4(b)(iv) Surviving Entity Section 2.1(a)(i) Takeover Statutes Section 4.25 Tax Protection Agreement Section 4.11(m) Taxable REIT Subsidiary Section 4.11(f) Transfer Taxes Section 8.7(a7.9(b) Proceeding UBOAPA Section 4.17 Royalties 2.1(a)(i) UBOTA Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g2.1(a)(i)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: “Accounting Principles” Section hereof in which such term is defined: Agreement 2.3(a) “Accounts Receivable” Section 3.25 “Agreement” Preamble Biogen Idec License Agreement “Base Stockholders’ Equity” Section 4.7 Biogen Idec Supply Agreement 2.3(e) “Buyer Indemnified Parties” Section 4.7 Books and Records 7.2(a) “Buyer Indemnified Party” Section 2.12(f)(27.2(a) Claim Notice “Buyer Indemnifying Party” Section 8.3(a7.2(c) Closing “Buyer” Preamble “Cash Escrow Amount” Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL 2.5 “Cash Purchase Price” Section 2.1 Document Retention Period “Closing” Section 2.12(f)(22.4 “Closing Balance Sheet” Section 2.3(a) Drug Regulatory Agency “Closing Balance Sheet Delivery Date” Section 4.25 Effective Time 2.3(f) “Closing Debt” Section 2.2 ERISA 2.2(a) “Closing Stockholders’ Equity” Section 4.13(a2.3(d) ERISA Affiliate “Company Instruments” Section 4.13(a3.15(g) Finally Determined “Company Intellectual Property” Section 8.5(b3.15(a) First Milestone “Company” Recitals “Continuing Employees” Section 2.10(e5.6(a) First Milestone Payment Amount “Damages” Section 2.10(e7.2(a) Indemnifying Party “Escrow Account” Section 8.3(a2.5 “Escrow Agreement” Section 6.2(i) Instrument “Escrow Amount” Section 2.12(c2.5 “Financial Statements” Section 3.6(a) Merger “Health Care Laws” Section 3.18(b) “Holder” Section 2.2(a) “Independent Accountant” Section 2.3(a) “Interim Financial Statements” Section 3.6(a) “Leased Real Property” Section 3.12(b) “Licenses” Section 3.8 “Material Contracts” Section 3.17(a) “Net Cash Purchase Price” Section 2.1 Merger Certificate “Non-Competition Agreements” Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties 6.2(o) “Notice” Section 8.2(a)(i7.3(a) parties Preamble Payee “Objection Notice” Section 8.5 Payor 7.3(d) “Outside Date” Section 8.5 Per Diem Taxes 8.1(b) “Permissible Carrybacks” Section 8.7(a5.9(g) Proceeding “Post-Closing Tax Period” Section 4.17 Royalties 5.9(d) “Pre-Closing Return” Section 2.10(h5.9(d) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation “Purchase Price” Section 2.1 “Regulatory Conditions” Section 8.1(b) “Representatives” Section 5.4(a) “Seller Indemnified Parties” Section 7.2(c) “Seller Indemnified Party” Section 7.2(c) “Seller Indemnifying Parties” Section 7.2(a) “Seller Indemnifying Party” Section 7.2(a) “Sellers” Preamble “Sellers’ Accountant” Section 2.3(a) “Shares” Recitals “Stockholders’ Equity Deficiency” Section 2.3(b) “Stockholders’ Equity Surplus” Section 2.3(c) “Tax Contest” Section 5.9(d) “Termination Date” Section 8.1 “Third Milestone Party Claim” Section 2.10(g7.4(a) Third Milestone Payment Amount “Threshold” Section 2.10(g7.2(d)(i) “Transfer” Section 5.10 “Transfer Taxes” Section 5.9(e) “Year-End Financial Statements” Section 3.6(a)

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Agreement Acquisition Proposal Section 7.7(a) ARRA Section 4.11(g) Audited Financial Statements Section 6.13 Auditor’s Consent Section 6.13 Bankruptcy and Equity Exception Section 4.2(a) Buyer Preamble Biogen Idec License Agreement Business Software Section 4.7 Biogen Idec Supply Agreement 4.13(i) Buyer Indemnitees Section 4.7 Books and Records 12.2(a) Cap Section 2.12(f)(212.3(c)(i) Calculation Notice Section 3.2(b) Change In Control Customer Contracts Section 4.14(d) Closing Section 9.1 Closing Date Section 9.1 Closing Date Interest Rate Section 3.2(d) CMS Preamble CMS Group Charter Documents Section 4.1(b) CMS Group Release Section 7.8 COBRA Section 4.11(g) Coventry Preamble Cure Period Section 11.1(b) Deductible Section 12.3(a) Disputed Items Section 3.2(b) D&O Obligations Section 6.12 D&O Released Parties Section 12.6 Excluded Assets Section 2.2(a) FHC Recitals FHC Stock Recitals FHS Recitals FHS Closing Date Balance Sheet Section 3.2(a) FHS Closing Date Payment Section 2.4(a) FHS Estimated Working Capital Section 3.1(a) FHS Financial Statements Section 4.5(a) FHS Initial Calculation Section 3.2(a) FHS Interim Financial Statements Section 4.5(a) FHS Material Permits Section 4.17 FHS Negative Estimated Working Capital Adjustment Section 3.1(a) FHS Positive Estimated Working Capital Adjustment Section 3.1(a) FHS Restricted Business Section 7.3(a) FHS Stock Recitals FHS Working Capital Adjustment Amount Section 3.2(d) FHS Year End Financial Statements Section 4.5(a) Final FHS Working Capital Section 3.2(d) FIRPTA Affidavit Section 9.2(l) First Health Group Preamble Foreign Plans Section 4.11(h) Fundamental Representations Section 12.1(a) Governmental Damages Section 10.2(e) Governmental Investigation Section 10.2(e) HIPAA Section 4.11(g) Hired Employees Section 7.2(b)(i) HSR Filing Section 6.5(b) Indemnifiable Losses Section 12.2(b) Indemnification Notice Section 12.5(a) Indemnified Party Section 12.2(c) Infringes Section 4.13(b) Injunctions Section 10.1(b) Labor Union Section 4.12(a) Legal Actions Section 10.1(c) Loss of Profits Section 12.3(f) Material Contract Section 4.14(b) Party or Parties Preamble Policies Section 4.15 Property Taxes Section 8.2(b)(i) Provider Synergies Recitals Provider Synergies Interests Recitals Purchase Price Section 2.4(a) Re-Calculated FHS Working Capital Section 3.2(e) Re-Calculated FHS Working Capital Adjustment Amount Section 3.2(e) Registered IP Section 4.13(a) Related Persons Section 4.19 Releasing Parties Section 12.6 Restraints Section 10.1(c) Seller Indemnifiable Losses Section 12.2(b) Seller Indemnitees Section 12.2(b) Settlement Firm Section 3.2(c) Shares Recitals Tax Claim Notice Section 8.3(a) Closing Tax Return Notice Section 2.3 Closing 8.1(b)(i) Tax Settlement Firm Section 8.1(b)(i) Termination Date Section 2.3 Company Preamble Company Common Stock 11.1(e)(i) Third Party Claim Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii12.4(a) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Transfer Taxes Section 8.7(a8.2(a) Proceeding Unsold Securities Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)7.9

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: Aggregate Outstanding Claims Section 2.9(b) Agreement Preamble Biogen Idec License Agreement Basket Amount Section 4.7 Biogen Idec Supply Agreement 8.5(a) Benefit Plan(s) Section 4.7 Books and Records 4.14(a) CERCLA Section 2.12(f)(2) 4.13 Claim Notice Section 8.3(a) Closing Section 2.3 Closing Amount Section 2.10(a) Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 2.8(a) Company Preamble Company Disclosure Schedule Article IV Company Expenses Schedule Dissenting Shares Section 2.13 2.11 Company Indemnified Parties Partner Section 8.2(a)(ii) Contracts Section 4.8(a) 4.27 Covered Party (Parties) Section 8.2(a)(ii8.2(a) Damages Section 8.2(a)(i8.2(a) DGCL Section 2.1 Document Retention Period Dispute Notice Section 2.12(f)(22.13(h) Drug Regulatory Agency Section 4.25 4.27 Effective Time Section 2.2 Employee Loans Section 4.8(a) Environmental Laws Section 4.13 Equityholder Representative Preamble ERISA Section 4.13(a4.14(a) ERISA Affiliate Section 4.13(a4.14(a) Finally Determined Escrow Account Section 8.5(b2.9(a) Escrow Agent Section 2.9(a) Escrow Agreement Section 2.9(a) Escrow Amount Section 2.9(a) Escrow Earnings Section 2.9(c) First Milestone Section 2.10(e) First Milestone MAA Subsequent Payment Amount Section 2.10(e) Indemnifying Party First NDA Subsequent Payment Amount Section 8.3(a2.10(f) Hazardous Materials Section 4.13 HSR Act Section 4.17 Instrument Section 2.12(c2.13(c) IRS Section 4.14(d) Majority Section 2.13(b) Material Contracts Section 4.8(a) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Net Cash Section 4.10(b) Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Parent-Prepared Tax Return Section 8.2(a)(i6.2(a) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Preferred Stock Section 2.8(a) Proceeding Section 4.17 Royalties 4.18 Real Property Section 4.5(c) Required Company Stockholder Vote Section 4.3 Retained Escrow Amount Section 2.9(b) Rules Section 4.28 Second MAA Subsequent Payment Amount Section 2.10(g) Second NDA Subsequent Payment Amount Section 2.10(h) Second Milestone Series A Preferred Stock Section 2.10(f2.8(a) Second Milestone Payment Amount Section 2.10(fStockholder(s) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Tax Consent Section 2.10(g6.2(c) Third Milestone Payment Amount Transaction Fee Schedule Section 2.10(g)2.14

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 5.15 Acceptance Time Section 2.4(a) Acquisition Proposal Termination Fee Section 9.4(b)(iii) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 7.5(c)(ii) Articles of Merger Section 4.7 Books and Records 3.3 Board Appointment Date Section 2.12(f)(22.4(a) Claim Notice Certificates Section 8.3(a4.2(b) Closing Section 2.3 3.2 Closing Date Section 2.3 3.2 Company Preamble Company Adverse Recommendation Change Section 7.5(c)(i) Company Board Recitals Company Board Recommendation Section 2.3(a)(iii) Company Common Stock Recitals Company Disclosure Documents Section 5.10(a) Company Financial Advisor Section 5.3(c) Company Financial Statements Section 5.7(b) Company Intellectual Property Section 5.17(b) Company Material Contract Section 5.13(a) Company Non-Voting Common Stock Section 2.8 5.2(a) Company Disclosure Schedule Article IV Company Expenses Schedule Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (PartiesPlan(s) Section 8.2(a)(ii5.11(a) Damages Company Preferred Stock Section 8.2(a)(i5.2(a) DGCL Company Representatives Section 2.1 Document 7.4(a) Company Retention Period and Severance Plan Section 2.12(f)(27.17(b)(ii) Drug Regulatory Agency Company SEC Filings Section 4.25 5.7(a) Company Shareholders Recitals Company Shareholders’ Meeting Section 7.2(a) Company Shareholder Approval Section 5.3(b) Company Subsidiary Section 5.1 Company Systems Section 5.17(f) Compensation Committee Section 5.24 Continuing Directors Section 2.4(a) D&O Insurance Policies Section 7.12(c) Determination Notice Section 7.5(d) Dissenting Shares Section 4.3 Dissenting Shareholder Section 4.3 Effective Time Section 2.2 3.3 EMEA Section 5.6(a) Employment Compensation Arrangement Section 5.24 End Date Section 9.1(b) Enforceability Exception Section 5.13(b) ERISA Section 4.13(a5.11(a) ERISA Affiliate Section 4.13(a5.11(a) Finally Determined Event Section 8.5(b1.1(l) First Milestone Exchange Fund Section 2.10(e4.2(a) First Milestone Payment Amount FDA Section 2.10(e5.6(e) Indemnifying Party Follow-On Period Section 8.3(a9.4(b)(iii) Instrument Indemnified Parties Section 2.12(c7.12(a) Independent Directors Section 2.4(b) Intervening Event Change of Recommendation Section 7.5(d)(ii) Intervening Event Termination Fee Section 9.4(b)(iv) Investments Section 5.2(e) IRS Section 5.11(b) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 4.1(a) Merger Sub Preamble Minimum Condition Section 2.1(b) Notice Period Section 7.5(d) Offer Recitals Offer Documents Section 2.1(g) Offer Price Recitals Offer to Purchase Section 2.1(g) Parent Preamble Parent Disclosure Schedule Insiders Section 2.4(a) Parent Representatives Section 7.4(a) Party Preamble Paying Agent Section 4.2(a) Plan of Merger Section 3.3 Proxy Statement Section 7.2(b) Recent SEC Reports Article V Parent Indemnified Parties Schedule TO Section 8.2(a)(i2.1(g) parties Preamble Payee Schedule 14D-9 Section 8.5 Payor 2.3(b) Short-Form Election Section 8.5 Per Diem Taxes 7.3 Short-Form Threshold Section 8.7(a7.3 Social Security Act Section 5.6(b) Proceeding Specified Contracts Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent 5.14 Support Agreements Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone 3.1 Tail Period Section 2.10(g7.12(c) Third Milestone Payment Amount Takeover Provisions Section 2.10(g)5.22(a) Top-Up Option Section 2.2(a) Transaction Litigation Section 7.8 Transition Committee Section 7.1(c) Transferred Employee Section 7.17(a)(ii) Transitioned Employees Section 7.17(a)(ii) WARN Act Section 5.12

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Adverse Effect on Debt Financing Section hereof in which such term is defined: 7.5(b) Adverse Recommendation Change Section 6.3(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.3(c) Alternative Financing Section 4.7 Books and Records 7.5(b) Alternative Financing Documents Section 2.12(f)(27.5(b) Claim Notice Arbitrator Section 8.3(a10.8(b) Base Premium Section 7.6(c) Benefit Plan Section 4.14(b) Benefit Plans Section 4.14(b) CICL Recitals Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Board Recitals Company Board Recommendation Recitals Company Equity Interests Section 2.8 4.2(b) Company Disclosure Schedule Article IV Group Section 9.3(f) Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.3(a) Consenting Warrantholder Section 8.2(a)(ii) Contracts Section 4.8(a3.2(b) Covered Party (PartiesPersons Section 7.6(a) Debt Commitment Letters Section 8.2(a)(ii5.5(a) Damages Debt Financing Section 8.2(a)(i5.5(a) DGCL Dissenting Shareholders Section 2.1 Document Retention Period 3.5(a) Dissenting Shares Section 2.12(f)(23.5(a) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.3 Enforceability Exceptions Section 4.13(a4.3 Environmental Claim Section 4.17(a) ERISA Affiliate Equity Commitment Letters Section 4.13(a5.5(a) Finally Determined Equity Financing Section 8.5(b5.5(a) First Milestone Exchange Act Section 2.10(e4.5 Exchange Fund Section 3.6(a) First Milestone Payment Amount Financial Statements Section 2.10(e4.6(b) Indemnifying Party Financing Section 8.3(a5.5(a) Instrument Financing Documents Section 2.12(c5.5(a) Governmental Entity Section 4.5 HKIAC Section 10.8(b) HoldCo Preamble HoldCo Group Section 9.3(f) HoldCo Option Section 3.3(b) HoldCo RSU Award Section 3.3(c) HoldCo Share Plan Section 3.3(b) HoldCo Termination Fee Section 9.3(b) IFRS Section 4.6(b) Indemnification Agreements Section 7.6(a) Intervening Event Section 6.3(e) Leased Real Property Section 4.11(a) Limited Guarantee Recitals Material Contract Section 4.15(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 3.6(a) Merger Sub Preamble Non-U.S. Benefit Plan Section 4.14(h) NYSE Section 4.2(c) Operating Subsidiary Section 4.15(a)(xi) Parent Preamble Parent Disclosure Parties Preamble Parties Preamble Party Preamble Paying Agent Section 3.6(a) Per Share Merger Consideration Section 3.1(a) Per Warrant Consent Fee Section 3.2(b) Per Warrant Merger Consideration Section 3.2(a) Plan of Merger Section 2.3 Rules Section 10.8(b) S▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.6(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.4(a) parties Preamble Payee SEC Section 8.5 Payor 4.5 SEC Documents Section 8.5 Per Diem Taxes 4.6(a) Securities Act Section 8.7(a4.6(a) Proceeding Share Certificates Section 4.17 Royalties 3.6(b)(i) Shareholder Proxy Statement Section 2.10(h4.5 Shareholder Record Date Section 6.5(a) Second Milestone Social Insurance Section 2.10(f4.14(j) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Special Committee Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Support Agreement Recitals Surviving Corporation Entity Section 2.1 Third Milestone Takeover Statute Section 2.10(g4.23 Tax Returns Section 4.12(a) Third Milestone Payment Amount Transaction Litigation Section 2.10(g7.9 Transactions Recitals Uncertificated Shares Section 3.6(b)(i) Uncertificated Warrants Section 3.6(b)(i) US$ Section 1.3(c) Warrant Amendment Section 6.6 Warrant Certificates Section 3.6(b)(i) Warrantholder Consent Deadline Section 6.6(b) Warrantholder Proxy Statement Section 4.5 Warrantholder Record Date Section 6.6(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 2016 Budget Section hereof in which such term is defined: 5.1(j) 2018 Indenture Section 5.14(a) 2018 Notes Section 5.14(a) 2018 Supplemental Indenture Section 5.14(a) 2020 Indenture Section 5.14(a) 2020 Notes Section 5.14(a) 2020 Supplemental Indenture Section 5.14(a) Agreement Preamble Biogen Idec License Agreement Annual Bonus Plan Section 4.7 Biogen Idec Supply Agreement 5.6(d) Apex Preamble Apex Shareholder Approval Section 4.7 Books and Records 4.11 Applicable Pro-Ration Factor Section 2.12(f)(22.4(b) Claim Book-Entry Shares Section 2.2(b)(ii) Bribery Legislation Section 3.17(a) Cancelled Shares Section 2.1(c) Capitalization Date Section 3.2(a) Certificate of Merger Section 1.2 Certificates Section 2.2(b)(i) CFIUS Notice Section 8.3(a3.5 CFIUS Turndown Section 5.4(d) Change of Board Recommendation Section 5.3(a) Class B Common Stock Section 3.2(a) Closing Section 2.3 1.2 Closing Date Section 2.3 1.2 Commitment Letters Section 4.12 Company Preamble Company Common Stock Balance Sheet Section 2.8 3.9 Company Board Recitals Company Board Recommendation Section 3.3(a) Company Bylaws Section 3.1(b) Company Charter Section 3.1(b) Company Disclosure Schedule Article IV 3 Company Expenses Schedule Employees Section 2.13 5.6(a) Company Indemnified Filings Section 3.7(a) Company Financial Advisor Section 3.22 Company Financial Statements Section 3.7(c) Company Material Contract Section 3.13(a) Company Option Section 2.4(a) Company Permits Section 3.6(a) Company Preferred Stock Section 3.2(a) Company Registered IP Section 3.16(a) Company Related Parties Section 8.2(a)(ii7.3(e) Contracts Company RSU Award Section 4.8(a2.4(b) Company SEC Documents Section 3.7(a) Company Subsidiaries Section 3.1(a) Company Subsidiary Section 3.1(a) Company Termination Fee Section 7.3(a) Confidentiality Agreement Section 5.2(b) control Section 8.5 Covered Party (PartiesPersons Section 5.7(a) D&O Insurance Section 8.2(a)(ii5.7(c) Damages Debt Commitment Letter Section 8.2(a)(i4.12 Debt Financing Sources Section 4.12 Debt Offer Section 5.14(a) Debt Offer Documents Section 5.14(a) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period 2.3(a) DRAA Section 2.12(f)(28.13(b) Drug Regulatory Agency Effect Section 4.25 8.5 Effective Time Section 2.2 ERISA 1.2 Equity Commitment Letters Section 4.13(a) 4.12 Equity Financing Sources Section 4.12 ERISA Affiliate Section 4.13(a3.11(c) Finally Determined Exchange Fund Section 8.5(b2.2(a) First Milestone Fairness Opinion Section 2.10(e3.22 FCPA Section 3.17(a) First Milestone Payment Amount Financing Section 2.10(e4.12 Financing Sources Section 4.12 Government Contract Section 3.26 Holdings Preamble Indenture Section 5.14(a) Indemnifying Party Initial Outside Date Section 8.3(a7.1(b) Instrument Insurance Policies Section 2.12(c3.21 Issuing Bank Recitals LC Cure Deadline Section 5.15(c) LC Delivery Deadline Section 5.15(a) LC Expiration Date Section 5.15(a) Letter of Credit Recitals LTIP Section 5.6(e) Material Company Lease Section 3.20(b) Material Jurisdiction Section 6.1(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 2.1(a) Merger Sub Preamble New Plans Section 5.6(b) Notes Section 5.14(a) Notice Period Section 5.3(d) NYSE Section 3.5 Old Plans Section 5.6(b) Other Regulatory Termination Fee Section 7.4(d) Outside Date Section 7.1(b) Parent Preamble Parent Disclosure Schedule Article V 4 Parent Indemnified Related Parties Section 8.2(a)(i7.4(h) parties Preamble Payee Parent Subsidiaries Section 4.3 Parent Subsidiary Section 4.3 Parent Termination Fee Section 7.4(a) Patents Section 8.5 Payor Paying Agent Section 8.5 Per Diem Taxes 2.2(a) PRC Regulatory Approvals Section 8.7(a4.4 Prohibitive Law Section 6.1(a) Proceeding Proposed Changed Terms Section 4.17 Royalties 5.3(d)(ii) Proxy Statement Section 2.10(h3.5 Replacement LC Credit Facility Section 5.15(f) Second Milestone Replacement Letter of Credit Section 2.10(f5.15(d) Second Milestone Payment Amount Required Financial Information Section 2.10(f5.13(a) Restricted Commitment Letter Amendments Section 5.12(e) Retention Program Section 5.6(f) Rules Section 8.13(b) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 3.7(a) SBLC Commitment Letter Section 4.12 SBLC Financing Sources Section 4.12 Section 16 Section 5.9 Seine 5.4(f) Shares Recitals Significant Company Subsidiary Section 3.1(b) Solvent Section 4.13 Stockholder Approval Section 3.3(a) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Meeting Section 2.12(b3.3(a) Surviving Corporation Section 2.1 Third Milestone 1.1(a) SZSE Section 2.10(g) Third Milestone Payment Amount 4.4 SZSE Clearance Section 2.10(g4.4 Trademarks Section 8.5 Tribunal Section 8.13(b)(i)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acquired Assets Section hereof in which such term is defined: 1.01(a) Acquired Assets Permits Section 2.12(a) Acquired Assets Regulatory Filings Section 2.12(a) Aggregate Threshold Section 6.05(b)(ii) Agreed Amount Section 6.04(b) Agreement Preamble Biogen Idec License Agreement Antitrust Approvals Section 4.7 Biogen Idec Supply Agreement 4.03(b) Assigned Contracts Section 4.7 Books and Records 1.01(a)(iv) Assigned IP Contracts Section 2.12(f)(21.01(a)(iv) Assumed Liabilities Section 1.01(d) Assumption Agreements Section 1.01(d) ▇▇▇▇ of Sale Section 1.03(b)(iii) Burdensome Term or Condition Section 4.03(f) Americas 92425100 Buyer Preamble Buyer FDA Letter Section 5.03(e) Buyer Group Section 1.01(a) Buyer Indemnified Parties Section 6.02 Buyer Orphan Designation Letter Section 5.03(e) Cap Section 6.05(b)(i) CF Enterprise Recitals Claim Notice Section 8.3(a6.04(b) Claimed Amount Section 6.04(b) Closing Section 2.3 1.03(a) Closing Date Section 2.3 Company 1.03(a) Confidentiality Agreement Section 4.02 Contingent Payment Section 1.02(b) CTAs Section 2.10(a)(viii) DOJ Section 4.03(a) Electronic Delivery Section 10.07 Excluded Assets Section 1.01(b) Excluded Liabilities Section 1.01(e) FDA Section 2.12(a) FDCA Section 2.12(a) FTC Section 4.03(a) Fundamental Representations Section 6.01(a) Guarantor Preamble Company Common Stock HSR Act Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.05(c) Indemnified Party Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e6.04(a) Indemnifying Party Section 8.3(a6.04(a) Instrument IP Assignment Agreements Section 2.12(c1.03(b)(iv) Merger Material Contract Section 2.1 Merger Certificate 2.10(a) MTAs Section 2.2 Merger Sub 2.10(a)(viii) NDAs Section 2.10(a)(viii) Non‑Compete Period Section 9.05(a) Outside Date Section 7.01(f)(ii) Parties Preamble Parent Party Preamble Parent PHSA Section 2.12(a) Pre‑Closing Period Section 4.01(a) Research and Testing Agreement Recitals Registered Business IP Section 2.09(a) Regulatory Authority Section 2.12(a) Regulatory Filings Section 4.03(a) Related Agreements Section 2.03 Restricted Names Section 9.02 Safety Notice Section 2.12(d) Americas 92425100 Seller Preamble Seller Board Section 2.03 Seller Board Approval Section 2.20 Seller Change of Recommendation Section 4.07(c) Seller Disclosure Schedule Letter Article V Parent II Seller FDA Letter Section 5.02(f) Seller Indemnified Parties Section 8.2(a)(i6.03 Seller Orphan Designation Letter Section 5.02(f) parties Preamble Payee Supplement Section 8.5 Payor 4.04 Termination Fee Section 8.5 Per Diem 7.02(b) Third Party Claim Section 6.04(a) Third Party IP Section 2.09(f) Transfer Taxes Section 8.7(a8.01(a) Proceeding Transferred IP Section 4.17 Royalties 1.01(a)(ii) Transferred IP Documentation Section 2.10(h1.01(a)(iii) Second Milestone Transferred Permits Section 2.10(f1.01(a)(vi) Second Milestone Payment Amount Transition Services Agreement Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g1.03(b)(vii)

Terms Defined Elsewhere. The Each of the following is a list of additional terms used in this Agreement and a reference has the meaning ascribed to the Section hereof in which such term is definedin the Article or Section set forth opposite such term: 2023 45X Credit Section 2.9(a) 2024 45X Credit Section 2.9(a) 2025 45X Credit Section 2.9(a) 401(k) Plan Section 7.3(b) Accounting Firm Section 2.4(b) Active Job Section 3.5(i) Affiliate Arrangements Section 3.22 Agreement Preamble Biogen Idec License Allocation Schedule Section 7.2(e) Antitrust Laws Section 7.12(c) Benefits Transition Period Section 7.3(a) Benefits Transition Services Section 7.3(a) Binder Agreement Section 4.7 Biogen Idec Supply Agreement 7.11 Buyer Preamble CBA Section 4.7 Books and Records 3.7(d) Claims Section 2.12(f)(2) Claim Notice Section 8.3(a) 7.8 Closing Section 2.3 2.7(a) Closing Date Section 2.3 2.7(a) Closing Item Section 2.4(a) Closing Payment Section 2.7(d)(vi) Closing Statement Section 2.4(a) Company Preamble Company Common Employee Benefit Plan Section 3.15(a) Company Interests Recitals Company Licenses Section 3.17(b) Company Proprietary Rights Section 3.12(a) Company Transaction Section 7.1(d) Confidential Information Section 7.13(a) Customer Assets Section 3.28 Deferred Consideration Section 2.6(a) Deferred Consideration Anniversary Section 2.6(a) Deferred Consideration Installment Section 2.6(a) Deferred Consideration Shares Section 2.6(a) Dispute Notice Section 2.4(b) Earnout Stock Section 2.8 Company Disclosure Schedule Article IV Company 2.5 Effective Date Preamble Employed Guarantor Section 2.6(c) End Date Section 8.1(d) Estimated Cash Section 2.3(a)(i) Estimated Closing Statement Section 2.3(a) Estimated Indebtedness Section 2.3(a)(i) Estimated Transaction Expenses Schedule Section 2.13 Company Indemnified Parties 2.3(a)(i) Estimated Working Capital Section 8.2(a)(ii2.3(a)(i) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Excess Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g2.4(d)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: “401(k) Plan” Section hereof 6.12 “Agreement” Introduction “Appointment Date” Section 5.1 “Appointment Time” Section 1.3(a) “Appraisal Rights” Section 2.3(a) “Assignee” Section 9.13 “Balance Sheet Date” Section 3.8(a) “Base Premium” Section 6.5(e) “Benefit Plans” Section 3.11(a) “Certificate of Merger” Section 1.5 “Certificates” Section 2.2(b) “Closing” Section 1.6 “Closing Date” Section 1.6 “Code” Section 2.2(e) “Common Stock” Section 3.2(a) “Company” Introduction “Company Agreements” Section 3.5 “Company Board of Directors” Recitals “Company Bylaws” Section 1.3(b) “Company Certificate” Section 1.3(b) “Company Change in which such term is defined: Agreement Preamble Biogen Idec License Agreement Recommendation” Section 4.7 Biogen Idec Supply Agreement 5.3(b) “Company Collective Bargaining Agreement” Section 4.7 Books and Records Section 2.12(f)(23.16(a) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 “Company Disclosure Schedule Schedule” Article IV III “Company Expenses Schedule Financial Advisor” Section 2.13 3.20 “Company Indemnified Parties Governing Documents” Section 8.2(a)(ii1.3(b) Contracts “Company IP Agreements” Section 4.8(a3.15(b) Covered Party (Parties“Company Material Contract” Section 3.13(a) “Company Options” Section 8.2(a)(ii2.5(a) Damages “Company Permits” Section 8.2(a)(i3.17(b) DGCL “Company Recommendation” Section 2.1 Document Retention Period 5.3(a) “Company Scheduled Agreements” Section 2.12(f)(2) Drug Regulatory Agency 3.13 “Company SEC Documents” Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g3.6(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 280G Stockholder Approval Section hereof in which such term is defined: 5.6(b) 401(k) Plan Section 1.4(b)(i) Adjustment Resolution Period Section 1.15(b) Adjustment Review Period Section 1.15(b) Agreement Preamble Biogen Idec License Agreement Date Preamble Allocation Schedule Section 4.7 Biogen Idec Supply Agreement 4.3(a) Anti-Corruption Laws Section 4.7 2.24 Balance Sheet Date Section 2.7(b) Behavioral Data Section 2.12(a)(i) Board Recitals Books and Records Section 2.12(f)(22.17(b) Cancelled Shares Section 1.7(e) Cash Portion Section 4.2(f) CCPA Section 2.12(a)(xiv) Certificate of Incorporation Section 2.1(d) Certificate of Merger Section 1.2(a) Certificates of Merger Section 1.2(b) Charter Documents Section 2.1(d) Closing Section 1.4(a) Closing Date Section 1.4(a) Company Preamble Company Authorizations Section 2.15 Company Board Resolutions Section 2.4(a) Company Data Section 2.12(a)(ii) Company Indemnitees Section 4.5(a) Company IP Section 2.12(a)(iii) Company Owned IP Section 2.12(a)(iv) Company Prepared Returns Section 4.2(a)(i) Company Privacy Policy Section 2.12(a)(v) Company Products Section 2.12(a)(vi) Company Products Data Section 2.12(a)(vii) Company Registered IP Section 2.12(b) Company Software Section 2.12(a)(viii) Company Source Code Section 2.12(a)(ix) Company Stockholder Approval Recitals Company Voting Debt Section 2.2(f) Confidentiality Agreement Section 5.7 Contaminant Section 2.12(a)(x) Continuing Claim Section 7.4(f) Converted Option Section 1.7(b)(ii) Converted Option Exercise Price Section 1.7(b)(ii) Current Balance Sheet Section 2.7(b) D&O Indemnifiable Matters Section 4.5(a) D&O Tail Policy Section 4.5(b) Deductible Amount Section 7.3(a) Delaware LLC Act Section 1.1(b) Determination Date Section 1.15(c) DGCL Section 1.1(a) Director and Officer Resignation Letters Section 1.4(b)(iv) Disclosure Schedule Article II Dissenting Shares Section 1.11(a) Effective Time Section 1.2(a) Eligible Continuing Employee Section 5.19 Embargoed Countries Section 2.23 End Date Section 8.1(b) Engagement Letter Section 7.6(b) ePrivacy Directive Section 2.12(a)(xiv) Escrow Agreement Section 1.4(b)(xi) Escrow Fund Section 1.10(a) Estimated Closing Cash Amount Section 1.15(a) Estimated Closing Indebtedness Amount Section 1.15(a) Estimated Closing Statement Section 1.15(a) Estimated Closing Third Party Expenses Section 1.15(a) Estimated Closing Working Capital Adjustment Amount Section 1.15(a) Exchange Documents Section 1.9(b) Expense Fund Section 7.6(c) Expense Fund Account Section 7.6(c) Export Approvals Section 2.23 FCPA Section 2.24 Final Closing Statement Section 1.15(c) Financials Section 2.7(a) FIRPTA Compliance Certificate Section 1.4(b)(x) First Merger Recitals GDPR Section 2.12(a)(xiv) HSR Act Section 2.6(b) HIPAA Section 2.12(a)(xiv) Inbound Licenses Section 2.12(d)(i) Indemnification Claim Notice Section 8.3(a7.4(a) Closing Indemnification Claim Objection Notice Section 2.3 Closing Date 7.4(b) Independent Accountant Section 2.3 Company Preamble Company Common Stock 1.15(b) Intellectual Property Rights Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 2.12(a)(xi) Interested Party Section 2.13 Company Indemnified Parties 2.14(a) Invoice Section 8.2(a)(ii1.4(b)(vi) Contracts Lease Agreements Section 4.8(a2.11(b) Covered Party (PartiesLeased Real Property Section 2.11(b) Letter of Transmittal Section 1.9(a) Material Contract(s) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c2.13(b) Merger Section 2.1 Merger Certificate Section 2.2 Sub I Preamble Merger Sub II Preamble Merger Subs Preamble Mergers Recitals Notice of Adjustment Disagreement Section 1.15(b) Notices Section 5.11(c) OFAC Section 2.23 Open Source Material Section 2.12(a)(xii) Open Source Licenses Section 2.12(a)(xii) Outbound Licenses Section 2.12(d)(ii) Parent Preamble Parent Disclosure Schedule Article V Arrangement Section 2.9(b) Parent Certificate Section 6.3(c) Parent Financial Statements Section 3.5(b) Parent Indemnified Parties Section 8.2(a)(i7.2(a) parties Preamble Payee Parent Prepared Returns Section 8.5 Payor 4.2(a)(ii) Parent SEC Documents Section 8.5 Per Diem Taxes 3.5(a) Parent Stock Issuance Recitals Patent Rights Section 8.7(a2.12(a)(xi) Proceeding Paying Agent Agreement Section 4.17 Royalties 1.4(b)(xv) Payoff Letter Section 2.10(h1.4(b)(vi) Permitted Transferee Section 4.4(b) Personal Data Section 2.12(a)(xiii) Personnel Agreements Section 2.12(f)(i) PNO Section 2.6(b) Post-Closing Deficit Amount Section 1.15(d) Post-Closing Excess Amount Section 1.15(e) Post-Closing Statement Section 1.15(b) Privacy Requirements Section 2.12(a)(xiv) Prohibited Party Lists Section 2.23 PTO Section 2.12(b) Recovered Fraud Amounts Section 7.3(b) Registered IP Section 2.12(a)(xv) Reorg Threshold Section 4.2(f) Representative Losses Section 7.6(b) Resolved Matters Section 1.15(b) Restricted Shares Section 2.2(a) Retained Escrow Amount Section 7.4(f) Retention Pool Section 4.6 Second Certificate of Merger Section 1.2(b) Second Milestone Effective Time Section 2.10(f1.2(b) Second Milestone Payment Amount Merger Recitals Secretary Certificate Section 2.10(f1.4(b)(v) Section 280G Payments Section 5.6(b) Securityholder Representative Preamble Shrink-Wrap Software Section 2.12(a)(xvi) Standard Form Agreements Section 2.12(d)(iii) Stock Portion Section 4.2(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Notice Section 2.12(b4.1(b) Surviving Corporation Section 2.1 1.1(a) Surviving Entity Section 1.1(b) Systems Section 2.12(p) Tax Attribute Section 7.2(c) Technology Section 2.12(a)(xvii) Terminated Agreements Section 5.12 Third Milestone Party Claim Section 2.10(g7.5 Third Party Notice Section 7.5 Top Customers Section 2.25(a) Third Milestone Payment Amount Top Resellers Section 2.10(g2.25(a) Top Suppliers Section 2.25(a) Total Stockholder Consideration Section 4.2(f) Trade Laws ▇▇▇▇▇▇▇ ▇.▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ Real Property Holding Corporation Section 2.9(a)(viii) Unresolved Matters Section 1.15(b) Warrant Cancellation Agreement Section 1.4(b)(xii)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: Action Section 4.13 Agreement and a reference to the Section hereof in which such term is defined: Agreement Preamble Biogen Idec License Introduction Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.4(b)(iii) Alternative Financing Section 4.7 Books and Records 6.6(b) Alternative Financing Commitment Section 2.12(f)(26.6(b) Claim Antitrust Laws Section 4.4(b) Capped Damages Section 8.2(a)(ii) Certificate of Merger Section 2.3 Certificates Section 3.2(b), Section 3.2(b) CFIUS Section 4.4(b) Change of Recommendation Notice Section 8.3(a6.4(e)(i) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 COBRA Section 4.10(i) Company Preamble Introduction Company Common Adverse Recommendation Change Section 6.4(d)(i) Company Financial Advisor Section 4.21 Company Financial Statements Section 4.6(b) Company Group Section 8.2(b)(v) Company Insurance Policies Section 4.17 Company Material Contract Section 4.12(a) Company Preferred Stock Section 2.8 4.2(a) Company Disclosure Schedule Article IV Recommendation Section 4.3(b) Company Expenses Schedule Representatives Section 2.13 6.3(a) Company Indemnified Parties SEC Filings Section 8.2(a)(ii4.6(a) Contracts Company Stock Rights Section 4.8(a4.2(c) Covered Party (PartiesCompany Stockholders Meeting Section 6.2(d) Company Subsidiary Section 8.2(a)(ii4.1(a) Damages Condemnation Actions Section 8.2(a)(i4.18(d) Cut-Off Date Section 6.4(b)(vi) D&O Insurance Section 6.12(b) Debt Commitment Letters Section 5.6(a) Debt Financing Section 5.6(a) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 3.3 Effective Time Section 2.2 ERISA 2.3 End Date Section 4.13(a8.1(b)(i) ERISA Affiliate Enforcement Exceptions Section 4.13(a4.3(a) Finally Determined Equity Commitment Letter Section 8.5(b5.6(a) First Milestone Equity Financing Section 2.10(e5.6(a) First Milestone Payment Amount Exchange Fund Section 2.10(e3.2(a) Indemnifying Party Existing Debt Section 8.3(a4.2(h) Instrument Exon-▇▇▇▇▇▇ Section 2.12(c4.4(b) FCPA Section 4.27 Financing Section 5.6(a) Financing Commitments Section 5.6(a) Guarantee Recitals Guarantor Recitals Leased Real Property Section 4.18(a) Liability Section 4.7 Merger Recitals Merger Consideration Section 3.1(a) Merger Sub Introduction NDA Consent Section 2.1 Merger Certificate 6.5(e) New Plans Section 2.2 Merger Sub Preamble 6.10(c) NRC Consents Section 4.4(b) Option Cash Payment Section 3.5(b) Original Date Section 6.2(e) Owned Real Property Section 4.18(a) Parent Preamble Introduction Parent Disclosure Schedule Article V Group Section 8.2(c)(iii) Parent Indemnified Representatives Section 6.3(a) Parties Introduction Party Introduction Paying Agent Section 8.2(a)(i3.2(a) parties Preamble Payee Performance-Based Company Phantom Share Award Section 8.5 Payor 3.5(d) Present Fair Salable Value Section 8.5 Per Diem Taxes 5.11 Proxy Statement Section 8.7(a4.20 Real Property Section 4.18(a) Proceeding Real Property Leases Section 4.17 Royalties 4.18(a) Required Financial Information Section 2.10(h6.7(a) Second Milestone Restricted Stock Payment Section 2.10(f3.5(c) Second Milestone Payment Amount Solicitation Period End Date Section 2.10(f6.4(a) Solvent Section 5.11 Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Approval Section 2.12(b) 4.23 Surviving Corporation Section 2.1 Third Milestone Takeover Statute Section 2.10(g) Third Milestone Payment Amount 4.19 Transaction Litigation Section 2.10(g)6.8

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: 401(k) Plan Section hereof in which such term is defined: 7.7(d) Acceptance Time Section 1.1(d) Acquisition Sub Preamble Aggregate Cash Amount Section 5.7(a) Agreement Preamble Biogen Idec License Agreement Arrangements Section 4.7 Biogen Idec Supply Agreement 7.10 Book-Entry Shares Section 4.7 Books and Records 3.1(a) Bribery Legislation Section 2.12(f)(24.13(a) Claim Notice Cancelled Shares Section 8.3(a3.1(b) Certificate of Merger Section 2.3(a) Certificates Section 3.1(a) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Benefit Plans Section 4.11(a) Company Board of Directors Recitals Company Board Recommendation Recitals Company Capitalization Date Section 4.2(a) Company Common Stock Recitals Company Compensation Committee Section 2.8 7.10 Company Disclosure Schedule Letter Article IV Company Expenses Schedule DSU Award Section 2.13 3.4(d) Company Leased Real Property Section 4.19(b) Company License-In Agreement Section 4.17(c) Company LTIP Award Section 7.7(d) Company Option Section 3.4(a) Company Permits Section 4.9(b) Company Preferred Stock Section 4.2(a) Company PU Award Section 3.4(c) Company RSU Award Section 3.4(b) Company SEC Documents Section 4.5(a) Company Shares Recitals Company Terminating Breach Section 9.1(c) Continuing Employees Section 7.7(a) Creators Section 4.17(f) D&O Insurance Section 7.4(c) Debt Commitment Letter Section5.7(a) Debt Financing Section 5.7(a) Debt Financing Agreements Section7.13(b) Debt Providers Section 5.7(a) DGCL Recitals Dissenting Shares Section 3.3(a) DOJ Section 7.2(b) Effective Time Section 2.3(a) Enforceability Limitations Section 4.3(c) Exchange Fund Section 3.2(a) FCPA Section 4.13(a) Financing Extension Notice Section1.1(c)(ii)(C) First Extended Outside Date Section9.1(d) FTC Section 7.2(b) GAAP Section 4.5(b) Indemnified Parties Section 8.2(a)(ii7.4(a) Contracts Initial Outside Date Section 4.8(a9.1(d) Covered Party (Parties) Major Customers Section 8.2(a)(ii) Damages 4.21 Major Suppliers Section 8.2(a)(i) DGCL 4.21 Material Contract Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c4.20(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate 3.1(a) Minimum Condition Section 2.2 Merger Sub Preamble 1.1(a)(i) New Plans Section 7.7(b) Offer Recitals Offer Closing Section 2.6 Offer Documents Section 1.1(e)(i)(1) Offer Price Section 1.1(a) Offer to Purchase Section 1.1(a) Old Plans Section 7.7(b) Outside Date Section 9.1(d) Parent Preamble Parent Disclosure Schedule Letter Article V Parent Indemnified Governing Documents Section 5.1(a) Parent Terminationg Breach Section 9.1(b) Parties Preamble Party Preamble Paying Agent Section 8.2(a)(i3.2(a) parties Preamble Payee Regulatory Fee Section 8.5 Payor 9.2(c) Requisite Financing Section1.1(c)(ii)(C) Retention Program Section 8.5 Per Diem Taxes 7.7(f) Sarbanes Oxley Act Section 8.7(a4.6 Schedule 14D-9 Section 1.2(b) Proceeding Schedule TO Section 4.17 Royalties Section 2.10(h1.1(e)(i)(1) Second Milestone Extended Outside Date Section 2.10(f9.1(d) Second Milestone Payment Amount Secretary of State Section 2.10(f2.3(a) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Stockholders Meeting Section 2.12(b) 7.11 Surviving Corporation Section 2.1 Third Milestone Termination Fee Section 2.10(g9.2(b)(i) Third Milestone Payment Amount Section 2.10(g)Transactions Recitals

Terms Defined Elsewhere. The following is a list of additional terms As used in this Agreement, the following capitalized terms are defined in this Agreement and a reference to as referenced in the Section hereof in which such term is definedfollowing table: Agreement Preamble Biogen Idec License Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2Bylaws 3.2 Capitalization Date 5.2(a) Claim Notice Section 8.3(aChange of Recommendation 7.2(d)(i)(F) Charter 3.1 Closing Section 2.3 2.1 Closing Date Section 2.3 2.1 Company Preamble Company Common Stock Section 2.8 Approvals 5.4(a) Company Disclosure Schedule Letter Article IV V Company Expenses Schedule Section 2.13 Personal Information 5.18(l) Company Indemnified Parties Section 8.2(a)(iiRecommendation 5.3(b) Contracts Section 4.8(aCompany Tax Representation Letter 7.18(c) Covered Party (PartiesContinuation Period 7.11(a) Section 8.2(a)(iiD&O Insurance 7.12(b) Damages Section 8.2(a)(iDelisting Period 7.17(a) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(aExchange Fund 4.3(a)(i) ERISA Affiliate Section 4.13(aFDA 5.20(a) Finally Determined Section 8.5(bFDA Licenses 5.20(a) First Milestone Section 2.10(eFundamental Action 7.2(d)(iii) First Milestone Payment Amount Section 2.10(eGovernmental Antitrust Entity 7.6(b)(ii) Indemnifying Party Section 8.3(aInterim Period 7.1(a) Instrument Section 2.12(cLegal Restraint 8.1(c) Material Contract 5.11(a) Material Customer 5.12(a) Material Vendor 5.12(b) Merger Section 2.1 Merger Certificate Section 2.2 Recitals Merger Sub Preamble Non-Wholly Owned Subsidiary 5.2(f) Notice of Redemption 7.13(a) Notice 7.2(d)(iii) Notice Period 7.2(d)(iii) Outside Date 9.2(a) Parent Preamble Parent Disclosure Schedule Article V Approvals 6.4(a) Parent Indemnified DSU 4.2(f) Parent Option 4.2(a) Parent RSU 4.2(c) Parent Tax Representation Letter 7.18(c) Parent SAR 4.2(e) Parties Section 8.2(a)(iPreamble Permitted Confidentiality Agreement 7.2(b)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(aPotential Purchasers 7.6(d) Proceeding Section 4.17 Royalties Section 2.10(hPotential Sale Transaction 7.6(d) Second Milestone Section 2.10(fPrivacy and Security Measures 5.18(k) Second Milestone Payment Amount Section 2.10(fPrivacy-Related Contracts 5.11(a)(vi) Stockholder Consent Proxy Statement 7.3(a) Stock Ownership Rep 6.8 Support Agreement Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g2.3 Tax Representation Letters 7.18(c) Third Milestone Payment Amount Section 2.10(gThird-Party Consents 7.8 Transaction Litigation 7.15 TRA Terminations 7.13(d) Vote-Down 9.2(b)

Terms Defined Elsewhere. The Solely for convenience, the following is a list of additional terms used that are defined in the section of this Agreement and a reference to the Section hereof in which set forth after each such term is definedbelow: Accounting Firm Section 3.2 Accounts Receivable Section 2.1(j) Agreement Preamble Biogen Idec License Agreement Allocation Schedule Section 4.7 Biogen Idec Supply Agreement 3.2 Alternate Debt Financing Section 4.7 7.18(c) Alternative Financing Commitment Section 7.18(c) Assumed Liabilities Section 2.3 Balance Sheet Date Section 5.6 ▇▇▇▇ of Sale Section 4.2(a) Books and Records Section 2.12(f)(22.1(e) Business Related Software Section 5.14(b) Cash Purchase Price Section 3.1 Claim Notice Section 8.3(a10.4(a) Closing Section 2.3 4.1 Closing Date Section 2.3 4.1 Code Section 3.2 Company Cash Section 2.1(q) Comprint Preamble Company Common Stock Confidentiality Agreement Section 2.8 Company 7.4 Consents Section 5.5 Contract Section 2.1(g) Controversy Section 11.10 Disclosure Schedule Letter Article IV Company Expenses Schedule V Domain Name Assignment Section 2.13 Company Indemnified Parties Section 8.2(a)(ii4.2(c) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Exchange Act Article V Excluded Assets Section 2.2 ERISA Financial Statements Section 4.13(a5.6 Financing Section 6.4 Financing Commitment Section 6.4 Flex Plan Section 7.16(f) ERISA Affiliate Form 8594 Section 4.13(a3.2 Grant Deed Section 4.2(b) Finally Determined Guarantor Preamble ▇▇▇▇▇-▇▇▇▇▇ ▇▇▇▇ and Logo Section 8.5(b2.2(f) First Milestone HH Shoppers Preamble Indemnified Party Section 2.10(e) First Milestone Payment Amount Section 2.10(e10.4(a) Indemnifying Party Section 8.3(a10.4(a) Instrument of Assignment and ▇▇▇▇ of Sale Section 2.12(c4.2(a) Merger Inventory Section 2.1 Merger Certificate 2.1(i) Lease Assignment Section 2.2 Merger Sub Preamble 4.2(e) Leased Real Property Section 2.1(a)(ii) Licensed Software Section 5.14(b) Licenses and Permits Section 2.1(h) Machinery Section 2.1(c) Material Agreement Section 5.9(a) Natural Hazard Areas Section 11.20 Notice Section 11.10 Notice Period Section 10.4(c) Owned Real Property Section 2.1(a)(i) Parent Preamble Parent Disclosure Schedule Article V Benefit Plans Section 5.12 Parent Deductible Section 10.2(b)(i) Parent Indemnified Parties Section 8.2(a)(i10.3(a) parties Personal Property Leases Section 2.1(b) Party Preamble Payee Proprietary Software Section 8.5 Payor 5.14(b) Purchase Price Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation 3.1 Purchased Assets Section 2.1 Third Milestone Purchasers Preamble Purchasers Deductible Section 2.10(g10.3(b)(i) Third Milestone Payment Amount Purchasers Indemnified Parties Section 2.10(g10.2(a) Purchasers Plan Section 7.16(c) Purchasers Savings Plan Section 7.16(d) RE Purchaser Preamble Response Section 11.10 Retained Liabilities Section 2.4 Reverse Termination Fee Section 9.2 SEC Article V Sellers Preamble Software Section 5.14(b) Tax Refunds Section 2.2(b) Trademark Assignment Section 4.2(c) Transfer Tax Returns Section 7.8(a) Transferred Employees Section 7.16(a) Transferred Intellectual Property Section 2.1(d) Transition Services Agreement Section 4.2(d)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acquisition Proposal Section hereof in which such term is defined: 5.3(g)(i) Agreement Preamble Biogen Idec License Agreement Board Recitals Board Recommendation Section 4.7 Biogen Idec Supply Agreement 3.3(b) Change of Board Recommendation Section 4.7 Books and Records 5.3(a) China JV Section 2.12(f)(2) Claim Notice Section 8.3(a) 5.12 Closing Section 2.3 2.2(a) Closing Date Section 2.3 2.2(a) Closing Date Payment Section 2.2(b) Company Preamble Company Benefit Plan Section 3.14(a) Company Bylaws Section 3.1 Company Charter Section 3.1 Company Common Stock Section 2.8 3.2(a) Company Designees Section 5.18(a) Company Disclosure Schedule Article IV 3 Company Expenses Schedule Financial Statements Section 2.13 3.7(c) Company Indemnified Parties Leased Real Property Section 8.2(a)(ii3.17(a) Contracts Company Material Contract Section 4.8(a3.19 Company Meeting Section 5.4(b) Covered Party (PartiesCompany Options Section 3.2(a) Company Owned Real Property Section 8.2(a)(ii3.17(a) Damages Company Preferred Stock Section 8.2(a)(i3.2(a) Company Real Property Section 3.17(a) Company RSUs Section 3.2(a) Company SEC Documents Section 3.7(a) Company Termination Fee Section 7.3(a) Competing China JV Proposal Section 5.3(h) Confidentiality Agreement Section 5.2(b) DGCL Section 2.1 Document Retention Period 4.7 Dispute Section 2.12(f)(28.8(b) Drug Regulatory Agency ECL Claims Section 4.25 Effective Time 7.4(c) Escrow Agent Section 2.2 ERISA 5.21 Escrow Agreement Section 4.13(a5.21 FCPA Section 3.26 Guarantor Recitals Guarantee Recitals ICDR Section 8.8(b) ERISA Affiliate Intervening Event Section 4.13(a5.3(g)(v) Finally Determined Investor Preamble Investor Designees Section 8.5(b5.18(a) First Milestone Investor Sub Section 2.10(e5.22 Investor Termination Fee Release Event Section 7.4(a) First Milestone Payment Amount Letter of Credit Section 2.10(e5.23 Minority Transaction Termination Fee Section 7.3(a) Indemnifying Party OFAC Section 8.3(a3.27 Outside Date Section 7.1(d) Instrument Section 2.12(c) Merger Per Share Price Section 2.1 Merger Certificate Proposed Changed Terms Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i5.3(d)(ii) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Purchase Price Section 2.1 Third Milestone Service Provider Section 2.10(g3.14(a) Third Milestone Payment Amount Shares Section 2.10(g2.1 Superior Majority Proposal Section 5.3(g)(ii) Superior Minority Proposal Section 5.3(g)(iii) Superior Proposal Section 5.3(g)(iv)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: Acceptable Confidentiality Agreement and a reference to the Section hereof in which such term is defined: 7.4(b) Acquisition Agreement Section 7.4(a) Agreement Preamble Biogen Idec License Agreement Articles of Merger Section 4.7 Biogen Idec Supply Agreement 2.1(b)(ii) Book-Entry Share Section 4.7 Books and Records 3.1(b)(i) Certificate Section 2.12(f)(23.1(b)(i) Claim Notice Certificate of Limited Partnership Section 8.3(a4.1(c) Certificate of Partnership Merger Section 2.1(d)(ii) Change in Company Recommendation Section 7.4(b)(iii) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Code Recitals Company Preamble Company 401(k) Plan Section 4.14(b) Company Articles of Merger Section 2.1(a)(ii) Company Common Stock Shares Recitals Company Development Properties Section 2.8 4.12(h) Company Development Property Section 4.12(h) Company Disclosure Schedule Article IV Company Expenses Schedule Employee Programs Section 2.13 4.14(a) Company Equity Award Section 4.3(c) Company Governing Documents Section 4.1(c) Company Merger Section 2.1(a)(i) Company Merger Effective Time Section 2.1(a)(ii) Company Mergers Section 2.1(b)(i) Company Parties Preamble Company Preferred Shares Section 4.3(a) Company Properties Section 4.12(a) Company Recommendation Section 4.2(b) Company SEC Reports Section 4.8(a) Company Shareholder Approval Section 4.18 Company Shareholder Meeting Section 7.1(c) Company Subsidiaries Section 4.1(b) Company Subsidiary Section 4.1(b) Company Tax Protection Agreement Section 6.1(w) Consent Solicitations Section 7.22(b) Continuing Employee Section 7.8(a) Continuing Employees Section 7.8(a) Contribution Section 2.1(c)(i) Contribution and Issuance Effective Time Section 2.1(c)(ii) Debt Offer Documents Section 7.22(b) DLLCA Section 2.1(d)(i) Drop Dead Date Section 9.1(b)(iii) DSOS Section 2.1(d)(ii) Encumbrances Section 4.12(a) Exchange Agent Section 3.4(a) Exchange Fund Section 3.4(a) Exchange Ratio Section 3.1(b)(i) Form S-4 Section 4.6 Fractional Share Consideration Section 3.1(b)(i) HCERA Section 4.14(i) Health Plan Section 4.14(i) Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e7.5(a) Indemnifying Party Section 8.3(a7.5(a) Instrument Interim Period Section 2.12(c6.1 Intervening Event Notice Period Section 7.4(b)(v) Issuance Section 2.1(c)(i) Letter of Transmittal Section 3.4(c) Maryland Court Section 10.7(b) Maximum Premium Section 7.5(c) Merger Consideration Section 2.1 Merger Certificate 3.1(b)(i) Mergers Section 2.2 Merger Sub 2.1(d)(i) MLLCA Section 2.1(a)(i) MRL Section 2.1(a)(i) New Liberty Holdco Preamble New Liberty Holdco Common Share Section 3.1(a)(ii) New Liberty Holdco Equity Award Section 3.3(a) New Liberty Holdco Governing Documents Section 4.1(c) New OP Units Section 3.2(c) Note Offers and Consent Solicitations Section 7.22(b) Notice Period Section 7.4(b)(iv) Offers to Exchange Section 7.22(b) Offers to Purchase Section 7.22(b) OP Unit Form S-4 Section 7.1(a) Other Filings Section 7.2 Parent Preamble Parent Preamble Bylaws Section 5.1(d) Parent Charter Section 5.1(d) Parent Development Property Section 5.11(e) Parent Disclosure Schedule Article V Parent Indemnified Equity Award Section 5.3(c) Parent Governing Documents Section 5.1(d) Parent OP Preamble Parent OP Certificate of Limited Partnership Section 5.1(d) Parent OP Governing Documents Section 5.1(d) Parent Parties Preamble Parent Partnership Agreement Section 8.2(a)(i5.1(d) parties Parent Preferred Stock Section 5.3(a) Parent Properties Section 5.11(a) Parent SEC Reports Section 5.7(a) Parent Subsidiary Section 5.1(c) Parent Tax Protection Agreement Section 6.2(j) Parent-Approved Transaction Section 7.18 Parties Preamble Payee Partnership Preamble Partnership Agreement Section 8.5 Payor 4.1(c) Partnership Governing Documents Section 8.5 Per Diem 4.1(c) Partnership Merger Section 2.1(d)(i) Partnership Merger Certificates Section 2.1(d)(ii) Partnership Merger Common Consideration Section 3.2(c) Partnership Merger Effective Time Section 2.1(d)(ii) Partnership Merger Preferred Consideration Section 3.2(d) Partnership OP Unit Recitals Party Preamble Pennsylvania Law Section 2.1(d)(i) Permit Section 4.7 PPACA Section 4.14(i) Prologis Merger Sub Preamble Prologis OP Merger Sub Preamble Proxy Statement/Prospectus Section 3.4(a) Qualified REIT Subsidiary Section 4.11(f) Qualifying Income Section 9.4(a) Registered Intellectual Property Section 4.21(a) REIT Section 4.11(b) REIT Dividend Section 7.17(b) S▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.8(a) SDAT Section 2.1(a)(ii) Securities Laws Section 4.8(a) Superior Proposal Notice Section 7.4(b)(iv) Supplemental Indenture Section 7.22(b) Surviving Entity Section 2.1(b)(i) Takeover Statutes Section 4.25 Tax Protection Agreement Section 4.11(m) Taxable REIT Subsidiary Section 4.11(f) Topco Articles of Merger Section 2.1(b)(ii) Topco Merger Section 2.1(b)(i) Topco Merger Effective Time Section 2.1(b)(ii) Transfer Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g7.9(b)

Terms Defined Elsewhere. The For purposes of this Agreement, each of the following is a list of additional terms (as capitalized below) when used in this Agreement and a reference will have the meaning ascribed to such term in the Section hereof in which set forth opposite such term is definedterm: Absence of Legal Restraint Condition Exhibit A Acceptance Time Section 1.1(c) Agreement Preamble Biogen Idec License Alternative Proposal Section 5.4(f) Appraisal Rights Section 2.1(b) Benefits Continuation Period Section 5.5(a) Book-Entry Shares Section 2.2(a) Cancelled Shares Section 2.1(a)(ii) Capex Budget Section 5.1(b)(xvi) Certificate of Merger Section 1.5 Certificates Section 2.2(a) Change of Recommendation Section 5.4(c) Clean Team Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2) Claim Notice Section 8.3(a5.3(b) Closing Section 2.3 1.4 Closing Date Section 2.3 1.4 Code Section 2.2(b)(iv) Collection Costs Section 7.3(b) Common Stock Recitals Company Preamble Company Common Stock Approvals Section 2.8 3.4 Company Board Recitals Company Disclosure Schedule Letter Article IV 3 Company Expenses Schedule Employees Section 2.13 5.5(a) Company Indemnified ESPP Section 3.2(b)(i) Company Recommendation Section 3.3 Company Registered IP Section 3.11(a) Company Related Parties Section 8.2(a)(ii7.3(c) Contracts Company SEC Reports Section 4.8(a3.6(a) Covered Party (PartiesCompany Termination Fee Section 7.3(a) Confidentiality Agreement Section 8.2(a)(ii5.3(b) Damages Continuing Directors Section 8.2(a)(i8.10 Depository Agent Section 2.2(a) DGCL Recitals Dissenting Shares Section 2.1 Document Retention Period 2.1(b) DTC Section 2.12(f)(22.2(b)(ii) Drug Regulatory Agency Section 4.25 EDGAR Article 3 Effective Time Section 2.2 ERISA 1.5 End Date Section 4.13(a7.1(b) ERISA Affiliate ESPP Offering Period Section 4.13(a2.3(c) Finally Determined Existing Loan Documents Section 8.5(b2.4 Fair Value Section 8.14 FCPA Section 3.14(d) First Milestone FDA Application Integrity Policy Section 2.10(e3.16(g) First Milestone Payment Filed SEC Reports Article 3 Indemnified Party Section 5.9(a) Intervening Event Section 5.4(h) Intervening Event Notice Section 5.4(d) Intervening Event Notice Period Section 5.4(d) Leases Section 3.10(a) Legal Restraint Section 6.1(a) Material Contract Section 3.12(a) Maximum Amount Section 2.10(e5.9(c) Indemnifying Party Measurement Time Section 8.3(a) Instrument Section 2.12(c3.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate 2.1(a)(i) Minimum Tender Condition Exhibit A New Plans Section 2.2 Merger Sub Preamble 5.5(b) Offer Recitals Offer Conditions Section 1.1(b) Offer Documents Section 1.1(e) Old Plans Section 5.5(b) Parent Preamble Parent Approvals Section 4.2(b) Parent Disclosure Schedule Letter Article V 4 Parent Indemnified Material Adverse Effect Section 4.1 Parent Related Parties Section 8.2(a)(i7.3(c) parties Preamble Payee Paying Agent Section 8.5 Payor 2.2(a) Payment Fund Section 8.5 Per Diem Taxes Section 8.7(a2.2(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Payoff Amount Section 2.10(f2.4 Payoff Letter Section 2.4 PMA Section 3.16(e) Stockholder Consent Regulatory Condition Exhibit A Remedy Action Section 5.6(a) Representatives Section 5.3(a) Schedule 14D-9 Section 1.2(b) Security Incident Section 3.11(i) Share Recitals Stockholder Representative Preamble Super Majority Superior Proposal Section 2.12(b5.4(g) Superior Proposal Notice Section 5.4(c) Superior Proposal Notice Period Section 5.4(c) Surviving Corporation Section 2.1 Third Milestone 1.1 Takeover Statute Section 2.10(g3.21 Termination Condition Exhibit A Termination Date Section 5.1(a) Third Milestone Payment Amount Trade Authorizations Section 2.10(g3.14(f)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Acceptance Time Section hereof in which such term is defined: 2.4(a) Action Section 5.14 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 7.5(c)(ii) Articles of Merger Section 4.7 Books and Records 3.3 Bankruptcy Exception Section 2.12(f)(25.3(a) Claim Board Appointment Date Section 2.4(a) Book-Entry Shares Section 4.2(b) Certificates Section 4.2(b) CFIUS Notice Section 8.3(a) 7.19 Closing Section 2.3 3.2 Closing Date Section 2.3 3.2 Company Preamble Company Adverse Recommendation Change Section 7.5(c)(i) Company Board Recitals Company Board Recommendation Section 2.3(a)(v) Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Article IV Documents Section 5.10(a) Company Expenses Schedule Financial Advisor Section 2.13 5.3(c) Company Indemnified Parties Financial Statements Section 8.2(a)(ii5.7(b) Contracts Company Intellectual Property Section 4.8(a5.16 Company Material Contract Section 5.13(a) Covered Party (PartiesCompany Plan(s) Section 8.2(a)(ii5.11(a) Damages Company Preferred Stock Section 8.2(a)(i5.2(a) DGCL Company Representatives Section 2.1 Document Retention Period 7.4(a) Company SEC Filings Section 2.12(f)(25.7(a) Drug Regulatory Agency Company Shareholder Approval Section 4.25 5.3(b) Company Shareholders Recitals Company Shareholders’ Meeting Section 7.2(a) Company Subsidiary Section 5.1 Compensation Committee Section 5.23 Continuing Directors Section 2.4(a) Determination Notice Section 7.5(d)(i)(C) Dissenting Shareholder Section 4.3 Dissenting Shares Section 4.3 Effective Time Section 2.2 3.3 Employment Compensation Arrangement Section 5.23 End Date Section 9.1(b)(i) ERISA Section 4.13(a5.11(a) ERISA Affiliate Section 4.13(a5.11(a) Finally Determined Exchange Fund Section 8.5(b4.2(a) First Milestone Expiration Date Annex A FCPA Section 2.10(e5.6(b) First Milestone Payment Governmental Antitrust Entity Section 7.6(e)(i) Indemnified Parties Section 7.13(a) Independent Directors Section 2.4(b) Intervening Event Change of Recommendation Section 7.5(d)(ii) Investments Section 5.2(d) IRS Section 5.11(b) Loan Payoff Amount Section 2.10(e7.7(b) Indemnifying Party Measurement Date Section 8.3(a) Instrument Section 2.12(c5.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 4.1(a) Merger Sub Preamble MGBCL Recitals Minimum Condition Section 2.1(b) Notes Section 7.7(a) Notice Period Section 7.5(d)(i)(C) Offer Recitals Offer Documents Section 2.1(g) Offer Price Recitals Offer to Purchase Section 2.1(g) Parent Preamble Parent Disclosure Schedule Documents Section 6.7(b) Parent Representatives Section 7.4(a) Party, Parties Preamble Paying Agent Section 4.2(a) Proxy Statement Section 7.2(b) Recent SEC Reports Article V Parent Indemnified Parties Redemption Section 8.2(a)(i7.7(a) parties Preamble Payee Schedule TO Section 8.5 Payor 2.1(g) Schedule 14D-9 Section 8.5 Per Diem Taxes 2.3(b) Short-Form Threshold Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) 7.3 Surviving Corporation Section 2.1 Third Milestone 3.1 Tail Period Section 2.10(g7.13(c) Third Milestone Payment Amount Takeover Provisions Section 2.10(g)2.3(a)(iv) Top-Up Option Section 2.2(a) Transaction Litigation Section 7.8 WARN Act Section 5.12

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement, as indicated below: Acceptable Confidentiality Agreement and a reference to the Section hereof in which such term is defined: 7.4(b) Acquisition Agreement Section 7.4(a) Agreement Preamble Biogen Idec License Agreement Articles of Merger Section 4.7 Biogen Idec Supply Agreement 2.1(b)(ii) Book-Entry Share Section 4.7 Books and Records 3.1(b)(i) Certificate Section 2.12(f)(23.1(b)(i) Claim Notice Certificate of Limited Partnership Section 8.3(a4.1(c) Certificate of Partnership Merger Section 2.1(d)(ii) Change in Company Recommendation Section 7.4(b)(iii) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Code Recitals Company Preamble Company 401(k) Plan Section 4.14(b) Company Articles of Merger Section 2.1(a)(ii) Company Common Stock Shares Recitals Company Development Properties Section 2.8 4.12(h) Company Development Property Section 4.12(h) Company Disclosure Schedule Article IV Company Expenses Schedule Employee Programs Section 2.13 4.14(a) Company Equity Award Section 4.3(c) Company Governing Documents Section 4.1(c) Company Merger Section 2.1(a)(i) Company Merger Effective Time Section 2.1(a)(ii) Company Mergers Section 2.1(b)(i) Company Parties Preamble Company Preferred Shares Section 4.3(a) Company Properties Section 4.12(a) Company Recommendation Section 4.2(b) Company SEC Reports Section 4.8(a) Company Shareholder Approval Section 4.18 Company Shareholder Meeting Section 7.1(c) Company Subsidiaries Section 4.1(b) Company Subsidiary Section 4.1(b) Company Tax Protection Agreement Section 6.1(w) Consent Solicitations Section 7.22(b) Continuing Employee Section 7.8(a) Continuing Employees Section 7.8(a) Contribution Section 2.1(c)(i) Contribution and Issuance Effective Time Section 2.1(c)(ii) Debt Offer Documents Section 7.22(b) DLLCA Section 2.1(d)(i) Drop Dead Date Section 9.1(b)(iii) DSOS Section 2.1(d)(ii) Encumbrances Section 4.12(a) Exchange Agent Section 3.4(a) Exchange Fund Section 3.4(a) Exchange Ratio Section 3.1(b)(i) Form S-4 Section 4.6 Fractional Share Consideration Section 3.1(b)(i) HCERA Section 4.14(i) Health Plan Section 4.14(i) Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties) Section 8.2(a)(ii) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e7.5(a) Indemnifying Party Section 8.3(a7.5(a) Instrument Interim Period Section 2.12(c6.1 Intervening Event Notice Period Section 7.4(b)(v) Issuance Section 2.1(c)(i) Letter of Transmittal Section 3.4(c) Maryland Court Section 10.7(b) Maximum Premium Section 7.5(c) Merger Consideration Section 2.1 Merger Certificate 3.1(b)(i) Mergers Section 2.2 Merger Sub 2.1(d)(i) MLLCA Section 2.1(a)(i) MRL Section 2.1(a)(i) New Liberty Holdco Preamble New Liberty Holdco Common Share Section 3.1(a)(ii) New Liberty Holdco Equity Award Section 3.3(a) New Liberty Holdco Governing Documents Section 4.1(c) New OP Units Section 3.2(c) Note Offers and Consent Solicitations Section 7.22(b) Notice Period Section 7.4(b)(iv) Offers to Exchange Section 7.22(b) Offers to Purchase Section 7.22(b) OP Unit Form S-4 Section 7.1(a) Other Filings Section 7.2 Parent Preamble Parent Preamble Bylaws Section 5.1(d) Parent Charter Section 5.1(d) Parent Development Property Section 5.11(e) Parent Disclosure Schedule Article V Parent Indemnified Equity Award Section 5.3(c) Parent Governing Documents Section 5.1(d) Parent OP Preamble Parent OP Certificate of Limited Partnership Section 5.1(d) Parent OP Governing Documents Section 5.1(d) Parent Parties Preamble Parent Partnership Agreement Section 8.2(a)(i5.1(d) parties Parent Preferred Stock Section 5.3(a) Parent Properties Section 5.11(a) Parent SEC Reports Section 5.7(a) Parent Subsidiary Section 5.1(c) Parent Tax Protection Agreement Section 6.2(j) Parent-Approved Transaction Section 7.18 Parties Preamble Payee Partnership Preamble Partnership Agreement Section 8.5 Payor 4.1(c) Partnership Governing Documents Section 8.5 Per Diem 4.1(c) Partnership Merger Section 2.1(d)(i) Partnership Merger Certificates Section 2.1(d)(ii) Partnership Merger Common Consideration Section 3.2(c) Partnership Merger Effective Time Section 2.1(d)(ii) Partnership Merger Preferred Consideration Section 3.2(d) Partnership OP Unit Recitals Party Preamble Pennsylvania Law Section 2.1(d)(i) Permit Section 4.7 PPACA Section 4.14(i) Prologis Merger Sub Preamble Prologis OP Merger Sub Preamble Proxy Statement/Prospectus Section 3.4(a) Qualified REIT Subsidiary Section 4.11(f) Qualifying Income Section 9.4(a) Registered Intellectual Property Section 4.21(a) REIT Section 4.11(b) REIT Dividend Section 7.17(b) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.8(a) SDAT Section 2.1(a)(ii) Securities Laws Section 4.8(a) Superior Proposal Notice Section 7.4(b)(iv) Supplemental Indenture Section 7.22(b) Surviving Entity Section 2.1(b)(i) Takeover Statutes Section 4.25 Tax Protection Agreement Section 4.11(m) Taxable REIT Subsidiary Section 4.11(f) Topco Articles of Merger Section 2.1(b)(ii) Topco Merger Section 2.1(b)(i) Topco Merger Effective Time Section 2.1(b)(ii) Transfer Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g7.9(b)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: $ Section hereof in which such term is defined: 1.3(c) Adverse Recommendation Change Section 6.2(c) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.2(c) Arbitrator Section 4.7 Books and Records 10.8(b) Base Premium Section 2.12(f)(27.4(d) Claim Notice CICL Section 8.3(a) 2.1 Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Board Recitals Company Board Recommendation Recitals Company Equity Interests Section 2.8 4.2(a) Company Disclosure Schedule Article IV Group Section 9.2(h) Company Expenses Schedule Intellectual Property Rights Section 2.13 4.11(a) Company Indemnified Parties Termination Fee Section 8.2(a)(ii9.2(e) Contracts Competing Proposal Section 4.8(a6.2(g) Covered Party (PartiesPersons Section 7.4(a) Dissenting Shareholders Section 8.2(a)(ii3.3(a) Damages Dissenting Shares Section 8.2(a)(i3.3(a) DGCL Dollars Section 2.1 Document Retention Period Section 2.12(f)(21.3(c) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA 2.3 Enforceability Exceptions Section 4.13(a4.3 Equity Commitment Letter Section 5.5(a) ERISA Affiliate Equity Financing Section 4.13(a5.5(a) Finally Determined Exchange Act Section 8.5(b4.5 Exchange Fund Section 3.2(a) First Milestone Financial Statements Section 2.10(e4.6(b) First Milestone Payment Amount Fuling Global, Inc. Section 2.10(e2.6 GAAP Section 4.6(b) Indemnifying Party Governmental Entity Section 8.3(a4.5 HKIAC Section 10.8(b) Instrument Indemnification Agreements Section 2.12(c7.4(a) Legal Proceeding Section 4.12 Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 3.2(a) Merger Sub Preamble Nasdaq Section 4.5 Non-Required Remedy Section 7.2(e) Parent Preamble Parent Disclosure Group Section 9.2(h) Parent Termination Fee Section 9.2(f) Parties Preamble Party Preamble Paying Agent Section 3.2(a) Per Share Merger Consideration Section 3.1(a) Plan of Merger Section 2.3 Proxy Statement Section 4.5 Record Date Section 6.4(a) Regulatory Filings Section 4.5 Rollover Shareholders Recitals Rules Section 10.8(b) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.6(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.3(a) parties Preamble Payee SEC Section 8.5 Payor 4.5 SEC Documents Section 8.5 Per Diem Taxes 4.6(a) Securities Act Section 8.7(a4.8 Share Certificates Section 3.2(b)(i) Proceeding Special Committee Recitals Superior Proposal Section 4.17 Royalties Section 2.10(h6.2(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Support Agreements Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Entity Section 2.1 Third Milestone Takeover Statute Section 2.10(g) Third Milestone Payment Amount 4.16 Transaction Litigation Section 2.10(g7.7 Transactions Recitals Uncertificated Shares Section 3.2(b)(i)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Action Section hereof in which such term is defined: 4.12 Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement 6.4(c)(ii) Alternative Financing Section 4.7 Books 6.6(b) Alternative Financing Agreements Section 6.6(b) Anti-Corruption Laws Section 4.5(b) Articles of Merger Section 2.3 Bankruptcy and Records Equity Exception Section 2.12(f)(24.3(a) Claim Notice BVI Companies Act Preamble Certificates Section 8.3(a3.2(c)(i) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Common Stock Adverse Recommendation Change Section 2.8 6.4(c)(i) Company Disclosure Schedule Article IV Board Preamble Company Expenses Schedule Financial Advisor Section 2.13 4.3(b) Company Financial Statements Section 4.6(b) Company Group Section 8.2(f)(i) Company Intellectual Property Section 4.14(b) Company Material Contract Section 4.11(b) Company Plan(s) Section 4.9(a) Company Recommendation Section 4.3(b) Company Representatives Section 6.3(a) Company SEC Filings Section 4.6(a) Company Shareholders Meeting Section 6.2(e)(i) Company Subsidiary Section 4.1 Company Workers Section 4.14(e) D&O Insurance Section 6.12(b) Debt Commitment Letter Section 5.6(a) Debt Financing Agreement Section 6.6(a) Dissenter Rights Section 3.1(e) Dissenting Shareholders Section 3.1(e) Dissenting Shares Section 3.1(e) Effective Time Section 2.3 End Date Section 8.1(b)(i) Exchange Fund Section 3.2(b) Financing Section 5.6(a) Financing Agreements Section 6.6(b) Guarantor Preamble HKIAC Section 9.7(b) Indemnified Parties Section 8.2(a)(ii6.12(a) Contracts Intervening Event Section 4.8(a6.4(e)(i) Covered Party (PartiesInvestments Section 4.2(d) Leased Real Property Section 8.2(a)(ii4.17(b) Damages Section 8.2(a)(i) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Limited Guarantee Preamble Merger Section 2.1 Merger Certificate Section 2.2 Preamble Merger Sub Preamble Notice Period Section 6.4(d)(iii) Owned Real Property Section 4.17(a) Parent Preamble Parent Disclosure Group Section 8.2(f)(i) Parent Representatives Section 6.3(a) Party Preamble Paying Agent Section 3.2(a) Per Share Merger Consideration Section 3.1(b) Plan of Merger Section 2.3 PRC VIEs Section 4.21(a) Proxy Statement Section 6.2(a) Registrar of Companies Section 2.3 Rollover Securities Preamble Rollover Securityholder Preamble SAFE Rules and Regulations Section 4.5(c) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i4.4(b) parties Special Committee Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Support Agreement Preamble Super Majority Section 2.12(b) Surviving Corporation Company Section 2.1 Third Milestone Transaction Litigation Section 2.10(g) Third Milestone Payment Amount 6.8 Uncertificated Shares Section 2.10(g3.2(c)(i)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: “401(k) Plan” Section hereof 6.12 “After Consultation” Section 5.2(b) “Agreement” Introduction “Appointment Date” Section 5.1 “Appointment Time” Section 1.3 “Appraisal Rights” Section 2.3(a) “Assignee” Section 9.13 “Balance Sheet Date” Section 3.8(a) “Bankruptcy Claims/Interest Section 3.25(b) “Bankruptcy Confirmation Order” Section 3.25 “Base Premium” Section 6.6(d) “Benefit Plans” Section 3.11(a) “Certificate of Merger” Section 1.5 “Certificates” Section 2.2(b) “Closing” Section 1.6 “Closing Date” Section 1.6 “Code” Section 2.2(e) “Common Stock” Section 3.2(a) “Company” Introduction “Company Agreements” Section 3.5(a) “Company Board of Directors” Recitals “Company Bylaws” Section 1.3(b) “Company Certificate” Section 1.3(b) “Company Change in which such term is defined: Agreement Preamble Biogen Idec License Agreement Recommendation” Section 4.7 Biogen Idec Supply Agreement 5.3(b) “Company Collective Bargaining Agreement” Section 4.7 Books and Records Section 2.12(f)(23.16(a) Claim Notice Section 8.3(a) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Section 2.8 “Company Disclosure Schedule Schedule” Article IV III “Company Expenses Schedule Financial Advisor” Section 2.13 3.20 “Company Indemnified Parties Governing Documents” Section 8.2(a)(ii1.3(b) Contracts “Company IP Agreements” Section 4.8(a3.15(d) Covered Party (Parties“Company Material Contract” Section 3.13 “Company Options” Section 2.5(a) “Company Permits” Section 8.2(a)(ii3.17(b) Damages “Company Recommendation” Section 8.2(a)(i5.3(a) DGCL “Company Rights” Section 2.1 Document Retention Period 3.2(a) “Company Rights Agreement” Section 2.12(f)(23.2(a) Drug Regulatory Agency “Company Scheduled Agreements” Section 4.25 Effective Time 3.5(a) “Company SEC Documents” Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g3.6(a)

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Agreement, as indicated below: Adjusted Exchange Ratio Section hereof in which such term is defined: 4.1(a) Agreement Preamble Biogen Idec License Agreement Amended and Restated Bylaws Section 4.7 Biogen Idec Supply Agreement 2.6(b) Book-Entry Company Shares Section 4.7 Books and Records 4.2(b)(i) Certificate of Merger Section 2.12(f)(22.3 Certificates Section 4.2(b)(i) Claim Notice Chosen Courts Section 8.3(a11.8(b) Closing Section 2.3 2.2 Closing Date Section 2.3 2.2 Company Preamble Company Adverse Recommendation Change Section 7.4(c) Company Agreements Section 5.14(a) Company Benefit Plans Section 5.11(a) Company Board Recitals Company Board Recommendation Recitals Company Common Stock Section 2.8 Recitals Company Disclosure Schedule Letter Article IV V Company Expenses Schedule Equity Interests Section 2.13 5.2(b) Company Indemnified Parties Financial Statements Section 8.2(a)(ii5.6(b) Contracts Company IP Agreements Section 4.8(a5.17(b) Company Leased Real Property Section 5.19(b) Company Material Contract Section 5.14(b) Company Owned Real Property Section 5.19(a) Company Permits Section 5.18(b) Company Preferred Stock Section 5.2(a) Company Properties Section 5.19(b) Company SEC Documents Section 5.6(a) Company Subsidiary Section 5.1(b) Company Title Insurance Policies Section 5.19(i) Company Title Insurance Policy Section 5.19(i) Company Transaction Litigation Section 8.10 Competing Proposal Section 7.4(k) Continuing Employees Section 8.4(a) Covered Party (Parties) Persons Section 8.2(a)(ii) Damages Section 8.2(a)(i8.5(a) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Recitals Effective Time Section 2.2 ERISA 2.3 Electronic Delivery Section 4.13(a11.5 Enforceability Exceptions Section 5.3 Exchange Act Section 5.5 Exchange Agent Section 4.2(a) ERISA Affiliate Exchange Fund Section 4.13(a4.2(a) Finally Determined Form S-4 Section 8.5(b5.5 Fractional Share Consideration Section 4.1(a) First Milestone Fractional Shares Section 2.10(e4.6(b) First Milestone Payment Amount GAAP Section 2.10(e5.6(b) Indemnifying Party Governmental Entity Section 8.3(a5.5 HSR Act Section 5.5 Indemnification Agreements Section 8.5(a) Instrument Initial Year of Participation Section 2.12(c8.4(b) Interim Period Section 7.1(a) Joint Proxy Statement Section 5.5 Legal Proceeding Section 5.10 LLC Act Recitals Measurement Date Section 5.2(a) Merger Recitals Merger Consideration Section 2.1 Merger Certificate Section 2.2 4.1(a) Merger Sub Preamble New Plans Section 8.4(b) NYSE Section 3.2(c)(i) Old Plans Section 8.4(b) Parent Preamble Parent Adverse Recommendation Change Section 7.4(g) Parent Agreements Section 6.14(a) Parent Benefit Plans Section 6.11(a) Parent Board Recitals Parent Board Recommendation Recitals Parent Common Shares Recitals Parent Disclosure Schedule Letter Article V VI Parent Indemnified Equity Interests Section 6.2(b) Parent Financial Statements Section 6.6(b) Parent IP Agreements Section 6.17(b) Parent Leased Real Property Section 6.19(b) Parent Material Contract Section 6.14(b) Parent Owned Real Property Section 6.19(a) Parent Permits Section 6.18(b) Parent Preferred Shares Section 6.2(a) Parent Properties Section 6.19(b) Parent SEC Documents Section 6.6(a) Parent Subsidiary Section 6.1(b) Parent Title Insurance Policies Section 6.19(i) Parent Title Insurance Policy Section 6.19(i) Parent Transaction Litigation Section 8.10 Parent Welfare Plans Section 8.4(b) Parties Preamble Party Preamble Pre-Merger Financing Transaction Section 8.2(a)(i8.12(b) parties Preamble Payee Qualifying Income Section 8.5 Payor 10.2(e) REIT Section 8.5 Per Diem Taxes 5.13(b) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 8.7(a5.6(a) Proceeding SEC Section 4.17 Royalties 3.2(c)(i) Securities Act Section 2.10(h5.6(a) Second Milestone Special Parent Distribution Section 2.10(f7.6(a) Second Milestone Payment Amount Specified Date Section 2.10(f10.1(d) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Superior Proposal Section 2.12(b7.4(l) Surviving Corporation Entity Section 2.1 Third Milestone Transaction Litigation Section 2.10(g) Third Milestone Payment Amount Section 2.10(g)8.10 Transactions Recitals

Terms Defined Elsewhere. The following is a list of additional terms used are defined elsewhere in this Agreement and a reference to the Section hereof in which such term is definedAgreement, as indicated below: Action ‎Section 4.14(a) Agreement Preamble Biogen Idec License Alternative Acquisition Agreement Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books and Records Section 2.12(f)(2‎Section 6.4(c)(ii) Claim Notice Section 8.3(aArticles of Merger ‎Section 2.3 Bankruptcy Exception ‎Section 4.3(a) Certificates ‎Section 3.2(b) Closing Section 2.3 ‎Section 2.2 Closing Date Section 2.3 ‎Section 2.2 Company Preamble Company Common Stock Section 2.8 Adverse Recommendation Change ‎Section 6.4(c)(i) Company Board Recommendation ‎Section 4.3(d) Company Disclosure Schedule Article IV Documents ‎Section 4.10(a) Company Expenses Schedule Section 2.13 Financial Advisor ‎Section 4.3(c) Company Indemnified Parties Section 8.2(a)(iiFinancial Statements ‎Section 4.7(b) Contracts Section 4.8(aCompany Intellectual Property ‎Section 4.16(a) Covered Party (PartiesCompany Material Contract ‎Section 4.13(a) Section 8.2(a)(iiCompany Plan(s) Damages Section 8.2(a)(i‎Section 4.11(a) DGCL Section 2.1 Document Retention Period Section 2.12(f)(2Company Preferred Stock ‎Section 4.2(a) Drug Regulatory Agency Section 4.25 Company Representatives ‎Section 6.3(a) Company SEC Filings ‎Section 4.7(a) Company Shareholder Approval ‎Section 4.3(b) Company Shareholders Recitals Company Shareholders’ Meeting ‎Section 6.2(c) Company Subsidiary ‎Section 4.1 Determination Notice ‎Section 6.4(d)(i)(C) Effective Time Section 2.2 ‎Section 2.3 End Date ‎Section 8.1(b)(i) ERISA Section 4.13(a‎Section 4.11(a) ERISA Affiliate Section 4.13(a‎Section 4.11(a) Finally Determined Section 8.5(bExchange Fund ‎Section 3.2(a) First Milestone Section 2.10(eImprovements ‎Section 4.19(c) First Milestone Payment Amount Section 2.10(eIndemnified Parties ‎Section 6.11(a) Indemnifying Party Section 8.3(aIntervening Event Change of Recommendation ‎Section 6.4(d)(ii) Instrument Section 2.12(cInvestments ‎Section 4.2(d) IRS ‎Section 4.11(b) Measurement Date ‎Section 4.2(a) Merger Section 2.1 Recitals Merger Certificate Section 2.2 Consideration ‎Section 3.1(a) Merger Sub Preamble Multiemployer Plan ‎Section 4.11(c) Notice Period ‎Section 6.4(d)(i)(C) OFAC ‎Section 1.1(v) Parent Preamble Parent Disclosure Schedule Article V Expenses ‎Section 8.2(c) Parent Indemnified Parties Section 8.2(a)(iRepresentatives ‎Section 6.3(a) parties Party Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(aPaying Agent ‎Section 3.2(a) Proceeding Section 4.17 Royalties Section 2.10(hPerformance Awards ‎Section 3.5(d) Second Milestone Section 2.10(fProxy Statement ‎Section 6.2(a) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(bRecent SEC Reports ‎Article IV Rollover Option ‎Section 3.5(b) Surviving Corporation Section ‎Section 2.1 Third Milestone Section 2.10(gTail Period ‎Section 6.11(c) Third Milestone Payment Amount Section 2.10(g)Takeover Provisions ‎Section 4.21(a) TBCA Recitals Transaction Litigation ‎Section 6.6 WARN Act ‎Section 4.12

Terms Defined Elsewhere. The following is a list of additional terms used have the meanings set forth in this Agreement and a reference to the Section hereof in which such term is definedSections set forth below: Agreement Preamble Biogen Idec License Agreement Arbitrator Section 4.7 Biogen Idec Supply Agreement 10.8(b) Available Cash Section 4.7 Books and Records 7.13 Base Premium Section 2.12(f)(27.4(d) Claim Notice Change in Recommendation Section 8.3(a6.2(d) Closing Section 2.3 Closing Date Section 2.3 Company Preamble Company Common Stock Board Recitals Company Group Section 2.8 9.2(d) Company Disclosure Schedule Article IV Company Expenses Schedule Termination Fee Section 2.13 Company Indemnified Parties 9.2(b) Confidential Information Section 8.2(a)(ii) Contracts Section 4.8(a10.11(c) Covered Party (PartiesPersons Section 7.4(a) Deposit Agreement Section 8.2(a)(ii3.5 Depositary Section 3.5 Deposited Available Cash Section 7.13 Dissent Notice Section 3.6(b)(ii) Damages Dissent Right Section 8.2(a)(i3.6(b) DGCL Dissenting Shareholders Section 2.1 Document Retention Period 3.6(a) Dissenting Shares Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 3.6 Effective Time Section 2.2 ERISA 2.3 Enforceability Exceptions Section 4.13(a4.3 Financing Section 5.6(a) ERISA Affiliate GAAP Section 4.13(a4.6(d) Finally Determined Governmental Entity Section 8.5(b4.5 HKIAC Section 10.8(b) First Milestone HKIAC Rules Section 2.10(e10.8(b) First Milestone Payment Amount Indemnification Agreements Section 2.10(e7.4(a) Indemnifying Party Intervening Event Section 8.3(a6.2(e) Instrument Intervening Event Termination Section 2.12(c6.2(e) Limited Guarantee Recitals Loan Agreement Section 5.6(a) Material Company Permits Section 4.8 Merger Recitals Merger Consideration Section 3.2(a) Merger Consideration Fund Section 2.1 Merger Certificate Section 2.2 3.2(a) Merger Sub Preamble NASDAQ Section 4.2(b) Notice of Recommendation Change Section 6.2(d) Notice Period Section 6.2(d) Option Consideration Section 3.3(a)(i) Parent Preamble Parent Disclosure Group Section 9.2(d) Parent Termination Fee Section 9.2(c) Parties Preamble Paying Agent Section 3.2(a) Per ADS Merger Consideration Section 3.1(b) Per Share Merger Consideration Section 3.1(a) Plan of Merger Section 2.3 Record ADS Holders Section 6.3(c) Record Date Section 6.3(c) Rollover Agreement Recitals Rollover Shareholders Recitals Ruhnn1106 Section 5.6(a) ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Act Section 4.6(a) Schedule Article V Parent Indemnified Parties 13E-3 Section 8.2(a)(i6.3(a) parties Preamble Payee SEC Documents Section 8.5 Payor 4.6(a) Securities Act Section 8.5 Per Diem Taxes 4.6(a) Share Certificates Section 8.7(a3.2(c)(i) Proceeding Special Committee Recitals Subscription Agreement Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b5.6(a) Surviving Corporation Company Section 2.1 Third Milestone Takeover Statute Section 2.10(g7.5 Transaction Litigation Section 7.8 Transactions Recitals Uncertificated Shares Section 3.2(c)(i) Third Milestone Payment Amount Vista Section 2.10(g5.6(a)

Terms Defined Elsewhere. The Each of the following terms is a list of additional terms used defined in this Agreement and a reference to the Section hereof in which set forth opposite such term is definedterm: 401(k) Termination Date 8.03(c) Acceptable Confidentiality Agreement 6.02(b) Agreement Preamble Biogen Idec License Agreement Ancillary Scheme Documentation Section 4.7 Biogen Idec Supply Agreement Section 4.7 Books 3.01(a)(ii) Apple Preamble Apple Adverse Recommendation Change 6.02(a) Apple Approval Time 6.02(b) Apple Board Recitals Apple Board Recommendation 4.02(b) Apple Organizational Documents 4.01 Apple Payment Fund 2.01(b) Apple Permits 4.12 Apple Registered IP 4.19(a) Apple Regulatory Agency 4.14(a) Apple Regulatory Permits 4.14(a) Apple SEC Documents 4.07(a) Bankruptcy and Records Section 2.12(f)(2Equity Exceptions 4.02(a) Claim Notice Section 8.3(aCapitalization Date 4.05(a) Cash Consideration 2.01(a) Closing Section 2.3 1.02 Closing Date 1.02 Continuing Employees 8.03(a) Court Documentation 3.01(a)(viii) Court Order 1.03 CVR 2.01(a) CVR Agreement Recitals Depositary Custodian 2.01(b) Effect Material Adverse Effect definition Effective Time 1.03 EMA Section 2.3 Company Preamble Company Common Stock 4.14(e) End Date 10.01(b)(i) Excluded Benefits Section 2.8 Company Disclosure Schedule Article IV Company Expenses Schedule 8.03(a) FDA 4.14(a) FDCA 4.14(a) Forms of Proxy 3.01(a)(ii) In-the-Money Unvested Apple Share Option 2.02(c) 2.01(b) In-the-Money Vested Apple Share Option Section 2.13 Company Indemnified Parties Section 8.2(a)(ii) Contracts Section 4.8(a) Covered Party (Parties2.02(c) Section 8.2(a)(ii2.01(d) Damages Indemnified Party 7.01(b) Labor Agreement 4.15(a)(iii) Leases 4.21 Material Contract 4.15(a) Material Supplier 4.27 Maximum Amount 7.01(c) Nasdaq 4.03 New Plans 8.03(b) No-Vote Termination Fee Section 8.2(a)(i10.03(a)(iii) DGCL Non-U.S. Plan 4.17(j) Old Plans 8.03(b) Ordinary Termination Fee 10.03(a)(ii) Other Required Filing 3.01(a)(iii) Parties Preamble Paying Agent 2.01(b) Payoff Letter Section 2.1 8.08 Per ADS Cash Consideration 2.01(a) Per ADS CVR 2.01(a) Per ADS Transaction Consideration 2.01(a) PHSA 4.14(a) Proxy Statement 3.01(a)(i) Protected Data Section 4.20(c) Purchaser Preamble Purchaser Board Recitals Purchaser Organizational Documents Section 5.04 Real Properties 4.21 Regulation S-K 4.07(g) Relevant Participant Section 2.02(i) Retention Award Section 8.03(h) Retention Pool Section 8.03(h) Rights Agent Recitals Scheme Document Retention Period Section 2.12(f)(2) Drug Regulatory Agency Section 4.25 Effective Time Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(hAnnex 3.01(a)(i) Second Milestone Request 8.02(c) Senior Counsel 3.01(a)(x) Tail Coverage Section 2.10(f7.01(c) Second Milestone Payment Amount Takeover Code Section 2.10(f4.26 Transaction Recitals Transaction Consideration 2.01(a) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Transaction Documentation Section 2.12(b3.01(a)(iv) Surviving Corporation Transaction Litigation 6.03 Transfer Taxes 11.04 Transition Award Section 2.1 Third Milestone 2.02(i) Transitional Cash Plan Section 2.10(g2.02(i) Third Milestone Payment Amount Unvested Apple PSU Section 2.10(g)2.02(g) Unvested Apple RSU Section 2.02(f) Unvested Awards Section 2.02(i) Unvested Cash Consideration Section 2.02(j) Unvested CVR Consideration Section 2.02(j) IN THE HIGH COURT OF JUSTICE CR - [2023] - [●]

Terms Defined Elsewhere. The following is a list of additional terms used in this Agreement and a reference to the Section hereof in which such term is defined: 280G Approval Process Section 2.9 280G Waiver Section 2.9 401(k) Plan Section 2.8(a)(ix) Action Section 3.9 Aggregate Series B Liquidation Amount Recital E Agreement Preamble Biogen Idec License Agreement Allocation Methodology Section 4.7 Biogen Idec Supply Agreement 5.1(a)(i) Anti-Bribery Laws Section 4.7 Books and Records 3.12(b)(i) Audit Firm Section 2.12(f)(22.3(c) Audited Balance Sheets Section 3.7(a) Audited Financial Statements Section 3.7(a) Book-Entry Shares Section 1.7 Cap Section 6.4(a)(ii) Certificate of Merger Section 1.2 Chubb Schedule 6.2(a)(ix)(3) Claim Notice Section 8.3(a6.3(b)(i) Closing Section 2.3 2.1 Closing Date Section 2.3 2.1 Closing Date Volume Weighted Average Price Schedule 2.7(5)(c) Closing Statement Section 2.3(a) Closing Statement Delivery Period Section 2.3(a) Company Preamble Company Common Stock Board Recital B Company Covenant Breach Section 2.8 6.2(a)(iv) Company Disclosure Schedule Article IV Fundamental Representation Breach Section 6.2(a)(iii) Company Expenses Schedule General Representation Breach Section 2.13 6.2(a)(i) Company Indemnified Parties Group Systems Section 8.2(a)(ii3.13(j) Contracts Company Indemnitees Section 4.8(a6.2(b) Covered Party (PartiesCompany POA Section 3.24(b) Company Quasi-Fundamental Representation Breach Section 8.2(a)(ii6.2(a)(ii) Damages Company Quasi-Fundamental Representations Section 8.2(a)(i6.1(a) DGCL Consideration Allocation Section 2.1 Document Retention Period 5.1(a)(i) Contaminant Section 2.12(f)(23.13(k) Drug Regulatory Agency Corporate Compliance Program Section 4.25 Effective Time 3.25(a) CV-ITM Share Section 2.2 ERISA Section 4.13(a) ERISA Affiliate Section 4.13(a) Finally Determined Section 8.5(b) First Milestone Section 2.10(e) First Milestone Payment Amount Section 2.10(e) Indemnifying Party Section 8.3(a) Instrument Section 2.12(c) Merger Section 2.1 Merger Certificate Section 2.2 Merger Sub Preamble Parent Preamble Parent Disclosure Schedule Article V Parent Indemnified Parties Section 8.2(a)(i) parties Preamble Payee Section 8.5 Payor Section 8.5 Per Diem Taxes Section 8.7(a) Proceeding Section 4.17 Royalties Section 2.10(h) Second Milestone Section 2.10(f) Second Milestone Payment Amount Section 2.10(f) Stockholder Consent Recitals Stockholder Representative Preamble Super Majority Section 2.12(b) Surviving Corporation Section 2.1 Third Milestone Section 2.10(g) Third Milestone Payment Amount Section 2.10(g1.6(a)